Regulation of mammalian CDC6 by CDK phosphorylation and proteasome dependent degradation. by Petersen, Birgit Otzen
Open Research Online
The Open University’s repository of research publications
and other research outputs
Regulation of mammalian CDC6 by CDK
phosphorylation and proteasome dependent
degradation.
Thesis
How to cite:
Petersen, Birgit Otzen (1999). Regulation of mammalian CDC6 by CDK phosphorylation and proteasome
dependent degradation. PhD thesis. The Open University.
For guidance on citations see FAQs.
c© 1999 Birgit Otzen Petersen
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
' u M < 2 s S r e i c r c i )  •
Regulation of mammalian CDC6 by CDK phosphorylation 
and proteasome dependent degradation
A thesis submitted in partial fulfillment of the requirements of the Open University 
for the degree of Doctor of Philosophy (Ph.D.)
July 1999
Birgit Otzen Petersen 
Când. Scient. (M. Sc.)
European Institute of Oncology 
Via Ripamonti 435 
20141 Milano 
Italy
^  ■ y  ' - _ J
'Date of 3 0  SepreMBElL toiqq
ProQuest Number: C801620
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest C801620
Published by ProQuest LLC (2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
Abstract
Abstract
The mammalian cell cycle is regulated by periodic gene transcription, kinase 
activities and protein degradation. A human cDNA encoding a protein homologous 
to S. cerevisiae Cdc6p and S. pombe CdclS was identified. Mammalian CDC6 is 
essential for DNA replication, and the obtained data demonstrate that the 
mammalian CDC6 protein is regulated by several mechanisms. The subcellular 
localization of mammalian CDC6 is cell cycle regulated controlled by Cyclin 
A/CDK2 phosphorylation. The CDC6 protein interacts directly with the Cyclin 
A/CDK2 complex via a Cy-motif in the N-terminal of CDC6 and phosphorylation of 
hCDC6 results in relocation of hCDC6 from the nucleus to the cytoplasm during S- 
phase. The protein level of mammalian CDC6 is growth and cell cycle regulated.
The CDC6 protein is induced by stimulation of serum starved fibroblasts and the 
CDC6 protein level remains high throughout S-phase and G2. As cells progress 
through mitosis the amount of CDC6 protein declines abruptly. Mammalian CDC6 is 
an unstable protein. The level of CDC6 protein increases in the presence of 
proteasome inhibitors and, furthermore, poly-ubiquitinated CDC6 was identified in 
vivo, demonstrating that CDC6 is targeted for degradation by ubiquitination in 
mammalian cells. The instability of CDC6 was shown to be dependent on the N- 
terminal region. A peptide sequence with homology to destruction box sequences 
found in substrates of the anaphase promoting complex was identified in hCDC6 and 
shown to mediate the degradation of hCDC6 in quiescent cells. These data suggest 
that the mammalian CDC6 protein is highly regulated. In GO and early G1 
accumulation of the mammalian CDC6 protein is prevented by ubiquitin mediated 
degradation. During S-phase and G2 mammalian CDC6 is retained in the cytoplasm 
by Cyclin A/CDK2 phosphorylation.
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Introduction
2. Introduction
The control of cell growth and proliferation is essential for cell survival. The ability 
of cells to respond to environmental changes and to repair damages allows cells to 
recover from stress. A cell needs to duplicate the complete genome once and only 
once during each cell cycle and the chromosomes must be equally separated between 
the two daughter cells to ensure viability. The progression from one state to the next 
is dependent on the execution of certain cellular functions and achieved by 
checkpoint control mechanisms (Hartwell and Weinert, 1989). These checkpoints 
block initiation of DNA replication in the absence of growth stimulatory signals and 
induce cell cycle arrest in response to DNA damage, allowing the cell to repair the 
DNA before it continues through the cell division cycle. Initiation of mitosis is 
dependent on completion of chromosomal replication and the duplicated 
chromosomes are separated only when all sister chromatids are correctly associated 
with spindles and perfectly aligned on the metaphase plate. Disruption of cellular 
regulatory pathways involved in checkpoint control by inappropriate activation of 
oncogenes and/or the inactivation of tumor suppressors are believed to be key events 
in tumorigenesis as a consequence of genomic instability.
2.1 The eukaryotic cell cycle
The current understanding of cellular regulatory pathways has been obtained by 
studies in many different cellular systems. In particular, considerable progress has 
been made in the field of cell cycle regulation using the two yeast strains, 
Saccharomyces cerevisiae (5. cerevisiae) and Schizosaccharomyces pombe (S. 
pombe), which allow genetic studies not feasible in cultured mammalian cells. In 
addition, the Xenopus laevis model system has been very useful for elucidating the
13
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mechanisms regulating DNA synthesis. Many cell cycle regulatory mechanisms are 
conserved throughout evolution. Therefore, findings obtained in one species are 
often with some modifications applicable in other systems.
Common to all eukaryotic cells is the "cell cycle". The different periods of the cell 
division cycle were initially divided into the DNA-synthesis phase (S-phase) and 
mitosis (M). These phases are separated by two gaps where no physical changes 
were observed, G1 after mitosis and before S-phase, G2 after DNA synthesis and 
before M. During the gap-periods cells prepare for the next phase. Non dividing cells 
are described as being quiescent or in GO. Quiescent cells can be restimulated to 
enter the cell cycle whereas cells with a differentiated phenotype have withdrawn 
irreversibly from the cell cycle. Some cell types can be arrested in a GO-like state in 
vitro by serum deprivation and stimulated to re-enter the cell cycle by serum 
addition. The time for a GO cell to begin DNA synthesis is longer than for a G1 cell 
indicating that the GO and G1 states differ in their ability to support DNA 
replication.
Several kinases, especially the cyclin dependent kinases, are involved in regulating 
cell proliferation. The cyclin dependent kinases are well characterized, and their 
timed activation during cell cycle progression is essential for entry into S-phase and 
mitosis (reviewed by Dunphy, 1994; Sherr, 1994). In addition, phase transitions 
require timed degradation of specific proteins. High molecular weight complexes are 
responsible for ubiquitination and the following degradation of cell cycle regulatory 
proteins (reviewed by Hoyt, 1997 and Peters, 1998). Regulation of cell proliferation 
is obtained by connecting the different regulatory pathways. The transition from one 
phase to another is dependent on changes in protein expression and enzyme 
activities, which are regulated by phosphorylation and/or degradation of specific 
proteins. By coupling exit of one phase to entry into the next, the phases are
14
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mutually excluded. Therefore, cells in the various phases are completely different in 
their ability to support DNA replication and mitosis.
The molecular mechanism of initiation of DNA-replication is best understood in S. 
cerevisiae and S. pombe. The identification of mammalian homologues of yeast 
proteins involved in DNA replication suggests that the replication machinery has 
been conserved throughout evolution. The increased understanding of the regulation 
of initiation of DNA replication in eukaryotic cells demonstrates that the 
mechanisms regulating cell cycle progression are essential features controlling 
duplication and division of the genome (Stillman, 1996; Wuarin and Nurse, 1996).
2.2 Cell Cycle regulation by the cyclin dependent kinases
The classical regulators of the cell cycle are the cyclin dependent kinases (CDKs). 
The CDKs are essential for cell proliferation and together with several other kinases 
and phosphatases, they regulate cellular processes by changing the phosphorylation 
state of effector proteins.
In yeast only one cyclin dependent kinase is involved in cell cycle regulation, 
namely Cdc28 (S. cerevisiae) and Cdc2 (S. pombe). In mammalian cells nine cyclin 
dependent kinases (CDKs) have been identified to date. CDK1 (CDC2), CDK2, 
CDK4 and CDK6 are the main kinases involved in cell cycle regulation (reviewed 
by Morgan, 1997).
The CDK is the catalytic subunit of the kinase that is activated by interaction with a 
regulatory subunit, a cyclin. The cyclin dependent kinases can be divided into 
different groups depending on the timing of activation. In yeast, the timing of 
activation is based on the interaction of Cdc2 and Cdc28 with different cyclins. The
15
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G1 cyclins are important for the progression through G1 until the onset of DNA 
replication. S-phase cyclins are important for initiation of DNA replication and the 
mitotic cyclins are needed of entry into mitosis (reviewed by Morgan, 1997). The 
function of some cyclins may be redundant as a yeast strain deleted for two S-phase 
cyclins (Clb5 and Clb6) are viable. Although the initiation of S-phase in this strain is 
delayed until Cdc2p is activated by other S- and M-phase cyclins (Clbl-4) (Schwob 
and Nasmyth, 1993). In mammalian cells the variety of CDKs and cyclins create a 
more complex system. Both individual CDKs and specific cyclins are needed for 
distinct cell cycle transitions. In the following description of the CDKs and the 
cyclins only the mammalian enzymes will be discussed.
In mammalian cells the transition from GO to G1 is followed by the accumulation of 
D-type cyclins (Dl, D2 and D3) leading to the activation of CDK4 and CDK6 
(Matsushime et al., 1994; Meyerson and Harlow, 1994). In late G1 cyclin E is 
synthesized activating CDK2 (Ohtsubo et al., 1995). Both the Cyclin D and Cyclin E 
kinase complexes are essential for entry into S-phase (Baldin et al., 1993) and 
overexpression of either shortens G1 (Quelle et al., 1993; Resnitzky and Reed, 1995) 
. Cyclin A accumulates as cells enter S-phase and Cyclin A /CDK2 kinase activity is 
necessary for initiation of DNA replication (Girard et al., 1991). Both Cyclin A and 
Cyclin B can activate CDC2 (CDK1) (Murray et al., 1989; Nigg, 1992). Cyclin 
B/CDC2 is a component of the maturation promoting factor (MPF) (Gautier et al., 
1990) and the activation of Cyclin B/CDC2 triggers initiation of mitosis (reviewed 
by Dunphy, 1994). An overview of the cell cycle regulated timing of CDK activation 
is presented in figure 2.1.
16
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Cyclin A/CDC2 
Cyclin B/CDC2
Cyclin A/CDK2
pRB
Déphosphorylation
Cyclin Dl, D2 and D3 
CDK4 and CDK6
pRB
Cyclin E/CDK2 Phosphorylation
Figure 2.1 Cell cycle regulation by the cyclin dependent kinases.
CDK4 and/or CDK6 stimulate G1 progression in complex with a D-type cyclin. In late G1 Cyclin 
E/CDK2 is activated, and the activation of CDK2 by Cyclin A leads to initiation of DNA replication. 
Finally, Cyclin A and Cyclin B activate CDC2 in late S-phase and mitosis. The retinoblastoma protein 
is phosphorylated in G1 leading to activation of E2F and S-phase entry.
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Clearly, CDK activity is essential for cell cycle progression, but how the 
Cyclin/CDKs actually master cell cycle regulation is not well understood, since few 
kinase targets have been identified and characterized to date.
The best characterized substrate of the CDKs in mammalian cells is the 
retinoblastoma protein (pRB). RB-1 was the first tumor suppressor gene to be 
identified (Friend et al., 1986; Lee et al., 1987) and inactivation of the pRB pathway 
is involved in a high number of cancers (reviewed by Hunter and Pines, 1994). 
During cell cycle progression the level of phosphorylated pRB changes (see figure 
2.1). In GO and G1 the hypophosphorylated form prevails and as cell progress 
towards S-phases, pRB becomes hyperphosphorylated. (Buchkovich et al., 1989; 
Chen et al., 1989; Mihara et al., 1989; Ludlow et al., 1990; DeCaprio et al., 1992). 
Expression of pRB in pRB-/- cell lines has a growth inhibitory effect which is 
overcome by coexpression with cyclins (Cyclin D, E or A) (Hinds et al., 1992). The 
retinoblastoma protein has been shown to bind Cyclin D directly, suggesting that 
Cyclin D/CDK4 and Cyclin D/CDK6 may be the physiological kinases involved in 
pRB phosphorylation (Dowdy et al., 1993; Ewen et al., 1993; Kato et al., 1993). The 
result of pRB hyperphosphorylation is the release of E2F from the E2F-pRB 
complex allowing transcriptional activation of E2F target genes (reviewed by Helin 
and Harlow, 1993a). E2F is involved in cell cycle regulated transcription of many 
genes important for cell proliferation. These genes include Cyclin E and CDC25A 
which are primary targets of E2F essential for the G0-G1-S transition (reviewed by 
Helin, 1998). Cyclin E overexpression can overcome a cell cycle block imposed by 
pl6 (a specific inhibitor of CDK4 and CDK6, see below) or a non-phosphorylatable 
pRB mutant, suggesting that the activation of Cyclin E is the critical target activated 
by relief of pRB repression (Lukas et al., 1997).
E2F transcriptionally activates the Cyclin E (Ohtani et al., 1995; Botz et al., 1996; 
Geng et al., 1996) and Cyclin A (Schulze et al., 1995) genes leading to the synthesis
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of the Cyclin E and Cyclin A proteins and thereby activation of CDK2. Substrates of 
Cyclin E and Cyclin A kinase complexes have been identified, but it is not clear how 
this induces initiation of DNA-replication. As with Cyclin D, overexpression of 
either Cyclin E or A leads to an acceleration of the G 1/S transition (Resnitzky et 
al., 1995a; Resnitzky and Reed, 1995). Cyclin A has been localized to sites of DNA 
replication suggesting a role of Cyclin A near the replication fork (Cardoso et al., 
1993). The role of the Cyclin E/CDK2 and the Cyclin A/CDK2 complexes in 
stimulation of DNA replication was confirmed in vitro. These kinase complexes 
were shown to stimulate DNA replication in a mammalian cell free in vitro DNA 
replication system (Krude cl al., 1997). The Cyclin E and Cyclin A associated 
kinase, CDK2, has been shown to be required for centrosome duplication in Xenopus 
(Hinchcliffe et al., 1999; Lacey et al., 1999) and mammalian cells (Merialdi et al., 
1999). NPAT (nuclear protein mapped to the AT locus) was found to be a target of 
Cyclin E/CDK2 and the coexpression of NPAT with cyclin E/CDK2 led to the 
accumulation of cells in S-phase (Zhao et al., 1998), however, the molecular 
mechanism is unclear.
Both Cyclin E and Cyclin A kinase complexes interact with the pocketproteins pl07 
and p i30, homologues of the retinoblastoma protein (Ewen et al., 1992; Faha et al., 
1992; Hannon et al., 1993; Li et al., 1993). As for pRB, phosphorylation of pl07 and 
p i30 results in the release of active E2F (Beijersbergen et al., 1995). E2F is directly 
regulated by Cyclin A/CDK2. Both E2F-1 and DP-1 contain CDK phosphorylation 
sites and phosphorylation of either inhibits the DNA binding activity of the complex 
(Bandara et al., 1994; Dynlacht et al., 1994; Krek et al., 1994). Cyclin A/CDK2 is 
clearly necessary for initiation of DNA replication. Furthermore, Cyclin A is also 
required at later points during the cell cycle and for blocking mitosis until DNA- 
synthesis has been completed (Walker and Mailer, 1991; Pagano et al., 1992).
19
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The Cyclin B/CDC2 complex is part of the MPF activated in G2/M and essential for 
mitosis (Dunphy et al., 1988; Gautier et al., 1988; Gautier et al., 1990). The targets 
of Cyclin B/CDC2 are poorly characterized, but recently PRC1 (protein regulating 
cytokinesis 1) was shown to be phosphorylated on CDK phosphorylation sites and to 
be required for cytogenesis (Jiang et al., 1998). Chromosome condensation, nuclear 
envelope breakdown and the assembly of the mitotic spindles, are followed by the 
activation of the anaphase promoting complex, the APC (see below), leading to 
sister chromatid separation and destruction of the cyclins and thereby exit of mitosis.
CDK2 and CDC2 kinase activities are required for DNA replication, mitosis and 
probably also necessary for inhibition of reinitiation of DNA replication during S,
G2 and Mitosis. Treatment of Xenopus G2 nuclei with the kinase inhibitor DMAP 
allows reinitiation of DNA replication, suggesting a role for a protein kinase in 
blocking DNA synthesis in G2 (Coverley et al., 1996). The mammalian CDC2 
kinase was shown to be necessary for preventing rereplication, as inactivation of 
CDC2 in a cell line with a conditional CDC2 disruption, gave rise to polyploid cells 
(Itzhak! et al., 1997). In addition, p21, pRB and p53 have been demonstrated to be 
necessary for inhibition of DNA synthesis and cell cycle progression in cells treated 
with microtubulftdestabilizing agents (Di Leonardo et al., 1997; Lanni and Jacks, 
1998; Stewart et al., 1999). Mechanisms preventing reinitiation of replication in S, 
G2 and M, involving the homologues of CDC2 are well characterized in yeast 
(reviewed by Paulovich et al., 1997). These data provide evidence for existence of a 
similar system in mammalian cells.
The CDKs are dual specific kinases that phosphorylate serines and threonines. The 
consensus CDK phosphorylation sequence is S/T-P-X-K/R or simply S/T-P, which is 
sometimes sufficient. Several Cyclin E/CDK2 and Cyclin A/CDK2 substrates 
interact directly with the cyclin/CDK complex. A cyclin binding motif (Cy-motif) 
has been identified in several proteins shown to interact with Cyclin E and/or Cyclin
20
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A kinase complexes (Zhu et al., 1995; Adams et al., 1996; Russo et al., 1996). The 9 
amino acid sequence has been found in several proteins including the pocket 
proteins; pl07 and p i30, the cyclin dependent kinase inhibitors; p21, p27 and p57, 
E2F-1, -2 and -3. The direct binding of cyclins to the substrate suggests that the 
cyclin, besides activating the kinase also serves to bring the substrate and the kinase 
together. Indeed, a Cyclin A mutant unable to bind Cy-motif containing substrates is 
incapable of stimulating the G 1/S transition (Schulman et al., 1998). In addition to 
the targets described above, the cyclins them selves are also phosphorylated on CDK 
phosphorylation sites probably due to autocatalytic activity, which serves to 
inactivate the kinase complex (see below).
The molecular mechanism of how CDK phosphorylation actually regulates cell cycle 
progression is still unclear. In many situations phosphorylation targets the protein for 
degradation (see below). CDKs likely coordinate the progression through the cell 
cycle by phosphorylation of several target proteins that together trigger cell cycle 
transitions, The regulation of CDK activity is not achieved only by controlling 
expression of the cyclins. The kinase complexes are regulated at many levels that are 
important for proper cell cycle regulation.
21
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2.2.1 Regulation of CDKs
The activity of CDKs is regulated by several mechanisms. As mentioned above, the 
timed expression of the cyclin component is essential for the activation of the 
kinases. In addition, the kinase complex is regulated by subcellular localization, 
phosphorylation of the catalytic component, and by a group of proteins termed cyclin 
dependent kinase inhibitors (CKIs) (see figure 2.2).
The expression of the different cyclins is regulated by several mechanisms. The 
genes are transcriptionally activated at specific points during cell cycle progression. 
As mentioned above, E2F activation in G1 stimulates Cyclin E transcription and 
thereby promotes the activation of CDK2. Nuclear accumulation of Cyclin B/CDC2 
is prevented until the onset of mitosis by nuclear export of Cyclin B (Hagting et al., 
1998; Toyoshima et al., 1998; Yang et al., 1998). Finally, inactivation of CDK 
activity occurs every cycle due to ubiquitin mediated cyclin degradation (see below). 
The transcriptional activation and the regulated degradation of cyclins define short 
time intervals during cell cycle progression where the individual CDK-cyclin 
complexes are present in the cell.
In contrast to the cyclins, the expression of the CDKs changes minimally during cell 
cycle progression, but the activity of the kinases is regulated by phosphorylation of 
the catalytic subunit (see figure 2.3). Phosphorylation of Thr 14 and Tyr 15 (in 
CDC2 and homologous residues in other CDKs) by the Weel and Mikl like kinases 
inhibits the kinase activity. The CDC25 phosphatases (CDC25 A, B and C) activate 
the CDKs by removing the inhibitory phosphates (reviewed by Hunter and Pines, 
1994; Draetta and Eckstein, 1997). Phosphorylation of Thr 161 (in CDC2) by CDK 
activating kinase (CAK) activates the kinase, mainly by stabilizing the interaction 
with the cyclin component (Fesquet et al., 1993; Solomon et al., 1993; Desai et al.,
1995). This phosphorylation is reversed by the CDK associated phosphatase (KAP)
22
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(Poon and T., 1995). Changes in the phosphorylation level of the CDK subunit, due 
to up-or-down regulation of these regulatory kinases and phosphatases in response to 
environmental changes can modulate the kinase activities.
The CDKs and the cyclin-CDK complexes are inhibited by association with cyclin 
dependent kinase inhibitors (CKIs) (reviewed by Lees, 1995; Sherr and Roberts,
1995). Two families of CKIs have been described. One, composed of the pl5, pl6, 
pl8 and pl9 proteins that interact with CDK4 and CDK6 and block the cyclin 
interaction, thereby inhibiting the activation of the kinases. The second family of 
CKIs consists o f p21, p27 and p57, which have a broader Specificity due to their 
ability to bind directly to the cyclin component of the kinase (see figure 2.2). 
Overexpression of either of the CKIs arrests cells in G1 and the accumulation of one 
or more of these molecules are involved in physiological cell cycle arrests. TGF-6 
induces G1 arrest by accumulation of pl5 and p27 (Polyak et al., 1994; Reynisdôttir 
et al., 1995) and the p21 molecule is involved in cell cycle arrest due to p53 
activation in response to DNA damage (El-Deiry et al., 1993). Recently, it was 
shown that pl6 and p21 family members are in equilibrium between different kinase 
complexes, whereby a p i6 block leads to inhibition of both CDK4, CDK6 and 
CDK2 due to a redistribution of p21 to the CDK2 complexes (McConnell et al.,
1999; Parry et al., 1999). Furthermore, the level of the CDK4 and CDK6 kinase 
activities is reduced in p21"/" and p27'/- mouse embryo fibroblasts. The kinase 
activities can be restored by reintroducing the inhibitors ectopically, suggesting that 
p21 and p27 function as activators of the Cyclin D/CDK4/6 complexes (Cheng et al., 
1999).
The cyclin dependent kinases and their regulators are key targets in response to 
external stimuli since the system allows the cell to arrest at various stages of the cell 
cycle. Therefore, it is a very flexible and functional cell cycle control mechanism. 
Obviously, CDKs wouldn't be able to serve their function if their substrates were not
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regenerated, either by dephosphorylation or by destruction (see below) and de novo 
protein synthesis in the next cell cycle. The destruction of key molecules generates a 
switch in protein expression, whereas eB dephosphorylation provide a more 
economic and reversible way of altering protein activity.
The family of CDC25 phosphatases are also involved in cell cycle regulation 
(reviewed by Draetta and Eckstein, 1997). CDC25 A is required for serum starved 
cells to enter S-phase when restimulated with serum (Jinno et al., 1994) and it has 
recently been shown to be an essential target of E2F in order for E2F to induce DNA 
replication in quiescent fibroblasts (Vigo et al., 1999). As mentioned above, one role 
of CDC25 molecules is to dephosphorylate CDKs and thereby to activate the 
kinases. CDC25 A functions in G 1/S while CDC25 C acts during mitosis (Gautier et 
al., 1991).
The periodic expression of cyclins is achieved by both transcriptionally and post- 
transcriptionally regulatory mechanisms. The cell cycle regulated decrease in cyclin 
abundance is due to ubiquitin mediated degradation. The degradation pathway 
responsible for cyclin destruction is also involved in the degradation of many other 
proteins, and it is clear that regulated protein degradation controls cell cycle 
progression.
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Figure 2.2 Regulation of the cyclin dependent kinases.
The activity of the CDKs is regulated by several mechanisms. The phosphorylation state of the 
kinases and the interaction with cyclins and cyclin dependent kinase inhibitors determines the 
activity of the kinases.
25
Introduction
2.3 Cell cycle regulation by ubiquitin mediated degradation
Previously, the cellular function of the proteasome was believed mainly to be the 
removal of misfolded or damaged proteins. It is now clear that timed protein 
destruction function as a regulatory mechanism. The machinery responsible for the 
degradation of proteins has now been characterized. Most proteins are marked for 
degradation by covalent attachment of a ubiquitin-chain that targets them for 
destruction by the proteasome (reviewed by Hochstrasser, 1995).
Ubiquitination of a protein is a multi step process. Several enzymes are needed for 
the final addition of ubiquitin to the substrate (reviewed by Hershko, 1997). A 
ubiquitin activating enzyme (E l) binds ubiquitin via a thioester, ubiquitin is then 
transferred to an ubiquitin conjugating enzyme (E2 or UBC). The transfer of 
ubiquitin to the substrate normally requires a ubiquitin ligase (E3). So far only one 
E l has been identified and a modest number of E2s, whereas sequences present in 
various databases suggest that a big family of E3 ligases exist. It is therefore 
believed that the E3 is the substrate specific enzyme. Some E3 enzymes bind 
ubiquitin via a thioester whereas others facilitate the transfer of ubiquitin from an E2 
enzyme directly to the substrate. Recently, an enzyme responsible for multi-ubiquitin 
chain assembly was identified, and it is possibly the first member of an E4 family 
(Koegl et ah, 1999). Poly-ubiquitinated proteins are recognized by the 26S 
proteasome and degraded. The family of deubiquitinating enzymes (UBPs) can 
remove ubiquitin from ubiquitinated proteins, which might serve to recycle ubiquitin 
and/or have a regulatory function. So far, only two UBPs, UBP-M (Cai et al., 1999) 
and UBP-Y (Naviglio et al., 1998), have been shown to be involved in cell cycle 
regulation.
Ubiquitination of proteins at different time points during the cell cycle appears to be 
regulated by different mechanisms (reviewed by Elledge and Harper, 1998; Peters,
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1998). A group of proteins is degraded as cells enter S-phase and a second phase of 
protein destruction takes place in mitosis. The signals targeting the proteins for 
ubiquitination are different but the identification of the SCF (Skpl, Cullin or 
CDC53, and F-box) and the APC (anaphase promoting complex) as E3 ligases, and 
the similarities between the two complexes, suggest that a common degradation 
system evolved, which later specialized during evolution.
2.3.1 The SCF complex
The SCF complex is named after three of its components, namely S kpl, 
Cdc53/Cullin and an F-box protein. Cdc53 is a ubiquitin ligase (E3), and one of the 
other complex members, Cdc34, is a ubiquitin conjugating enzyme (E2). Skpl 
bridges Cdc53 and the F-box protein believed to be responsible for substrate 
recognition (reviewed by Peters, 1998). Recently, a novel member of the complex, 
Rbx 1/ROC 1, was identified. Rbx 1/ROC 1 promotes the association between Cdc53 
and Cdc34 and stimulates ubiquitination of SCF substrates (Kamura et al., 1999; 
Ohta et al., 1999; Skowyra et al., 1999; Tan et al., 1999). This last identified member 
of the SCF complex shows homology to A PC 11 (see figure 2.3. and below).
The S. cerevisiae proteins Cdc34, Cdc53 and Cdc4 are all essential for initiation of 
DNA replication and have been shown to form a complex in vivo (Mathias et al.,
1996). The human Cyclin F gene was cloned as a suppressor of a temperature 
sensitive S. cerevisiae cdc4 mutant (Bai et al., 1994), suggesting a role of Cyclin F 
related to Cdc4. Skpl binds both Cdc4 and Cyclin F. The binding regions in Cdc4 
and Cyclin F are similar and defined a new protein interaction m otif termed the "F- 
box" (Bai et al., 1996). In S. cerevisiae several F-box proteins have been identified 
and at least three have been shown to be involved in ubiquitin mediated degradation. 
Cdc4, G rrl and Met30 are all F-box proteins that are able to form a complex with
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Skpl and Cdc53 (Patton et al., 1998). In addition, F-box proteins frequently contain 
a W D40 repeat or a leucine-rich repeat believed to mediate protein-protein 
interactions and, in this situation, the association with the SCF substrates (see figure 
2.3).
Several S. cerevisiae proteins, such as the G1 cyclins (O n  1-3), have been shown to 
be short-lived and degraded at the G l/S  transition. In addition, Sic Ip, Far Ip and 
Cdc6p have been shown to be unstable protein (see below). Similarly, in S. pombe 
R um l and CdclB, functional homologues of the S. cerevisiae proteins mentioned, 
are known to be unstable proteins (see review by Elledge and Haper, 1998).
The protein sequences of the G1 cyclins contain a conserved PEST (Pro, Glu, Ser 
and Thr) motif. It has been suggested, according to the PEST hypothesis, that these 
sequences could be a stability determinant (Rogers et al., 1986). It has been shown 
that degradation of Cln2 is phosphorylation dependent (Lanker et al., 1996) and the 
minimal CDK consensus phosphorylation site, S/T-P could easily be part of a PEST 
sequence. The ubiquitination of phosphorylated Cln2 was shown to depend on 
Cdc53 (Willems et al., 1996), and mutation of the LLR in G rrl stabilizes Cln2 (Kishi 
and Yamao, 1998), demonstrating that the SCFGrrl complex targets phosphorylated 
Cln2 for degradation. The C ln 's  have a stimulatory effect on cell cycle progression, 
but the S. cerevisiae cdc53, cdc34 and cdc4 mutants arrest at the G l/S  boundary, 
suggesting that their phenotype can not be explained by a stabilization of the G1 
cyclins and that the degradation of other targets must be necessary for cells to enter 
S-phase.
The S. cerevisiae CDK inhibitor Sic Ip is phosphorylated in late G1 and thereafter 
degraded. The degradation of Sic Ip is dependent on Gin's and Cdc34 (Schneider et 
al., 1996). By reconstitution of the system in vitro using purified proteins it was 
demonstrated that Sic Ip can be ubiquitinated by SCF, and it is therefore likely, that
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the SCF is the E3 ligase responsible for ubiquitination of Sic Ip in vivo (Feldman et 
al., 1997; Skowyra et al., 1997). As for Cln2 the stability of Sic Ip is regulated by 
phosphorylation. The F-box protein responsible for Sic Ip degradation is Cdc4. A 
C ln l, Cln2 and Cln3 triple mutant is rescued by a sic l deletion (Schneider et al.,
1996) suggesting that the main role for the Cln's at the G l/S  transition is to 
phosphorylate Sic Ip, targeting the protein for degradation. Sic Ip is an inhibitor of 
the Cdc28 kinase and the degradation of Sic Ip allows activation of the S-phase 
kinase and thereby initiation of DNA synthesis (Verma et al., 1997). Similar, also in 
Xenopus the degradation of X icl, a Sic Ip homologue, is needed for initiation of 
DNA replication (Yew and Kirschner, 1997).
As mentioned above the SCF complex is conserved from yeast to higher eukaryotes. 
Skpl is homologous to p l9 SKP1 identified as a Cyclin A binding proteins in 
mammalian cells (Zhang et al., 1995). The identified complex also contained an F- 
box protein called p45SKP2. The mammalian Cdc53 protein (C ull) is a member of a 
large protein family termed Cullins and C ull has been shown to interact with SKP1 
and SKP2 demonstrating conservation of the SCF complex in higher eukaryotes 
(Lisztwan et al., 1998; Lyapina et al., 1998).
Putative targets, o f a mammalian SCF complex, are the G1 cyclins (D-type cyclins 
and Cyclin E), p27 and E2F-1. These proteins are negatively regulated by 
phosphorylation during cell cycle progression and/or degraded by the ubiquitin 
pathway (reviewed by Pagano, 1997). It is unclear if p45SKP2 is necessary for the 
degradation of these proteins, but Cyclin D l, Cyclin E and p27 are negatively 
regulated by CDKs and stabilized by mutation of a CDK phosphorylation site in the 
C-terminal (Clurman et al., 1996; Won and Reed, 1996; Diehl et al., 1997; Sheaff et 
al., 1997). Furthermore, ubiquitination of p27 was shown to depend both on 
phosphorylation and cyclin/CDK interaction (Montagnoli et al., 1999), and the 
phosphorylated p27 was found to associate with SKP2 (Tsvetkov et al., 1999). E2F-1
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degradation has been shown to be mediated by interaction of E2F-1 with SKP2, but 
to be independent of phosphorylation (Marti et ah, 1999). This indicates that the 
mammalian cell cycle is regulated by a mechanism similar to the system described in 
yeast, but that other mechanisms than phosphorylation can target proteins for 
degradation in mammalian cells. The phosphorylation sites in the putative 
mammalian SCF targets are single carboxyl-terminal CDK sites whereas in S. 
cerevisiae phosphorylation of a whole set of CDK sites is needed to stimulate 
ubiquitination and thereby degradation of the protein.
The SCF functions mainly at the G l/S  transition. This could simply be due to the 
specificity for CDK phosphorylated proteins, but the cell cycle regulated expression 
of p45SKP2 indicates that the complex itself and its ability to recognize potential 
substrates is regulated (Zhang et al., 1995). Interestingly, S. cerevisiae Skpl also has 
a function in G2/M and localizes to the kinetochore (Stemmann and Lechner, 1995; 
Connelly and Heiter, 1996). Human Cyclin F protein is expressed in S, G2 and M- 
phase, indicating that the protein could have a function in these periods of the cell 
cycle, although no functional role for Cyclin F in mammalian cells has been 
described so far (Bai et al., 1994; Bai et al., 1996). Furthermore, in S. cerevisiae 
Met30 has been shown to mediate SCF catalyzed ubiquitination of the CDK 
inhibitory kinase Swel (Kaiser et al., 1998). Likewise, W eel degradation in 
Xenopus, is dependent on Xenopus Cdc34 (Michael and Newport, 1998). These data 
indicate the function of the SCF complex is not restricted to the G l-S  transition but 
required also for initiation of mitosis, and that
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Figure 2.3 The SCF and APC complexes and their substrates.
Schematic drawing of SCF and APC illustrating their similarities. The list contains SCF and APC 
substrates in S. cerevisiae and mammals (humans), and indicates their timing of degradation and role 
in cell cycle regulation. For simplicity the term WD40 protein is used for all F-box/WD40/LLR 
proteins (see text for details).
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the specificity may change due to association with different F-box/W D40/LRR 
proteins.
Several Cdc53/Cullin family members have been identified and even more F- 
box/W D40/LLR domain containing proteins. The combinatory possibilities suggest 
that several different complexes might exist and perform similar functions. In 
mammalian cells CUL1 is the only family member found in complex with SKP1 and 
SKP2 (Michel and Xiong, 1998). In S. cerevisiae Skpl was, together with a Cdc53 
homologue and an F-box protein, found to be involved in linking a Rub-1 molecule 
to S. cerevisiae Cdc53, and thereby regulating the activity of the SCF (Lammer et 
al., 1998). The enzymatic mechanism is likely to be similar to ubiquitination, but the 
Rub 1 modification does not target proteins for degradation, Rbx 1 is part of both the 
SCF and the von Hippel-Lindau tumor suppressor complex (Kamura et al., 1999; 
Skowyra et al., 1999). The later being responsible for oxygen dependent 
ubiquitination of hypoxia-inducible factors (Maxwell et al., 1999). This 
demonstrates, that some complex members can function in several different 
complexes. The identification of several ubiquitin like proteins and the presence of 
Cullins and F-boxAVD40 proteins suggest that a general mechanism for catalyzing 
the formation of a covalent interaction between two proteins exists.
Although the SCF complex has a function at the G2-M transition, the major complex 
regulating ubiquitination as cells go through mitosis is performed by a different 
complex termed the anaphase promoting complex (APC). This complex has some 
similarity to the SCF but the recognition of the substrate seems to be differently 
regulated (reviewed by Peters, 1998; Morgan, 1999).
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2.3.2 The anaphase promoting complex
The anaphase promoting complex (APC) is a multisubunit complex of 8-12 
polypeptides identified in all eukaryotes (Yu et al., 1998; Zachariae et ah, 1998b). The 
cdclô , cdc23 and cdc27 S. cerevisiae mutants arrest in metaphase (Culotti and 
Hartwell, 1971) and a complex formed by the wild type proteins is required for mitosis 
(Lamb et ah, 1994). None of the APC complex members are able to form a high 
energy thioester with ubiquitin, suggesting that the complex function by assisting the 
transfer of ubiquitin from an E2/UBC to the target protein. UBCx and the human E2- 
C/UbcHlO regulate progression through mitosis (Yu et ah, 1996; Townsley et ah,
1997), likely, by stimulating ubiquitination of APC substrates, while an S. cerevisiae 
APC specific E2 has not been identified, yet. The components of the anaphase 
promoting complex have been identified in several organisms and for simplicity 
renamed APC 1-12. Interestingly, APC2 shows similarity to the Cdc53/Cullin family 
of proteins (Yu et ah, 1998; Zachariae et ah, 1998b) shown to interact with the E2 
enzyme of the SCF (see above and figure 2.3). Further homology between SCF and 
APC components was noticed recently, as the characterization of Rbx 1/ROC 1 showed 
that it is homologous to A PC 11 (Kamura et ah, 1999; Ohta et ah, 1999; Skowyra et ah, 
1999; Tan et ah, 1999).
The best described APC substrates are the S-phase and mitotic cyclins. Cyclin B was 
shown to be degraded by the ubiquitin-pathway and a conserved peptide sequence 
was identified in Cyclin A and B from several species, and shown to be necessary 
for mitotic degradation of Cyclin B (Glotzer et ah, 1991). The peptide m otif was 
termed a destruction box (D-box). More recently, similar sequences have been 
identified in several short-lived proteins degraded in mitosis (see below). The protein 
complex containing the C d c l6 , Cdc23 and Cdc27 proteins was shown to be needed 
for sister chromatid separation and ubiquitination of Cyclin B (Irniger et ah, 1995; 
King et ah, 1995). Strikingly, mutation of APC subunits results in cell cycle arrest at
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the metaphase to anaphase transition. This arrest can not be explained by 
stabilization of Cyclin B, since Cyclin B destruction is not necessary until exit of 
mitosis (Holloway et ah, 1993; Surana et ah, 1993; Yamano et ah, 1996). An 
inhibitor of anaphase progression, Pdslp  (precocious dissociation of sister 
chromatids), has been identified in S. cerevisiae (Yamamoto et ah, 1996). 
p d s llc d c lô  and pdsl/cdc23  double mutants arrest at the end of mitosis suggesting 
that the APC is dispensable for metaphase to anaphase progression when Pdslp  is 
inactivated (Yamamoto et ah, 1996). The degradation of P dslp  is needed for sister 
chromatid separation and the ubiquitination and the following degradation of P dslp  
by the APC and the proteasome is dependent on the destruction box sequence in 
P dslp  (Cohen-Fix et ah, 1996). Similarly, in S. pombe, a functional homologue of 
Pdslp , Cut2 has been identified and shown to be degraded in the beginning of 
mitosis (Funabiki et ah, 1996). Cut2 contains two destruction box sequences needed 
for ubiquitination in vitro (Funabiki et ah, 1997).
Expression of stable Pdslp  and Cut2 mutants, in which the destruction sequences had 
been mutated, led to cell cycle arrest before anaphase initiation (Cohen-Fix et ah, 
1996; Funabiki et ah, 1996). Non degradable mutants of Cyclin B arrest cells at a 
later point in mitosis defining a timing of degradation within mitosis of different 
proteins. A Xenopus protein, Geminin, was shown to be unstable in mitotic extracts 
and to contain a D-box sequence necessary for ubiquitination in vitro (McGarry and 
Kirschner, 1998). When Xenopus embryos were injected with a plasmid encoding a 
stable mutant of Geminin, DNA replication was inhibited but the expression of the 
protein allowed cell division to take place several times without intervening DNA 
synthesis (McGarry and Kirschner, 1998). This suggests that Geminin is an inhibitor 
of DNA replication that is degraded in mitosis and thereby involved in the restriction 
of DNA synthesis to once and only once per cycle. The roles of APC in cell cycle 
regulation are diverse and the coordination of the ubiquitination activity is regulated 
by several mechanisms.
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The sequential degradation of proteins containing D-box sequences suggests that 
different proteins must be involved in recognition of the substrates. As for the SCF 
complex, proteins containing WD40 repeats have been suggested to mediate the 
interaction between the substrate and the APC. The yeast proteins Cdc20 and 
H ctl/C d h l, and homologues in other species, activate the APC (Visintin et al., 1997; 
Fang et al., 1998b; Kramer et al., 1998). In addition, the different W D40 proteins 
have been shown to target different subgroups of proteins for degradation (see figure 
2.3). Cdc20 activates the ubiquitination of P dslp  while H ctl/C dhl directs 
ubiquitination of the mitotic cyclins (Schwab et al., 1997; Visintin et al., 1997; 
Zachariae et al., 1998a). Likewise, mammalian homologues of Cdc20 (p55cdc) and 
C dhl (hC D H l/hH C T l) were shown to activate the ubiquitination activity of the 
human anaphase promoting complex (Fang et al., 1998b; Kramer et al., 1998).
The association of Cdc20 and H ctl/C dhl with the APC and the activity of the 
formed complex is controlled by several mechanisms. The expression of p55cdc in 
human cells is cell cycle regulated peaking in mitosis whereas hC D H l/hH C T l is 
present throughout the cell cycle (Weinstein et al., 1994; Fang et al., 1998b; Kramer 
et al., 1998). Mad2 will, as a tetramer, block the ability of p55cdc to activate APC 
(Fang et al., 1998). This interaction is probably part of a checkpoint, but is also 
relevant for regulation of normal cell cycle progression (Wassmann and Benezra,
1998). The interaction of H ctl/C dhl with APC is negatively regulated by CDK 
dependent phosphorylation (Jaspersen et al., 1998; Zachariae et al., 1998a). This 
phosphorylation is reversed by the action of C dcl4 , stimulating the degradation of 
the mitotic cyclin (Jaspersen et al., 1998; Visintin et al., 1998). The result is, that 
Cdc20 interacts and activates APC in the beginning of mitosis and that H ctl/C dh l is 
needed for the activity of APC from exit of mitosis until it is inactivation in late G l. 
Ubiquitination and subsequent degradation of APC substrates is initiated as cells 
progress through mitosis, but the APC has been shown to remain active in G l and 
interestingly also in quiescent cells (Brandeis and Hunt, 1996). H ctl/C dhl associates
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with APC in G l and ensures that none of the APCHctl targets accumulate during this 
period. Though in G l, APC prevents the accumulation of mitotic cyclins but not the 
G l cyclins and the APC thereby controls the protein level of the different cyclins.
Thus, it appears that the degradation system switches from SCF to APC at the 
beginning of mitosis and back again at the G l-S  transition. The changes are 
paralleled by the periodic kinase activities and the two regulatory mechanisms are 
interconnected. The resulting oscillation of kinase activities in combination with 
timed degradation of specific proteins enables the cells to coordinate the duplication 
of the genome and chromosome separation.
In early G l, kinase activity is kept low, in part, by an active APC. As the G l cyclins 
accumulate the activated kinases may trigger the inactivation of the APC and the 
activation of SCF at the G l/S  transition. The SCF is active in the period with high S- 
phase kinase activity. When cells enter mitosis the APC is activated first by Cdc20 
and then by C dhl, correlating with the inactivation of SCF. The destruction of the S- 
phase and mitotic cyclins brings the cells back to start (see figure 2.4). Several 
cellular processes are dependent on either activity. W ithin the time windows, of high 
or low kinase activity, or high or low SCF and APC activity, the cells prepare for 
and execute DNA replication and mitosis. DNA replication and mitosis are thereby 
separated and fully controlled. As seen below, these changes restrict the formation of 
the preReplication Complex and the preinitiation Complex to specific points during 
the cell cycle separated from the period of DNA synthesis.
36
Introduction
C dc20
APC Cdh1APC
Metaphase-
anaphase
transition
Exit from 
mitosis
G ,/S
Transition
Clb-CDK
Cln-CDK
CDK
SCF/
APC
TimePro Meta Ana Telo
Cell cycle 
phase
Chromosome oococoe- 
status \  J " W
Current Opinion in Cell Biology
Figure 2.4 Schematic view of CDK, SCF and APC (Peters, 1998). The accumulation of G l cyclins 
and the activation of SCF lead to the destruction of Sic Ip and thereby activation of the S- and M- 
phase kinases. The activation of Gl and S-phase kinases may be responsible for inactivation of APC 
and the activation of SCF at the G l-S transition. In mitosis, APC is activated by Cdc20 and later 
C dhl/H ctl. This lead to sister chromatid separation and following exit from mitosis as the mitotic 
cyclins are degraded.
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2.4 Regulation of DNA replication
The yeast strain S. cerevisiae has to date been the most useful system to study the 
regulation of eukaryotic DNA replication. This is due to the identification of 
individual origins of replication and origin consensus sequences defined as 
autonomously replicating sequence (ARS) elements (Marahrens and Stillman, 1992; 
Rao et al., 1994). Similarly, DNA replication in S. pombe depends on defined 
sequences although the ARS element identified are larger than in S. cerevisiae 
(Clyne and Kelly, 1995) . This allows elucidation of origin function on artificial 
chromosomes. Xenopus egg extracts have also been used to study the mechanisms 
regulating DNA replication as they support one round of semi conservative sequence 
non specific DNA replication in vitro (Blow and Laskey, 1986).
An understanding of how mammalian cells regulate the duplication of their genomes 
has been more difficult to obtain, but some progress has been made in the 
identification of origins also in higher eukaryotes. Several potential origins of 
replication have been identified in the mammalian genome (reviewed by Huberman,
1995), but so far no consensus sequence motifs have been identified. CpG islands 
have been shown to be potential initiation zones (Delgado et al., 1998). Sequence 
dependent replication of the human 6 -Globin locus suggests that sequence specific 
origins of replication also exists in mammalian cells (Aladjem et al., 1998). The 
conservation of molecules involved in DNA replication from yeast to higher 
eukaryotes suggests that the mechanism regulating chromosomal duplication is 
conserved throughout evolution (reviewed by Dutta and Bell, 1997).
The restriction of DNA synthesis to the S-phase of the cell cycle is regulated by 
several mechanisms. Cell fusion experiments originally showed that a G l nucleus 
will replicate when fused to an S-phase cell whereas a nucleus from a G2 cell will 
not (Rao and Johnson, 1970). This suggests that the chromosomes in a G l cells are
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able to replicate upon stimulation, whereas the DNA in a G2 cell is significantly 
different and unable to replicate under the same conditions. Experiments in Xenopus 
egg extracts demonstrated that the ability to replicate depends on progression 
through mitosis and the succeeding breakdown and reformation of the nuclear 
membrane (Blow and Laskey, 1988). A model of replication licensing was suggested 
(see review by Tada and Blow, 1999). During mitosis, chromosomes are exposed to 
cytoplasmic proteins needed for DNA replication, the licensing factor, as S-phase 
proceeds the licensing factor is removed from DNA. The data also demonstrated a 
dependence on nuclear membrane formation for activation of DNA replication, 
separating the licensing of replication and the activation of DNA synthesis (Blow 
and Laskey, 1988). The role of the nuclear membrane could be to concentrate DNA 
replication activating factors and at the same time to prevent re-licensing of the 
DNA. Recent data provide further evidence for this hypothesis as an in vitro 
replication system using a highly concentrated nucleoplasmic extract from Xenopus 
eggs was shown to support DNA replication without the formation of a nuclear 
membrane (W alter et al., 1998). To understand the regulation of DNA replication it 
is essential to identify the proteins interacting with the origins of replication and to 
elucidate their function.
2.4.1 The Origin Recognition Complex
A multisubunit complex capable of binding a S. cerevisiae ARS sequence in vivo 
was identified (Bell and Stillman, 1992; Diffley and Cocker, 1992) and logically 
termed the origin recognition complex (ORC). Cell cycle regulated changes in 
DNase sensitivity of the origin sequence defined the pre- and postReplication 
Complex (Brown et al., 1991; Diffley et al., 1994). The footprint observed in S- and 
M -phase arrested cells, resembled the footprint observed when ORC was bound to 
the origin sequence in vitro, and is characterized as the postReplication Complex. In
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G l an extended footprint was observed, probably due to association of additional 
factors, and this complex was termed the preReplication Complex.
The Origin Recognition Complex identified in S. cerevisiae consists of 6 subunits 
named Orclp-Orcôp. Homologues have been identified in several species, although 
it is not known if they, as the S. cerevisiae molecules, physically interact with origin 
sequences (reviewed by Dutta and Bell, 1997). Mammalian homologues of all the 
ORC genes have now been identified (Gavin et al., 1995; Takahara et al., 1996;
Ishiai et al., 1997; Quintana et al., 1997; Quintana et al., 1998; Tugal et al., 1998). 
This makes it possible to test the function of the ORC components also in higher 
eukaryotes. The binding of ORC to DNA was initially demonstrated to be ATP 
dependent (Bell and Stillman, 1992) and the presence of ATPase domains in Ore Ip, 
Orc4p and Orc5p suggests that ATP binding and hydrolysis control ORC function. 
The important role of the ATPases has been demonstrated by mutagenesis of 
conserved residues in the ATPase domains leading to reduced activity of the proteins 
(Bell et al., 1995; Loo et al., 1995). The binding of ATP stimulate ORC association 
with the origin of replication, and this binding inhibits the ATP hydrolysis activity of 
Ore Ip (Klemm et al., 1997). The mammalian homologues of O rel, Orc4 and Orc5 
also contains putative ATPase domains (Gavin et al., 1995; Ishiai et al., 1997; 
Quintana et al., 1997; Quintana et al., 1998; Tugal et al., 1998). Furthermore, two 
alleles of the human ORC5L gene were identified encoding hOrc5 proteins with and 
with out the ATP binding site. The human ORC5 gene was found to be deleted in 
some tumors, suggesting a regulatory role of hOrc5 (Quintana et al., 1998). 
Interestingly, Orc5p in S. cerevisiae has been shown to be needed both at the G l/S  
transition and in mitosis suggesting a double role for ORC proteins in cell cycle 
regulation (Dillin and Rine, 1998).
In yeast the origin recognition complex binds DNA throughout the cell cycle. The 
extended DNA footprint observed in G l cells suggested that a larger complex is
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associated with origin sequences before DNA replication is initiated. The 
preReplication Complex is formed during mitosis and is dissociated as cells go 
through S-phase. According to the licensing hypothesis (see above) this would 
correspond to the expected behavior of a DNA replication licensing factor.
2.4.2 Cdc6p and CdclS molecules
The connection of Cdc6p and CdclS molecules to the regulation of DNA replication 
or more precisely to the formation of the preReplication complex, comes mainly 
from studies in yeast. The S. cerevisiae CDC6 and S. pombe C d cl8 + genes are 
essential for cell viability and deletion of either inhibit DNA replication suggesting 
that their encoded proteins are necessary for S-phase entry (Hartwell, 1976; Nurse et 
al., 1976) . The role of Cdc6p and CdclS in cell cycle regulation is more 
complicated as both proteins are also needed to block mitosis in the absence of DNA 
replication (Kelly et al., 1993; Piatti et al., 1995).
Transcription of the CDC6 gene is cell cycle regulated by Swi5 and Swi6 dependent 
mechanisms (Piatti et al., 1995). Likewise, the C d cl8 + gene is transcriptionally 
regulated by CdclO in S. pombe (Kelly et ah, 1993). Both Cdc6p and CdclS are 
highly unstable proteins with cell cycle regulated expression pattern. De novo 
protein synthesis of Cdc6p and CdclS is required in G l and the expression declines 
in S-phase (Piatti et al., 1995; Muzi-Falconi et al., 1996).
Cdc6p and CdclS proteins are essential for initiation of DNA replication (Nishitani 
and Nurse, 1995; Piatti et al., 1995). Cdc6p is essential for establishment and 
maintenance of the extended footprint observed in G l on an ARS sequence, 
indicating that Cdc6p together with the ORC is part of the postReplication Complex 
or promotes its formation (Cocker et al., 1996). The Cdc6p and CdclS proteins were
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shown to interact directly with the Origin Recognition Complex (Liang et al., 1995; 
Leatherwood et al., 1996) and to be subjected to regulation by CDKs through direct 
association with a CDK kinase complex. S-phase CDK activity inhibits Cdc6p and 
C dclS  activity by blocking the ability of Cdc6p and CdclS to stimulate DNA 
replication (Piatti et al., 1996; Brown et al., 1997). Cdc6p stimulates binding of 
minichromosome maintenance (MCM) proteins (see below) to origins of replication 
(Donovan et al., 1997; Tanaka et al., 1997). This suggests, that Cdc6p and likely 
C dclS  function by recruiting other molecules necessary for DNA replication to the 
origin of replication.
W hen overexpressed, CdclS activates DNA-replication in the absence of intervening 
mitosis resulting in endoreplication (Nishitani and Nurse, 1995; Muzi-Falconi et al.,
1996). The rereplication phenotype is enhanced by overexpression of ru m l+, 
confirming that CDK activity inhibits the ability of Cdc 18 to stimulate initiation of 
DNA replication (Nishitani and Nurse, 1995; Jallepalli and Kelly, 1996). 
Overexpression of Cdc6p does not stimulate rereplication but overexpression of a 
CDC6 mutant (CDC6-3) stimulates rereplication (Liang and Stillman, 1997), 
suggesting that Cdc6p also plays a direct role in restricting DNA replication to once 
and only once per cycle.
All CDC6 homologues contain an ATPase domain as do some of the ORC proteins 
and the members of the MCM complex (see below). The ATPase is needed for 
Cdc6p and CdclS to stimulate DNA replication and for recruitment of MCM 
proteins to DNA (Perkins and Diffley, 1998; Greenwood et al., 1998; W einreich, 
1999). Destruction of the W alker A m otif by changing the conserved lysine to 
alanine resulted in a temperature sensitive mutant whereas an glutamate substitution 
was lethal. The defect was explained by the inability of Cdc6p to load MCM proteins 
onto origins of replication (Perkins and Diffley, 1998; Wang et al., 1999; W einreich, 
1999), impaired by the disruption of the Cdc6p Ore Ip interaction (Wang et al.,
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1999). Alanine substitution of the aspartic acid and glutamic acid residues in the 
W alker B motif had no effect on cell viability (Weinreich, 1999), whereas mutation 
of the aspartic acid to glycine resulted in a dominant negative mutant (Perkins and 
Diffley, 1998). Interestingly, the cdc6 mutant cdc6-3 that stimulates rereplication 
contains a mutation in a low homology region close to the W alker A motif of the 
ATPase domain (Liang and Stillman, 1997; Neuwald, 1999).
The role of Cdc6p and CdclS in blocking mitosis is less well understood. The 
binding of C dclS  to the M-phase CDK suggested that the interaction could directly 
inhibit kinase activity and thereby, progression into mitosis (Brown et al., 1997). 
Recent data suggests that the interaction of the N-terminal region of C dclS  with the 
CDK does block mitosis, however, a CdclS molecule with an N-terminal deletion 
lacking the CDK binding region is also able to block mitosis (Greenwood et al., 
1998). The mitotic arrest induced by this CdclS mutant is dependent on the ATPase 
domain and requires the check point genes cut5, rad and hus (Greenwood et ah, 
1998). The Cdc6p mutant with a lysine to alanine mutation in the W alker A m otif 
arrests in G l, but a double mutant also lacking the N-terminal part enters mitosis 
with non-replicated DNA (Weinreich, 1999). The ability of Cdc6p and C dclS  to 
block mitosis depend on their ability to interact with the CDK and on their ability to 
support initiation of DNA replication. The temperature sensitive CDC6-3 allele 
allows the cells to rereplicate their DNA, probably by constant loading of MCM 
proteins even in the presence of high CDK activity (Liang and Stillman, 1997). 
Homologues of Cdc6p and CdclS have now been identified in higher eukaryotes. 
The human CDC6 protein is 31% and 34 % identical to Cdc6p and CdclS 
respectively (Williams et al., 1997). The Xenopus CDC6 homologue is 65 % 
identical to human CDC6 and the region with the highest degree of homology 
contains the central ATPase domain (Coleman et al., 1996; W illiams et al., 1997). 
The role of CDC6 in mammalian cell cycle regulation is less well understood but
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both human and Xenopus CDC6 proteins have been shown to be essential for DNA 
replication (Coleman et ah, 1996; Hateboer et al., 1998; Yan et al., 1998).
The role of Cdc6p and Cdc 18 and their homologues in other species, is likely to 
assist the origin recognition complex in recruiting other molecules needed for 
initiation of DNA synthesis to origins of replication. The formation of the 
preReplication Complex is regulated by the availability of the different cellular 
factors and controlled by the cyclin dependent kinases.
2.4.3 The preReplication Complex
In S. cerevisiae the preReplication complex is formed as cells progress through 
mitosis as demonstrated by the change in the DNA footprint on ARS sequences 
(Brown et ah, 1991; Diffley et ah, 1994). Today, the preReplication Complex is 
believed to consist of the ORC, Cdc6p, and MCM 2-7 (reviewed by Newlon, 1997; 
Leatherwood, 1998). The CDC6 gene is needed for the formation of the 
preReplication Complex in S. cerevisiae (Cocker et ah, 1996). More specifically, 
Cdc6p is necessary for loading of MCM proteins to origins of replication in S. 
cerevisiae (Donovan et ah, 1997; Tanaka et ah, 1997), and for recruitment of MCM 
proteins to DNA in Xenopus egg extracts (Coleman et ah, 1996). It is still not clear if 
the association of Cdc6p and MCM proteins with origins of replication directly 
causes the extended footprint observed on the ARS sequence before initiation of 
DNA replication.
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4.4.3.1 Minichromosome maintenance proteins
The existing model describing the pre- and postReplication complexes is based on 
experiments performed in yeast and Xenopus extracts. Originally the MCM proteins 
from yeast were identified in genetic screens for genes involved in cell cycle 
regulation and DNA replication (Maine et al., 1984). The family of MCM proteins 
consists of 6 polypeptides, which have a central homology domain. The region of 
homology contains an ATPase domain also identified in some of the Ore proteins. 
MCM2, 4, 6 and 7 share a zinc finger motif similar to DNA-binding domains but the 
function is not yet known (reviewed by Kearsey and Labib, 1998). Initial 
experiments showed that the subcellular localization of the MCM proteins is cell 
cycle regulated, correlating with their ability to support DNA replication as a 
licensing factor following the licensing model (reviewed by Kearsey and Labib,
1998). The Xenopus MCM3 protein was identified as a component of the replication 
licensing factor (RLF-M) and shown to be essential for DNA replication (Chong et 
al., 1995; Kubota et al., 1995; Madine et al., 1995). The cell cycle regulated 
chromatin association of Xenopus MCM proteins was shown to be dependent on 
X O R C 1 (Romanowski et al., 1996; Rowles et al., 1996). A six subunit complex 
containing all six MCM family members was identified in Xenopus egg extracts 
(Kubota et al., 1997; Thommes et al., 1997). Interestingly, two XM CM 6 gene have 
been identified, and shown to be differentially regulated during development (Sible 
et ah, 1998). The mammalian MCM3 and MCM7 homologues were identified as 
DNA polymerase a  associated proteins (Thommes et al., 1992), whereas the other 
mammalian MCM molecules were identified due to their sequence similarity to the 
yeast MCM proteins. As is the case for the yeast and Xenopus molecules, several of 
the mammalian MCM proteins have been shown to be needed for DNA replication 
(reviewed by Kearsey and Labib, 1998). In all higher eukaryotes six different MCM 
proteins are found, defining six families of MCM proteins across species. This
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suggests that the different MCM proteins have non-redundant functions and that the 
integrity of the complex(es) is important.
The exact function of the MCM proteins is not known. Besides the ability of the 
MCM proteins to form one six subunit complex, two subcomplexes have been 
observed. Xenopus MCM3 and MCM5 interact with each other while XMCM2, 
XMCM 4, XM CM 6 and XMCM7 form a different complex (Thommes et al., 1997).
It was suggested that the complex composition and DNA interaction is cell cycle 
regulated (Coué et al., 1998). Similar subcomplexes have been observed in 
mammalian cells (Fujita et al., 1997) and the MCM2, 4, 6 and 7 complex was shown 
to bind histone H3 (Ishimi et al., 1996). An MCM4, M CM 6 and MCM7 complex 
was shown to have DNA helicase activity (Ishimi, 1998a) which was inhibited by 
M CM2 (Ishimi et ah, 1998b). Therefore, the function of the MCM complex as a 
replicative DNA helicase regulated by MCM2 binding is an attractive model.
The phosphorylation of several MCM proteins is cell cycle regulated. 
Phosphorylation of MCM2 and MCM4 by CDC2/Cyclin B inhibits the association of 
the MCM complex with chromatin in mammalian cells (Hendrickson et ah, 1996; 
Fujita et ah, 1998). A second kinase complex, Cdc7/Dbf4 is essential for DNA 
replication and is thought to interact with origins of replication in S. cerevisiae 
(Dowell et ah, 1994). Both yeast Cdc7 and the mammalian homologue hCDC7 can 
phosphorylate MCM2 and MCM3 in vitro (Lei et ah, 1997; Sato et ah, 1997; 
Kumagai et ah, 1999). S. cerevisiae Cdc7/Dbf4 also phosphorylate MCM4 and 
M CM 6 in vitro and MCM2 in vivo at the G l-S  transition. The role of MCM 
phosphorylation could be to regulate the ability of the complex to bind DNA, to 
interact with other proteins needed for DNA replication, or to regulate the activity of 
the complex itself. It is tempting to speculate that the MCM2 phosphorylation 
relieves the inhibition of the helicase and thereby activates DNA synthesis. Genetic 
data from S. cerevisiae demonstrates that an mcm5 mutant {bob-1) can bypass the
46
Introduction
need for Cdc7 (Hardy et al., 1997) suggesting that phosphorylation of one or more 
proteins affects the activity of the complex, possibly by introducing conformational 
changes, which are not required in the mcm5 mutant.
The MCM proteins interact with chromatin in a cell cycle regulated manner, and the 
interaction with origin sequences in S. cerevisiae is dependent on ORC and Cdc6p 
(Aparicio et al., 1997; Donovan et al., 1997; Tanaka et al., 1997). As described 
above, ORC will bind directly to the origin sequences and the binding is very 
efficient as the number of ORC proteins equals the estimated number of origins in S. 
cerevisiae (Rowley et al., 1995). In contrast, many MCM complexes can bind DNA 
per replication origin in S. cerevisiae (Lei et al., 1996). Also in Xenopus extracts the 
chromatin bound MCM complexes are in excess to the chromatin bound ORCs 
(Mahbubani et al., 1997). Evidence exists, suggesting that ORC and MCM do not 
form one large stable complex. This was shown by the ability to release ORC and 
CDC6 proteins from chromatin leaving the MCM proteins bound (Donovan et al., 
1997; Hua and Newport, 1998). To examine the DNA associated ORC and MCM 
complexes human MCM and ORC proteins were immunoprecipitated from 
preparations of cross-linked nucleoproteins. This experiment showed no 
coimmunoprecipitation of ORC and MCM proteins (Ritzi et al., 1998), indicating 
that the proteins are not bound to the same DNA fragments. Finally, the ability of a 
Cdc6p mutant (E224G) to establish the G 1 in vivo footprint on an origin of 
replication without recruitment of MCM proteins, suggests that the MCM 
association with origins of replication does not directly reflect the periodic changes 
in DNA-protein interactions on origin sequences in S. cerevisiae (Perkins and 
Diffley, 1998). The binding of MCM proteins to the origins of replication might be a 
transient event. Sequence homology between O rel, Orc4, Orc5 and Cdc6p with 
replication factor C (RFC) suggests that their function might be similar. The RFC 
complex function as a clamp loader of PCNA (reviewed by Tsurimoto, 1998) and 
the role of ORC and CDC6 could be to load the MCM proteins on DNA (Perkins
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and Diffley, 1998; Neuwald, 1999) where after MCM association with chromatin is 
independent of ORC and CDC6 .
2.4.4 The preinitiation Complex
Recently, another replication intermediate complex was described. The S. cerevisiae 
Cdc45p protein was shown to associate with MCM proteins and to be essential for 
DNA-replication (Hopwood and Dalton, 1996). Furthermore, the binding of Cdc45p 
was observed only after Cdc6p release and was shown to be dependent on nuclear 
membrane formation and S-phase CDK activity (Aparicio et al., 1997; Zou and 
Stillman, 1998). The Xenopus XCDC45 molecule was shown to interact with DNA 
polymerase a (pol a) and to mediate the pol a chromatin interaction (M imura and 
Takisawa, 1998). This may also be the case in mammalian cells describing the 
missing link between MCMs and pol a, as the initial observed association between 
MCMs and polymerase a has not been shown to be a direct interaction. In contrast, 
with the above, the association of S. cerevisiae pol a is inhibited by S-phase kinase 
activity and is independent on the formation of the preReplication Complex 
(Desdouets et al., 1998). This may indicate that the recruitment of pol a to chromatin 
is differently regulated in yeast and higher eukaryotes.
W hen DNA replication is activated by Cdc7/Dbf4, Cdc45p and MCM proteins are 
released from the replication origin. Cdc45p and some of the MCM proteins stay 
associated with chromatin and become associated with DNA sequences distant from 
the origin of replication with kinetics similar to proteins know to be associated with 
the moving replication fork (Aparicio et ah, 1997; Mimura and Takisawa, 1998; Zou 
and Stillman, 1998). Origins of replication are not activated synchronously at the 
G l-S-transition, but some origins fire in early S and others in mid-and late S-phase 
(see review by Fangman and Brewer, 1992). The ability of the later origins to fire is
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dependent on Cdc7/Dbf4 kinase activity throughout S-phase (Bousset and Diffley, 
1998; Donaldson et ah, 1998).
The extensive control of the formation of different initiation intermediates ensures 
that the cell can replicate its DNA only once during each cycle. The cell cycle 
regulatory mechanisms involved in DNA replication are summarized in figure 2.5. 
The dependence of each step for changes in protein expression and kinase activity, 
compared to the previous step, leads to the fine-tuning of DNA replication. The 
origin recognition complex is, in yeast associated with chromatin throughout the cell 
cycle. In mitosis or early G l, Cdc6p /C d c l8 associates with ORC and mediates the 
loading of MCM proteins. Subsequently, Cdc45p joins the complex. Loading of 
MCM proteins by Cdc6 is inhibited by S-phases kinase activity, whereas the next 
step, the binding of Cdc45 is dependent of S-phase CDK activity. The preinitiation 
complex is then assembled and initiation of DNA replication is dependent on the 
activation of the Cdc7/dbf4 kinase complex.
The overall regulation of the cell division cycle is a result of a complex network of 
interacting regulatory mechanisms. As described above the preReplication 
Complexes and preinitiation Complexes are buildup in G 1. As cells progress through 
S-phase the components of the replication complexes are released from DNA. The 
reformation of the preRC and preIC is dependent on the inactivation of the S and M 
phase kinases and thereby on the progression through mitosis. The SCF and the APC 
controls DNA replication by controlling the availability of activators (Cdc6p and 
cyclins) and inhibitors (Geminin) of DNA replication. Thereby, SCF and APC 
contribute to the regulation of DNA replication by setting up the periodic changes 
that control chromosomal duplication and sister chromatid separation.
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Figure 2.5 Control of DNA replication by CDKs, SCF and APC.
The current model of eukaryotic DNA replication suggests that the origin recognition complex 
associates with origins of replication throughout the cell cycle. Cdc6p recruits MCM proteins to 
chromatin. The binding of MCM proteins is inhibited by S-phase kinase activity, in contrast, the next 
step, binding of Cdc45 requires activation of the S-phase CDK and possibly the release of Cdc6p. 
Activation of the CDC7/dbf4 kinase complex can now triggers initiation at individual origins at 
dillerent time. The high level of kinase activity in S, G2 and M prevents reformation of the 
preReplication Complex. The model is based on data obtained in yeast. The regulation of DNA 
replication in mammalian cells might be different as discussed in the text.
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3. Materials and methods
3.1 Materials
3.1.1 Molecular Biology
3.1.1.1 Medium, plates and antibiotics
Luria-Bertani medium (LB): 10g/l Casein hydrolysate peptone
5g/l Yeast extract 
pH 7.5
LB plates: LB
15 g/1 Bacto agar 
Antibiotics
NZY medium: 10 g/l NZ amine (casein hydrosylate)
5 g/1 NaCl 
5 g/1 Yeast extract
1 g/1 Casa amino acids
2 g/1 M gS 04 71120
pH 7.0
NZY medium 
15 g/1 Bacto agar 
NZY medium 
7 g/1 Agarose
NZY Pates:
NZY top agaros:
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Additive Stock Final concentration
Ampicillin (Amp) 50 mg/ml 100 pg/ml
Kanamycin (Kana) 10 mg/ml 20pg/ml
Tetracyclin (Tet) 5 mg/ml 10 pg/ml
IPTG 1 M 0.2 mM
X-gal 20 mg/ml 0.1 mg/ml
Table 3.1 Additives (bacterial culture)
List of antibiotics and other chemicals used. The stock 
concentration and the final concentration in use are listed.
3.1.1.2 Bacterial strains
D H 5aF :
LE392:
XLmutS:
XL 1-Blue:
F' /endA1 hsdR17 (ïy/ w k * )  supE44 thi-1 recAl gyrA (Nalr) 
relA l A(lacZYA-argF)ui69 (m80lacZAM15 ) 
supE44 supF58 lacY hsdR514 ïK~mK+) galK2 galT22 m etB l 
trp55 mcrA
A(mcr) 183 A(mcrCB-hsdSMR-mrr) 173 endA l supE44 thi-1 
gyrA96 relA l lac mutS::TnlO (teV)(F'proABlacFZAM 15 Tn5 
(Kanr))
recAl endAl gyrA96 thi-1 hsdR17 supE44 relA l lac 
(F'proABlacFZAM 15 TnlO  (tetr))
3.1.1.3 Competent cells
Transformation buffer 1 (TF1): 30 mM KO Ac
100 mM RbCli 
10 mM Ca CI2 
50 mM M nCl]
15 % v/v glycerol 
pH 5.8
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Transformation buffer 2 (TF2): 10 mM MOPS 
75 mM CaCl2 
10 mM RbCla 
15 % v/v glycerol 
pH 6.5
3.1.1.4 DNA
Solution 1 (Sol 1): 50 mM Glycose
10 mM EDTA
25 mM Tris-HCl pH 8.0
Solution 2 (Sol 2): 0.2 M NaOH
1 % SDS
Solution 3 (Sol 3): 60 ml 5 M potassiun acetate
11.5 ml glacial acetic acid 
(3 M K+, 5 M acetate)
Phenol/Chloroform mix: Phenol/Chloroform/ Isoamylalcohol (25:24:1) 
Phenol (pH 8.0)
8-Hydroxylquinoline
TE: 10 mM Tris-HCl pH8.0
1 mM EDTA
TEA: 0.04 M Tris-acetate pH 8.5 
0.001 EDTA
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DNA-loading buffer (6x): 50% Glycerol
12.5 mM EDTA pH 8.0 
0.25 % Bromophenol blue 
0.25 % Xylene cyanol FF
3.1.1.5 Plasmids
Name Reference
pCM VCyclin E (Hinds et al., 1992)
pCM VCyclin A (Hinds et al., 1992)
pGEX4Tp 107(252-816) (Ewen et al., 1992)
pC M V H A plô (Petersen et al., 1999)
pCM VCD20 (van den Heuvel and Harlow, 1993)
pGEM Cyclin E (Dulic et al., 1992)
pGEM Cyclin A (Pines and Hunter, 1989)
pGEMCyclin B 1 (Pines and Hunter, 1989)
pCM VM YEGFP (Helin, unpubl.)
pCM VneoBam (Baker et al., 1990)
pCMVHADP-1 (Helin et al., 1993b)
pCM VHANLSE2F-4 (Müller et al., 1997)
pMT123 (HA-ubiquitin) (Treier et al., 1994)
Table 3.2 Plasmids.
List of plasmids used, and their references.
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3.1.1.6 Primers
EST 1 5'-CTAGGATCCTCAGGAGATGTTCGCAAAGC-3'
EST 2 5-C T  AGGATCCTGGCTTCCAAG AGCCCTG
GDI 5'-CGAGGATCCATGCCTCAAACCCGATCC-3'
CD2 5'-CTAGGATCCGGAGACTTAATTGTCAGCTG-3'
CD3 5-CTAGGATCCATGCTCTTGATCAGGCAG-3'
CD4 5'-GACGGATCCTTAAGGCAATCCAGTAGC-3'
CD5 5-CTGCAGCATTGTCCAGAAC-3'
CD 6 5'-CTTGCAGAATCCGGCTT AAG-3'
S54A 5,-CCGTGTAAAAGCCCTGCCTCTGGCGCCg a g g a a a c g t c t g g g _3'
S74A S'-CCATTTACCTCCTTGCGCGCc c c CAAAGCAAGGCG'
S 106 A 5'-GCTGACAATTAAGGCTCCt t c GAAa a g a g a a c t a g c c _3'
S54D 5-CGTGTAAAAGCCCTGCCt c t a GAc c CCAGGAAACG
S74D 5'-GCAACACTCCCCa c c t GCc t CCTTGTGATCCACCAAAGCAAGG-3’
S106D 5'-GCTGACAATTAAGGATCCt t c g a a AAGAGAACTAGCC
N47 5'-CATGGATCCCGTGTAAAAGCCCTGCCT'-3
n u i 5'-CATGGATCCGAACTAGCCAAAGTTCACC-3'
N186 5'-CATGGATCCTTGAGGGAACACATCTGTG-3'
C290 5'-CATGGATCCGCTGTCCAGTTGATGATCCATC-3'
C363 5-CATGGATCCAGATACCTGATTAAGTCGATC-3'
C420 5-CATGGATCCAGGTGATTTACATTCAGACAG-3'
C484 5 ,-CATGGATCCCTTCCCCAGAGTGACCTC-3'
Cy93 5 '-C ATGTTA ACTGCTT A AGTGT ATGTG AGTGAG-3'
C ylO l 5'-C ATGTT A ACGATT AAGTCTCCT AGC AAA AG-3'
C la lA 5'-CATATCGATTTTCCTGGGGCTGAGAGG-3'
C lalB 5'-CAT ATCG AT AACCT ATGCAACACTCCCC-3'
Table 3.3 Primers.
List of CDC6 primers used in this study. In PCR primers the restriction sites used for cloning is 
underlined. In primers used to generate point mutations in CDC6, the codon for the mutated amino acid 
is underlined. The generated restriction sites are in superscript and bold characters indicate mutations.
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3.1.1.7 hCDC6 constructs
pBSKhCDC6 CD1 +CD4 BamHI
pBSKhCDC6 47-560 N47 + CD4 BamHI
PBSKhCDC6 111-560 Mi l l  +CD4 BamHI
pBSKhCDC6 186-560 N186 + CD4 BamHI
pBSKhCDC6 1-420 CD1 +C420 BamHI
pBSKhCDC6 1-363 CD1 +C363 BamHI
pBSKhCDC6 1-290 GDI +C290 BamHI
PBSKhCDC6 dl 93-100 (CyA)
CD1 +Cy93 
CylOO +CD4 BamHI/Hpal
pBSKhCDC6 SSA S54A,S74A, S I06A - / - /Sful
pBSKhCDC6 SAA S54A,S74A, S106A - /BssHII/Sful
pBSKhCDC6 AAA S54A,S74A, S106A NarEBssHIESful
pBSKhCDC6 AAS S54A,S74A, S106A Narl/BssHIE -
pBSKhCDC6 ODD S54D, S74D, S106D XbaEBspMI/Sful
pBSKhCDC6 dl 58-61 (d-box)
GDI + ClaAl 
ClaBl +CD 4 BamHI/Clal
pGEX4ThCDC6 BamHI
pGEX4ThCDC6 1-106 GDI +CD2 BamHI I
pGEX4ThCDC6 1-228 BamHEDrdESmal
Table 3.4 pBSKhCDC6 and PGEX4ThCDC6 constructs.
The name of the construct is listed together with PCR or mutagenesis primers used to generate 
the plasmids. The restriction enzymes used for cloning or identification of mutants is shown in 
the right column.
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3.1.1.8 Screening of X-phage cDNA
Denaturing solution: 1.5 M NaCl
0.5 M NaOH
Neutralizing solution: 1.5 M NaCl
0.5 M Tris-HCl pH 8.0
20x SSC: 3 M NaCl 
0.3 M Nagcitrate
pH 7.0
lOOx Denhardt's: 20 g Ficoll 400/1
20 g Polyvinylpyrrolidone/1 
20 g Bovine serum albumin/1
Hybridization solution: 4x SSC
50 % Formamide 
lOx Denhardt's
0.05 M sodium phosphate buffer pH 7.4 
0.1 mg/ml denatured herring sperm DNA 
1 % SDS
SM: 5.8 g/1 NaCL
2 g/1 M gS0 4
0.05 M Tris-HCl pH 7.5
0.01 % gelatin
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3.1.1.9 Sequencing
5x TBE: 54 g/l Tris Base 0.5x TBE: 0.045 M Tris-borate
27.5 g/1 Boric acid 0.002 M EDTA
40 ml 0.5 M EDTA/1
Sequencing gel: 6 % acrylaimde
0.04 % bis acrylamide 
0.5x TBE 
480 g urea/1 
+ APS and TEMED
3.1.2 Mammalian cell culture
Dulbecco's modified Eagles medium (DME M) (life tecnologies), suplemented with 
10 % ECS, penicillin (250 I.E/ml) and Streptomycin sulfate (25 pg/ml).
Cell lines used: U20S, HeLa, C33A, MRC5, CV-1, COS and R ati.
PBS"/-: 137 mM NaCl
2.7 mM KC1
4.3 mM Na2HP04
1.4 mM KH2PO4 
(pH 7.4)
Trypsin solution: 0.25 % (w:v) trypsin
1 mM EDTA 
(in PBS)
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2x Hepes buffered Saline: 280 mM NaCl
50 mM Hepes
1.5 mM Na2PC>4 
(pH 7.12)
PBS/EDTA: PBS"/"
+ 0.01 % EDTA
Propidium Iodide soloution: 10 mm Tris pH 7.5
5 mM M gCl2
50 pg/ml Propidium iodide 
100 pg/ml RNase A
Additive Stock Final concentration
Cyclohexamide 10 mg/ml (lOOOx) 10 pg/ml
Aphidicolin 0.5 M in ethanol (500x) 1 mM
Nocodazole 50 pg/ml in DMSO (lOOOx) 50 ng/ml
Thymidine 100 mM (50x) 2 mM
BrdU 50 mM (500x) 100 pM
MG 132 50 pM in DMSO (lO.OOOx) 5 nM
Lactacystein 20 mM in DMSO (2000x) 10 pM
LLM 20 mM in ethanol (2000x) 10 pM
Table 3.5 Additives (mammalian cell culture).
Different chemicals were used to syncronize cells and to study protein degradation. 
The table contains information about the stock concentration and the final 
concentration used.
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3.1.3 Protein- and immunochemistry
3.1.3.1 Protein lysis buffers
2x SDS-sample buffer: 120 mM Tris pH 6.8 
4 %  SDS 
20  % glycerol
+ DTT to 100 mM before use
E l A Lysis Buffer (ELB): 50 mM Hepes pH 7.0 
250 mM NaCl 
0.1 % NP40 
5 mM EDTA 
1 mM DTT 
0.2 mM PMSF 
1 pg/ml Leupeptin 
1 pg/ml Aprotinin
RIPA buffer: 50 mM Tris-HCl pH 7.0 
150 mM NaCl 
1% Triton X-100 
1 % Deoxycolate 
0.1 % SDS 
0.2 mM PMSF 
1 pg/ml Leupeptin 
1 pg/ml Aprotinin 
5 mM NEM
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Extraction buffer:
3.1.3.2 Kinase assays
Kinase buffer (KB):
Kinase reaction:
_____________________  Materials and Methods
50 mM Hepes
10 mM M gCl2
2.5 mM EGTA
1 mM DTT
1 mM NaF
0.1 mM N aV 0 4
10 mM 6 -glycerolphosphate
0.2 mM PMSF
1 pg/ml Leupeptin
1 pg/ml Aprotinin
50 mM Hepes pH 7.5 
10 mM M gCl2 
10 mM B-glycerolphosphate 
1 mM DTT 
1 mM NaF 
1 mM N aV 04
30 pi KB 
+ 25 pM ATP 
+ 1 pg Histone 1/reaction 
+ 10 pCi 32p-y-ATP/reaction
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3.1.3.3 SDS-PAGE and Western blotting
Materials and Methods
Acrylamide stock: 30 % acrylamide, 0.8 % bisacrylamide
Separation gel: 380 mM Tris-base pH 
0.1 % SDS 
8-12 % acrylamide 
+ APS and TEMED
Stacking gel: 130 mM Tris-HCl pH 6 . 
0.1 % SDS 
5 % acrylamide 
+ APS and TEMED
SDS Running Buffer: 0.025 M Tris-base pH 8 .
0.192 M glycine 
0.1 % SDS
Semidry buffer: 48 mM Tris-base pH 8 . 
39 mM Glycine 
0.0375 % SDS 
20 % Ethanol
PBST: PBS-/-
0.05% Tween 20
Ponceau S (100 ml): 0.5 g Ponceau S
1 ml glacial acetic acid
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Blocking solution: 
Primary antibody 
solutions:
5 % low fat milk in PBST
Primary antibodies were deluted in blocking solution + 0.02 % 
NaNg. Stored at 4C°.
Tissue culture supernatants were generally diluted 1:5.
Acites and polyclonal antisera were diluted 1:1000.
Secondary antibody The peroxidase coupled antibodies were diluted 1: 5000 in
solution: blocking solution.
3.1.3.4 Immunohistochemistry
M ethanol/Acetone : 50 % Methanol
50 % Acetone 
Stored at -20 C
Pipes buffer: SO mM Pipes
5 mM EGTA 
2 mM M gC h
4.0 % Pareformaldehyde in Pipes buffer 
0.01 % Triton X-100 in Pipes buffer
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3.1.3.5 Affinity purification of antibodies
Peptides: N-terminal peptide NH2-M PQTRSQAQAC-COOH
C-terminal peptide NH2-KIEEKEIEHALC-COOH
BSA (cationizated): 6 mg/ml in PBS
Sulfo-SMCC: 1.5 mg/ml in PBS
Aminolink coupling gel (Pierce)
Reducing agent: 
Coupling buffer: 
Quenching buffer: 
W ashing buffer: 
Storage buffer:
Sodium cyanoborohydride (64 mg/ml in 0.01 NaOH) 
0.1 M Sodium-phosphate buffer pH 7.4 
1 M Tris-HCl pH 7.4 
1 M NaCl
PBS + 0.05 % NaN3
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3.1.3.6 Antibodies
Antibody Target protein Source Reference
12CA5 HA-tag
hybridoma- 
supernatant, MAb. (Field et al., 1988)
DCS 180/181 CDC6
Acites, hybridoma- 
supernatant, MAb.
(Petersen et al., 
1999)
anti-cyclin A 
(H437) Cyclin A
rabbit serum, 
polyclonal Santa Cruz
GNS1 Cyclin B
hybridoma- 
supernatant, MAb. kind gift, S. Shiff,
HE 12 cyclin E
hybridoma- 
supernatant, MAb. (Dulic et al., 1992)
DO-1 p53
hybridoma- 
supernatant, MAb.
(Vojtesek et al., 
1992)
PC10 PCNA
hybridoma- 
supernatant, MAb.
(Waseem and P., 
1990)
X27 CDC6
rabbit serum, 
polyclonal
(Petersen et al., 
1999)
L20/I20
CDC6 N-terminal 
peptide
rabbit serum, 
polyclonal
(Petersen et al., 
1999)
M20
CDC6 C-terminal 
peptide
rabbit serum, 
Polyclonal This study
anti-BrdU BrdU
Pure monoclonal 
antibody Becton Dickinson
anti-BrdU-FITC BrdU
Pure monoclonal 
antibody Becton Dickinson
anti-mouse- 
Cy3 or FITC Mouse IgG Goat Becton Dickinson
anti-rabbit- 
Cy3 or FITC Rabbit IgG Goat Becton Dickinson
anti-mouse per­
oxidase conjugated
mouse
immunoglobulin polyclonal (sheep) Amersham
anti-rabbit per­
oxidase conjugated
rabbit
immunoglobulin
polyclonal
(donkey) Amersham
Table 3.6 Antibodies.
The table contains the source and reference for the different antibodies used in this study. Mouse 
monoclonal antibody (Mab.).
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3.1.3.7 Phosphopeptide- and phosphoamino acid analysis
Phospho Chromatography Buffer (2 L): n-butanol 750 ml
pyridine 500 ml
glacial acetic acid 150 ml
dH 20 600 ml
pH 1.9 buffer (2 L): formic acid 50 ml
glacial acetic acid 156 ml
dH2Q 1794 ml
pH 3.5 buffer (2 L): glacial acetic acid 100 ml
pyridine 10 ml
dH 20 1890 ml
Phosphoamino acid standards: 1 mg/ml phosphoserine, phospho-
threonine and phosphotyrosine
Dye: 5 mg/ml e-DNP-lysine (yellow) and 1 mg/ml xylene cyanol FF (blue)
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3.2 Methods
3.2.1 Molecular Biology 
Competent cells
Competent E. coli cells were prepared by a modified version of the CaCl^ method 
(Sambrook et ah, 1989). In brief, exponentially growing cells were harvested, 
washed in ice cold transformation buffer 1 (in 1/10 the volume of the original 
culture), and resuspended in 1/25 volume icecold transformation buffer 2. The 
competent cells were stored in aliquots at - 80 °C.
Transformation
An aliquot of cells was thawed on ice and the ligation mix was added (1 ng DNA/pl 
cells). The mixture was incubated 10 minutes at 20 °C (room temperature, RT.) and 
plated on LB plates including required antibiotics.
Analysis of DNA
The concentration of purified DNA was determined by measuring the absorbance at 
260 nm. A ^ =  l corresponds to 50 pg/ml of double-stranded DNA (Sambrook et al., 
1989), and a high quality DNA preparation should have an A260/A28O ratio of 1.8- 
2 .0 .
DNA samples were analysed by agarose gel electrophoresis. Agarose gels (0.7 - 1.5 
%) were prepared and run in Ix TAE. The DNA was visualized with Ethidium 
Bromide (0.5 pg/ml) and examined under UV light.
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DNA preparation
Small scale plasmid preparation (mini prep.). Single colonies were inoculated in 3 
ml LB (+ antibiotics) and grown over night (ON) at 37 C. 1.5 ml of cell culture was 
harvested (30 second at 15000g) resuspended in 100 pi solution 1. 200pl solution 2 
was added to lyse the cells and to denature the DNA. The mixture was left on ice for 
5 min. and 150 pi of solution 3 was added. After 5 minutes incubation on ice, 
proteins and chromosomal DNA was removed by Phenol/Chloroform extraction 
using 400 pi Phenol/Chloroform mix. The plasmid DNA was precipitated from the 
upper phase with 1 ml of 96% ethanol. After spinning (5 min 15.000g) the pellet was 
washed with 70% ethanol, dried in speed-vac. and resuspended in 50 pi TE + RNase 
(30 pg/ml).
Large scale DNA preparations (maxi prep.) were done using the QIAGEN Maxi Kit 
according to manufacture's instruction.
Enzymatic modification of DNA
Restriction analysis: To examine mini prep's, and prepare DNA fragments DNA 
was digested with restriction enzymes according to the manufacturer's (Boehringer 
Manheim) instructions.
Dephosphorylation : The 5'ends of open cloning vectors were dephosphorylated 
with Calf Intestinal alkaline Phosphatase (Boehringer Mannheim) - to prevent self 
ligation - according to the manufacture's instructions. The phosphatase was removed 
by phenol/chloroform extraction.
L igation: Vector DNA (ca. 100 ng) and insert were mixed with buffer and enzyme 
(T4 DNA-ligase) as recommended by the manufacture (Boeringer). Half of the 
ligation was used for transformation.
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PCR
PCR were performed using cloned PFU (Stratagene) in supplied buffer with 25 mM 
of dATP, dCTP, dGTP and dTTP, 70-100 ng of each primer, 0.5 unit of DNA 
polymerase (PFU) and 1 pi of DNA template (10 ng of plamid DNA or 1 pi of 
cDNA library). Generally a protecol with denaturing at 94 C, anneling at 55 °C and 
elongation at 72 °C, for 25 cycles were performed.
Purification of DNA fragments
DNA was precipitated using 1/10 volume 3M NaOAc pH 5.2 and 2 1/2 vol. ice cold 
99% ethanol. DNA fragments were extracted from agarose gels using the QIAEX 
DNA extraction kit following the supplied protocol.
DNA sequencing
Sequencing was done using the sequenase version 2.0 DNA sequencing kit 
(Amersham). The samples were run on a 6 % acrylamide sequencing gel at 60 Watt 
for 1-3 hours. Some sequences were analysed using an automated sequencer, Vistra 
725, M olecular dynamics, Amersham.
Site-directed mutagenesis
Introduction of point mutations were done using the Chameleo™  Double-Stranded 
Site directed Mutagenesis Kit (Stratagene), following the manufactures protecol.
3.2.1.1 Screening of X-phage cDNA library
A LE392 over night culture was spun and resuspended in 0.01 M MgSO^. An 
aliquote of the LE392 cells were infected with 106 phages by incubation for 15 
minutes at
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37 °C. The infected bacteria culture was deluted in prewarmed top agarose and 
spreaded on NZY-plates (10 ml per 15 cm plate). The plates were incubated 8-12 
hours at 37 °C, cooled and two sets of nitrocellulose filters were lifted from each 
plate. The filters were submerged in denaturing solution for 2 minutes, thereafter 
transfered to neutralising solution for 5 minutes and the filters were then rinsed in 
0.2 M Tris-HCl pH 7.5, 2x SSC. Filters were dried between watman filter for 30 
minutes and then baked at 80 °C for 1-2 hours in vacuum oven. The filters were 
washed twice at 65 °C for 20 minutesin in 0.5x SSC, 0.5 % SDS. Filters were stored 
in 2x SSC until hybridization. Prehybridization was done at 42 °C for minimum an 
hour. The probe was preparede using the multiprime labelling system (Amersham) 
following the manufactures protecol. The probe was labled with 32P-a-dCTP and 
purified on a G50 spin collumn. The probe (>109 CPM), was denatured by heating to 
95 °C for 5 minutes and cooled down on ice before addition to the hybridization mix. 
Hybridization was done at 42 °C over night. The filters were washed at 65 °C for 20 
minutes in buffers with increasing stringency (1. wash; 2x SSC, 1 % SDS, 2. wash;
Ix SSC, 1% SDS, 3. wash; 0.5x SSC, 1 % SDS). Filters were exposed and double 
positive plaques were picked in 0.5 ml SM buffer and the screening were repeated 
until single phage plaques were identified.
The pCEV 29 plasmids containing the cDNA from the individual phages were 
rescued by infection (60 minutes at 37 °C). Cells were platede and selected on 
ampicillin and kanamycin. The growing collonies containing the cDNAs of interest 
were cultured for DNA minipreps.
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3.2.2 Mammalian cell culture
All cell lines were cultured at 37 °C in a humid atmosphere containing 5 % CO2. For 
in vivo phosphate labeling the medium was prepared with dialysed serum and [32?]- 
orto-phosphate (0.75 mCi/ml).
Cells were subcultured by washing with PBS"A and a trypsin solution. When cells 
detached fresh media was added and the cells were resuspended and reseeded.
M ammalian cells were stored in liquid nitrogen. Cells were trypsinized, centrifuged 
(500g) and resuspended in cold freezing medium (DMEM, 10 % PCS and 10 % 
DMSO), aliquoted, packed in polystyrene and frozen at -80°C. After a few days the 
tubes were transferred to liquid nitrogen. Cells were recovered by quickly thawing 
the vial in a 37 °C water bath and washed once in pre-warmed media to remove 
DMSO.
3.2.2.1 Introduction of DNA in mammalian cells
3.2.2.1.1 Calcium-phosphate transfection
DNA was introduced into monolayer cultures via a precipitate that adheres to the 
cell surface and then is endocytozed by the cell. The DNA precipitate was made by 
mixing a solution containing calcium chloride and DNA with a HEPES-buffered 
saline solution (Ausubel et ah, 1988).
In general, a 10 cm dish was transfected with a total of 20 pg DNA (10 pg for a 6 cm 
dish) and salmon sperm DNA was used as carrier. The DNA was mixed with 0.5 ml 
250 mM CaClz- The DNA mix was added drop wise to 0.5 ml 2x HEPES buffer
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resulting in the formation of a fine precipitate. The mixture was distributed evenly 
over the cells, and the cells were incubated for upto 16 hours. The medium was 
removed and the cells were washed twice with PBS /" and feeded with fresh medium.
3.2.2.1.2 M icroinjection of DNA in mammalian cells
Microinjection of R ati cells were performed by Emanuela Frittoli. Injections were 
done with 10-100 ng/pl of expression plasmids.
3.2.2.2 Synchronization of mammalian cells
Synchronous cell populations were accomplished by different methods (Spector et 
ah, 1998).
Centrifugal élutriation (counterflow centrifugation): An elutriater (Beckman) was 
used to separate cells, primarily according to size. This is useful since cells increase 
in size as they progress through the cell cycle. The balance of two counteracting 
forces results in fractionation of the cell population. The centrifugal force causes 
sedimentation while the increasing liquid flow-rate, in the other direction, causes 
elution of cells as the two forces are balanced. Using this tecnic, G1 cells will be 
eluted first and following the S phase cells, and last the G2 and mitotic cells. The 
eluted cells were fractionated and the cell cycle profiles were analysed by FACS (se 
below).
Nocodazole treatment (Zieve et al., 1980): In the presence of nocodazole (50 
ng/ml) cells arrest at metaphase caused by inhibition of microtubules synthesis and 
elongation. After 12-16 hours (depending on the cell type) the mitotic cells were 
shaken off. The drug was removed by three washes with PBS"A and the cells were 
reseeded if needed.
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Aphidicolin treatment: Aphidicolin blocks cell cycle progression at the G 1/S 
transition. The cells were treated with aphidicolin (1 mM) for 16 hours.
Thymidine block: High concentration of thymidine (2 mM) in culture media causes 
a block of DNA replication by disturbing the dNTP pools in the cell. Cells were 
treated for 16 hours.
Serum starvation: CV-1 and Rati cells were synchronized in GO by removal of 
serum for 48-72 hours.
3.Z.2.3 Cell-cycle analysis
Fluorescence activated cell sorting (FACS): The cell cycle distribution of a cell 
population was evaluated by FACS analysis. In this situation flow cytometry was 
used to measuring the DNA content of the individual cell. The cells were stained 
with a fluorochrome, propidium iodide, that binds DNA. The amount of fluorescence 
emitted form each cell is proportional to the amount of DNA in the cell. A Becton 
Dickinson FACscan machine was used and the DNA-profile from approximately
10.000 cells were analysed using ModeFit. This program provides calculations of the 
percentages of cells in G j, S and Gj. Sample preparation; cells were washed, 
trypsinized, resuspended in PBS, centrifuged, washed and fixed in 70 % ice cold 
ethanol. After at least 30 minutes at 4 °C the cells were washed in PBS + 0.1%  FCS 
(centrifuged 5 minutes at 500g) and resuspended in Propidium Iodide solution (PI). 
The samples were incubated half an hour at 37 °C to digest RNA. The samples were 
vortexed prior to running.
CD20 gaiting: To obtain cell cycle profiles of transiently transfected cells, 
cotransfection with a CD20 expression plasmid was performed (van den Heuvel and 
Harlow, 1993). CD20 positive cells were identified with an anti CD20-FITC coupled 
antibody, and the gated population of cells was analysed. The cells were detached
73
Materials and Methods
with PBS'/"/EDTA, centrifuged for 3 minutes at 500 g, stained on ice for 1 hour, 
washed with PBS"/', fixed and process from here as a normal FACS sample.
BrdU (5-Bromo-2'-deoxy-Uridine) incorporation: The thymidine analog, BrdU 
was added to the medium and and cells synthesizing DNA in the tested period were 
detected using an anti-BrdU antibody.
3.2.3 Protein- and immunochemistry
3.2.3.1 Protein extraction
Total cell lysates used for SDS-PAGE were prepared by lysing cells directly in SDS- 
sample buffer (Ix  SDS-SB). The chromosomal DNA was sheared by sonication or 
denatured by boiling the samples for 10 min. The samples were heated (100 °C) for 
3-5 minutes prior to loading.
Cell lysate for immunoprécipitation were prepared by lysing the cells in ELB for 20 
minutes on ice, and cell debris were removed by spinning for 20 minutes at 15.000g. 
In few cases the cells were lysed in RIPA buffer instead. When extracts were needed 
for kinase assays Extraction buffer was used.
The bio-rad protein assay was used to determine the protein concentration, as 
recommended by the manufacture. A standard curve was made using bovine serum 
albumin (BSA), and used to evaluate the protein concentration in the samples. When 
total cell lysates were use the number of cells was used to equalize the samples.
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3.Z.3.2 In vïYro-binding experiments
GST, GSThCDC6, GSTplOV (252-816) (Ewen et a i ,  1992) were produced using 
standard methods. Protein expression was induced with 0.2 mM IPTG for 12 hours 
at room temperature. The bacteria were lysed in ELB and sonicated. After 
centrifugation, the supernatant was incubated with glutathione-agarose beads, and 
bound proteins were eluted with 20 mM glutathione (pH 7.0). GSTp27 was a kind 
gift of Heiko Müller. Cyclin E, Cyclin A and Cyclin B 1 were in vitro translated 
using TNT reticulocyte lysate (Promega) following the instructions of the 
manufacturer. Binding reactions were performed in 100 pi ELB for 1 hour on ice, 
using 2 pg GST fusion protein and 4 pi of the in vitro translation reactions. The 
protein complexes were bound to GSH agarose beads for 2 hours at 4 °C, washed 3 
times with ELB, eluted in Ix SDS-SB and separated by SDS-PAGE, dried and 
exposed. In vitro binding experiments using cell extract were done as above exept 
that the GST proteins were incubated with 100 pg of U20S cell extract and the 
composition of the bound protein complexes were analysed by W estern blotting (se 
below).
3.2.3.3 Immunoprécipitation and kinase assay
Immunoprécipitation were done using 0.5 - 1.0 mg of protein extract. The extracts 
were incubated with antibody for 1/2 hour on ice, Protein A sepharose or Protien G 
sepharose was added and the immunoprécipitations were rotated at 4 °C for 2 hours. 
The beads were washed 3 times in lysis buffer, Ix SDS sample buffer was added and 
the samples analysede by SDS-PAGE. For kinase assays the beads were washed 
twice more in Kinase Buffer (KB) and the kinase reactions were set up and 
incubated in shaker at 37 °C for 30 minutes.
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3.2.3.4 SDS-PAGE
SDS poly-acrylamide gel electrophoresis was performed as described in (Sambrook 
et al., 1989) using a discontinuous buffer system (Laemmli, 1970). This allows 
separation of proteins according to their relative molecular weight. Sodium dodecyl 
sulfate (SDS) and the reducing agent (DTT) denature and dissociate the proteins into 
polypeptides. SDS binds to the polypeptides independent of the amino acid sequence 
and in amounts proportional to the size of the protein. Because of the negative 
charge of the SDS-molecules the SDS-peptide complexes will migrate inversely 
proportional to the relative size of the polypeptides. The gels were run in a BIO­
RAD mini protean II™  apparatus at 20 mA per gel.
3.2.3.5 Western blotting
W estern blotting was used to analyse protein expression of both endo- and 
exogenous proteins. The method (Harlow and Lane, 1988) involves SDS-PAGE 
followed by immobilization of the proteins on a membrane by electroblotting. The 
proteins were detected using an antibody specific for the proteins of interest. The 
proteins were transferred from the gel using a semidry blotting apparatus 
(M illiBlot™  Graphite Electroblotter II). Filters and membranes were prewetted in 
semidry buffer and the sandwich was set up starting from the anode. First, 5 pieces 
of whatman no. 3, then the nitrocellulose membrane and the gel and then again 5 
filters. A current of 10 mA/cm2 was applied for 1-1 1/2 hour. After electro blotting 
the membranes were stained with Ponceau S (dye that binds irreversibly to proteins) 
to verify equal loading and transfer. The free protein binding sites were blocked by 
incubating the membrane in blocking soulution for at least 1 hour. The membrane 
was then incubated with a solution of the primary antibody for 1 hour, followed by 3 
washes in PB ST of 5 minutes each. After incubation with the secondary antibody (1
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hour) the membranes were washed and developed using enhanced 
chemiluminescence (ECL, Amersham).
3.2.3.6 Immunofluorescence
The cells were grown on cover slips to examine the protein expression and/or BrdU 
incorporation in the individual cell. The cover slips were lifted from the dish, 
washed with PBS-/- and fixed. Fixation was done in either ice cold methanol/acetone 
(1:1) or with 4 % formaldehyde for 10 minutes. The formaldehyde fixation was 
followed by three washes with PBS-/- and permalization for 10 minutes with 0.01 % 
Triton X 100. After drying, the cover slips were processed for immunostaining or 
stored at -20 °C for later use.
Antibodies were diluted in DMEM +10 % ECS + 0.01 % NaNg. All procedures 
involving FITC- or Cy3-coupled antibodies were done quickly and the cover slips 
were incubated in the dark. The cover slip was overlaid with approximately 70 pi of 
primary antibody solution and incubated for 1 hour at room temperature, washed in 
P B S '/ ' and subsequently incubated for 1 hour with the secondary antibody (a 1:500 
dilution of goat-anti-mouse/rabbit Cy3 coupled antibody or a 1:100 delution of goat 
anti mouse/rabbit FITC coupled antibody). The incorporated BrdU was visualized 
with anti-BrdU antibody. To accès the BrdU epitope the DNA was denatured with 2 
N HC1 (10 minutes) or 60 mM NaoH (1 minute). After neutralization with PBS'/" the 
cover slips were incubated with anti BrdU antibody. The nuclei were counterstained 
with DAPI (1 pg/ml). Finaly the cover slips were wash in water and left to dry. The 
cover slips were mounted on glass slides using 5 pi moviol each.
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3.2.3.7 Affinity purification of polyclonal antibodies
Polyclonal antibodies were obtained from Primm (Prodotti Immunobiotecnologici) 
raised against ovalbovine conjugated peptides or GST fusion proteins.
The polyclonal antibodies were purified on either a peptide or a protein column. The 
peptide column was prepared by conjugation of the peptide to BSA. The BSA- 
peptide was then coupled to the gel suspension in the same way as the protein.
To conjugate the peptides to BSA, sulfo-SMCC and BSA (6 mg) were reacted for 45 
minutes at room temperature. BSA-SMCC was then incubated with the peptides (3 
mg) for 2 hours at room temperature.
The columns were prepared by coupling of GSThCDCô 1-106 and BSA-peptides to 
aminolink beads by the following method. 4 ml coupling gel was transferred to a 
column. The column was equilibrated with 6 ml coupling buffer, and drained. The 
protein was applied and 200 pi of the reducing reagent (made 1 -2 hours before) was 
added. The column was rotated for 2 hours at room temperature and left standing for 
2 hours before the column was opened and drained. The column was then washed 
first with 4 ml of coupling buffer and then with 4 ml of quenching buffer. The 
column was closed and 2 ml of quenching buffer and 200 pi reducing reagent was 
added. The column was rotated for 30 minutes. The column was drained and washed 
4 times with 5 ml washing buffer and 3 times with storage buffer.
Purification of antibodies. The prepared column was washed with 3 volumes of PBS 
and 10 volumes of 0.1 M glycine pH 2.5. The column was equilibrated to neutral pH 
with PBS. The sera clarified was diluted 1:3 in PBS containing protease inhibitors 
(leupeptin and aprotinin). The beads containing the coupled antigen were transferred 
to a 50 ml tube and incubated with the sera for 30 minutes at room temperature. The 
column was repacked and washed with PBS until no protein was detected in the 
flow-through. The antibody was eluted with 0.1 M glycine pH 2.5 in 1 ml fractions
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and neutralized with 40 pi 1 M Tris pH 9.5. The purified antibody was dialyzed 
against PBS, aliquoted and stored at -20 °C.
3.2.3.S Phospho-peptide and phospho-amino acid analysis
A protecol by Boyle, J. W. was followed (Boyle et ah, 1991). In short, the labled 
proteins were cut from the gel, and rehydrated for 5 minutes in 1.2 ml 50 mM 
ammonium bicarbonate. 50 pi of 6-mercaptoethanol and 10 pi 10 % SDS were 
added and the samples were boiled for 5 minutes. The samples were incubate for 
more than 90 minutes at 37 °C, centrifuged and the supernatants recovered. The 
solution was chilled on ice, carrier protien (20 pg RNase A/sample) was added and 
the proteins precipitated with 15 - 20 % TCA and left on ice for 60 minutes. After 
centrifugation the precipitates were washed with absolute ethanol and airdried. The 
precipitates were dissolved in perfomic acid and left on ice for 60 minutes and dH^D
was added. The samples were lyophilized in speed vac. The pellets were 
resuspended in ammonium bicarbonate for tryptic maps and in 6N HC1 for 
phosphoamino acid analysis (se below).
3.2.3.8.1 Phospho-peptide analysis
Tryptic digestions were done with 10 pg trypsin (twice) and incubated over night or 
3-5 hours at 37 °C. The samples were re-lyophilized two times by water addition, 
freezing and speed wac'ing cycles. Last time 1.9 pH buffer was used instead of 
water. Finaly the samples were resuspended in 1.9 pH buffer.
Dye and samples was loaded on thin layer cellulose (TLC) plates. The plates were 
run in 1.9 pH buffer connected to the plates via whatman filter wicks. The
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airpressure was applied and the cooling system conected before the elecroforese was 
initiated. The plates were run at 1 kV for 25 minutes and dried in the hood. The 
chromatography was done in the second direction using Phospho chromatography 
buffer. A dye marker was loaded on the plates and the plates were inserted in the 
chromatographic tanks and run for 8-10 hours/ON. After drying autoradiografics 
were made.
3.2.3.8.2 Phospho-amino acid analysis
The samples for phospho-amino acid analysis were hydrolysed by heating to 110 °C 
for one hour, lyophilized and resuspended in 1.9 pH buffer. The samples were 
loaded on TLC plates together with phosphoamino acid markers. The first 
electoforese was done in 1.9 pH buffer for 20 minutes at 1.5 kV and the secound in 
pH 3.5 buffer at 1.3 kV for 10 minutes. To visualizethe phosphoamino acid 
standards, the plates were spraied with 0.25 % ninhydrin in acetone and baked at 65 
°C for 15 minutes and exposed.
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4 . Results
4.1 Identification of a human Cdc6p/Cdcl8 homologue
In order to start elucidating the mechanisms regulating DNA replication in 
mammalian cells the mammalian CDC6 gene and the interactions between the 
encoded protein and known regulator of cell cycle progression was studied. The 
interest in these molecules is based on results obtained in yeast and mammalian 
cells. The S. cerevisiae CDC6 gene and the S. pombe cd c l8 + gene are known to be 
essential for entry into S-phase and directly involved in the initiation of DNA 
replication (Liang et ah, 1995; Nishitani and Nurse, 1995; Muzi-Falconi et al.,
1996). Both genes are transcriptionally activated in late M and G1 by the 
transcription factors Swi5/BMP/SBF (S. cerevisiae CDC6 (Piatti et ah, 1995)) and 
Cdc 10/res l/res2 (S. pombe CDC18 (Kelly et ah, 1993; Nishitani and Nurse, 1995)). 
In mammalian cells the E2F transcription factors regulate S-phase entry by 
transcriptional activation of Cyclin E, Cyclin A and other E2F responsive genes 
(reviewed by Helin, 1998). Overexpression of E2F-1 stimulates DNA synthesis in 
serum starved Rat fibroblasts (Johnson et ah, 1993), indicating that the E2F target 
genes encode proteins which expression is essential and sufficient for initiation of 
DNA-replication. Both the Cyclin E/CDK2 and Cyclin A/CDK2 kinase complexes 
are essential for entry into S-phase, and the phosphorylation of key substrates 
believed to trigger initiation of DNA replication (reviewed by Sherr, 1996; Morgan,
1997). The characterization of new E2F regulated genes and substrates of the cyclin 
dependent kinases is needed to understand the regulatory mechanisms of cell cycle 
regulation and more specifically the initiation of DNA replication in mammalian 
cells.
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4.1.1 Identification of a putative Cdc6p/Cdcl8 human EST sequence
The conservation of molecules involved in cell cycle regulation and specifically 
DNA replication suggests that a mammalian CDC6/cdcl8+  gene exists. The 
putative CDC6 gene is potentially an E2F target gene encoding a protein involved 
in initiation of DNA replication in mammalian cells. The Cdc6p and Cdc 18 proteins 
are 28 % identical, and the region of homology includes the central ATPase domain 
and several stretches without any assigned function. In order to identify a putative 
mammalian homologue of Cdc6p and/or Cdc 18 both protein sequences were used to 
search the BLAST database. The search using the Cdc 18 protein sequence identified 
a human EST sequence (ID HSA45217, AC AA045217) with some sequence 
homology to Cdc 18 (E value M O5). The translatable sequence encodes 
approximately 140 amino acids and contains a short region with homology to the C- 
terminal of the Cdc 18 protein. When compared to the Cdc6p sequence the same 
regions of homology are conserved (figure 4.1). The sequences share 34 % of 
identity that is similar to the level of identity between Cdc 18 and Cdc6p in this 
region. This indicates that the sequence could be a partial cDNA clone of a human 
CDC6/CDC18 gene. A set of primers (EST1 and EST2) was designed to enable 
PCR amplification and cloning of the fragment from a cDNA library. The 3'end of 
the sequence contains an "n" indicating that the sequence is of low quality. A primer 
was designed at the 3'end of the sequence (EST1) and the 3'end primer was placed 
before the "n" (EST2). A human fetal brain library (Stratagene) was used as 
template and a PCR touchdown program (annealing temperature 55 0 C to 50 °C, - 
0.5 °C for 10 cycles) was used for amplification. One band of approximately 400 bp 
was obtained as was predicted from the length of the EST sequence. The fragment 
was cloned into pBSK using the Bam Hl site inserted in the primers. The fragment 
was sequenced to confirm that the fragment encoded the expected sequence.
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Cdc 18 MCETPIGCHTPRRCNRFIDSAALIDCTNKTNQREHSPSFSIEIPTTPSRK
RTLASSHFQTPTKRIKYELGELQEEKTDLYPNFPAQLKENKKPKLPTTPQ 
TPKTPKRTIQIVTPKSLNRTCNPVPFATRLLQSTPHRQLFPPTPSTPSTP 
SYNSTAKLSLRKSYRSAGWGRENEKSIVESFFRQHLDANAGGALYVSGA 
PGTGKTVLLHNVLDHWSDYPKVNVCYINCMTINEPKAIFEKIHSKIVKE 
EILENEDHHINFQCELESHFTQSANELYNPVIIVLDEMDHLIAREQQVLY 
TLFEWPSRPTSRLILVGIANALDMTDRFLPRLRTKHITPKLLSFTPYTAQ 
EISTIIKARLKTAATTSEKNNPFTP IKS IS EVSDDSINWSQHADETPFI
Cdc 18 HPAAIELCARKVAASSGDLRKALDICRHAIELAEREWKAQHDN.TLSSV
EST  AVSGDVRKALDVCRRAIEIVESDVKSQTIL......
CDC6p QPMAIKFAAKKCAGNTGDLRKLFDVLRGSIEIYELEKR FLLSPT
C d c 18 ............................DIPRASIAHW RATSAM SQSASAR
EST  KPLSECKSPSEPLIPKRVGLIHISQVISEVDGNRMTLSQEGA
CDC 6 RGSLNSAQVPLTPTTSPVKKSYPEPQGKIGLNYIAKVFSKFVNNNSTRTR
C dc 18 LKNLGLQQKAILCTLW C E K T SL S. . . . VADVFEKYSSLCLRDRLIYPLT
EST QDSFPLQQKILVCSLMLLIRQLKIKEVTL.GKLY.EAYSKVCRKQQVAAV
CDC 6 IAKLNIQ Q K LILC TIIQSLKLNSDATIDESFDHYIKAITKTDTLAPLQRN
Cdc 18 SSEFCDVANSLETLAIIRLRTKQRNGKPQDRIISLLVPEMDVITAVGDIG
EST DQSECLSLSGLLEAR
EST, rf 2 .............. GILGLKRNKETRLTKVFFKIEEKEIEHALKDKALIG
CDC 6 . . .EFLEICTILETCGLVSIKKTKCKGKTKRFVDKIDVDLDMREFYDEMT
Cdc 18 TLKRFFDRRZ
EST
CDC6 KISILKPFLH
Figure 4.1 Alignment of the translated EST sequence with CdclS and Cdc6p.
The translation of the EST sequence until the "n" is aligned with CdclS and Cdc6p. After 
identification of the human CDC6 cDNA it was noticed that also the last part of the EST 
sequence encoded a part of human CDC6 translated in the second reading frame (EST, rf2).
The regions of homology are underlined.
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4.1.2 Cloning of a full length human CDC6 cDNA
The cloned fragment was used as probe to screen a lambda phage cDNA library. A 
library from primary human fibroblasts (M426, gift from P. Di Fiore) was used. 
Approximately M O6 phages were screened and 8 double positive plagues were 
identified. Secondary and third screens were done to obtain single phage plagues.
The plasmids containing the cDNAs of interest were rescued as described in 
Material and Methods. The obtained pCEV29 plasmids were digested with Sail to 
examine the length of the cDNA inserts. The obtained clones represented two 
different primary clones with inserts of approximately 2.0 kb and 3.0 kb (se figure 
4.2). The clones were sequenced using the PCR primers to verify that cDNAs 
containing the sequence of interest had been identified. The clones all contained the 
sequence of the EST clone and the entire insert of clone 6 was sequenced. Plasmid 
primers were used to sequence the insert from both the 5'- and 3 - end, subsequently, 
internal primers were designed to enable sequencing of the entire clone. The cDNA 
clone contained an open reading frame encoding a polypeptide of 560 amino acid 
with 31 % identity to Cdc6p and 34 % identity to CdclS. The 5'end contained an in 
frame upstream stop codon and the 3' end a poly-A sequence, indicating that a full 
length cDNA had been identified. The putative human CDC6/CDC18 protein 
contains, as Cdc6p and CdclS, an ATPase domain and other sequences with 
homology to O rel proteins. In addition, several CDK phosphorylation sites was 
identified in the N-terminal. While this work was in progress, a sequence identical to 
the one obtained was published by Williams et. al. (Williams et al., 1997), describing 
the cloning of human p62cdc6. in addition to the human CDC6, a mouse homologue 
was identified in the EST database using the human sequence as query (Hateboer et 
al., 1998). A Xenopus Cdc6p homologue, XCDC6, has been identified by PCR 
(Coleman et al., 1996; Williams et al., 1997). As seen in figure 4.3 the CDC6 
proteins from higher eukaryotes are very homologous.
84
Results
Figure 4.2 pCEV29 hCDC6/hCDC18 clones.
The isolated cDNA clones represent two groups with insert lengths of 2.0 kb and 3.0 kb. Two (A 
and B) or three colonies (A, B and C) from each rescued phage was analysed to guarantee that pure 
clones had been obtained. pCEV29 plasmids were digested with Sail and the digests were separated 
on a 1 % agarose gel together with lambda Hindlll/EcoRl marker.
85
Results
hC DC 6 
mCDC6 
XCDC6
47-117
.............................MPQTRSQAQATISFPKRKLSRALNKAKNSSDAKLEPTNVQTV..TCSP
MSAGKELKYYRNKWRQTSGIIQVCVAIMPQTRSQTQATIGFPKKKLSNTLKKP.NSRDCEVKLRNVQPVPTTPCV 
.............................MPSTRSRSQSSIQFPKKKTSQTL..AKEVSRAKSKSEICSSVSLPLSP
d-box Cy-motif
RVKALPLSPRKRLGDDNLCNTPHLPPCSPPKQGKKENGPPHSHTLKGRRLVFDNQLTIK....SPSKRELAKVH 
DVKLLPLSPRKRLGDDNLCNTPRLSPCSPPKLGKKENGPPRSHTWKGCRLVFDDEPTFK...ASPPKE.QDRVR 
LPKELPLSPRKRLGDDNRCNIPPTLSCSPPKQSRKETGQP..TTPKGRRLLFDENQAAAATPLSPLKKLQDPY.
118-191 QNKILSSVRKSQEITTNS.EQRCPLKKESACVRLFKQEGTCYQQAKLVLNTAVPDRLPAREREMDVIRNFLREHI 
QHQIRSSSAQRSPESKADPEQKCPPEKESVCIRLFKQEGTCYQQAKLVLNTAVPDRLPAREQEMGVIRNFLKEHI 
...LLSPVRKGQETPPSSRKQR NSVGVQLFKQEGSCYQKAKHALNTAIPERLLARESETAFIKTFLTSHV
Walker A
192-260 CGKKAGSLYLSGAPGTGKTACLSRILQDLKKELKGFKTIMLNCMSLRTAQAVFPAIAQEICQEEVSRPAGKDMMR 
CGKKAGSLYLSGAPGTGKTACLSRILQDFKKEVKGFKSILLNCMSLRSAQAVFPAIAQEIGREELCRPAGKDLMR 
SAGKAGSLYISGAPGTGKTACLNKLLQESKDDLKQCKTVYINCMSLRSSQAVFPAIAEEIS.GGKSSLAAKDMVR
Walker B  Leusine-Zipper_____
2 61-341 KLEKHMTAEKGPMIVLVLDEMDQLDSKGQDVLYTLFEWPWLSNSHLVLIGIANTLDLTDRILPRLQAREKCKPQL 
KLEKHLTAEKGPMIVLVLDEMDQLDSKGQDVLYTLFEWPWLSNSRLVLIGIANTLDLTDRILPRLEARENCKPQL 
NLEK.LVTSKGPIILLVLDEMDQLDSRGQDVLYTVFEWPWLPNSRMVLIGIANALDLTDRILPRLQARPQCKPQL
3 42-416 l n f p p y t r n q i v t i l q d r l n q v s r d q v l d n a a v q f c a r k v s a v s g d v r k a l d v c r r a i e i v e s d v k s q t i l k p l s
LNFPPYTRNQIAAILQDRLSQVSKDQVLDSAAIQFCARKVSAVSGDIRKALDVCRRAIEIVESDVRSQTVLKPLS
LNFSPYTKDQIATILQDRLNQVSGDQVLDNAAIQFCARKISAVSGDARKALDICRRAVEIVEADVRGQTVLKPLT
417-487 ECKSPSE....PLIPKRVGLIHISQVISEVDGNRMTLSQEGAQDSFPLQQKILVCSLMLLIRQLKIKEVTLGKLY 
ECKSPSE....SPVPKRVGLAHISQVISEVDGNRVTLSQENTQDSLPLQQKILVCSLLLLTRRLKIKEVTLGKLY 
ECLSPSKEAPSNPVPKKASLPHISRVLSDVYGDKMAI.NGGS SDSFPLQQKLLVCALLLITRQ SKIKEVTLGKVH
488-560 e a y SKVCRKQQVAAVDQSECLSLSGLLEARGILGLKRNKETRLTKVFFKIEEKEIEHALKDKALIGNILATGLP 
EAYSSICRKQQVTAVDQSECLSLSGLLESRGLVGLKKNKESRLTKVSLKIEEKEIEHVLNGKAFTGNILAAGLP 
EAYSKVCRKQQVPGVGQSECLSLCQLLETRGILGLKKAKEARLTKVSLKIEERDIEHAFKDKLLIGNVLNSGI
Figure 4.3 The mammalian CDC6 proteins.
Alignment of the human, mouse and Xenopus laevis CDC6 proteins. Conserved CDK 
phosphorylation sites, the K and DE of the Walker A and B motifs, and the Leucines in 
the L-zipper are in bold characters. The Cy motif and the putative d-box sequence are 
underlined
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In addition to the ATPase domain, several other parts of the proteins, including a 
putative leucine zipper, the position of CDK phosphorylation sites and regions 
without any predictable functions are conserved.
4.2 Generation of human CDC6 vectors
To enable studies of human CDC6 in vitro and in vivo the coding region of the 
human CDC6 cDNA was cloned into several vectors. The coding region was 
generated by PCR using CD1 and CD4 and cloned into pBSK using the Bam H l sites 
inserted in the primers. The hCDC6 fragment was subsequently sequenced to 
guarantee that no mutation was introduced. Vectors useful for expression of hCDC6 
in E. coli and mammalian cells were generated. The hCDC6 fragment was cloned 
into the Bam H l site of pGEX4T and the mammalian expression vectors 
pCM VneoBam. HA- and HANLS-fusions were created by substituting DP-1/E2F-4 
in pCMVHADP-1 and pCMVHANLSE2F-4 with hCDC6. In addition two N- 
terminal hCDC6 fragment were cloned into pGEX4T (1-106 and 1-228). During the 
progress of the work, several additional hCDC6 constructs were made. Primers and 
restriction sites used for generation and identification of the various constructs are 
listed in table 3.3 and table 3.4. hCDC6 mutants were cloned in pBSK and then 
subcloned into various pCMV vectors (only the pBSK constructs are listed). The 
point mutants and deletion mutants were generated as described in materials and 
methods. A graphic illustration of hCDC6 mutants used throughout this study is 
presented in figure 4. 4.
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Figure 4.4 Schematic illustration of hCDC6 and hCDC6 mutants.
The figure shows deletion and point mutants used in this project. Phosphorylation sites, the Cy- 
motif and the D-box sequence are indicated as well as the ATPase domain and the leucine zipper.
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4.3 Human CDC6 interacts directly with Cyclin A/CDK2
The primary sequence of hCDC6 contains three consensus CDK phosphorylation 
sites at position 54, 74 and 106. The presence of several phosphorylation sites in 
hCDC6 suggests that hCDC6 is a putative target of the CDKs. To test if hCDC6 is 
phosphorylated by the cyclin dependent kinase GSThCDCô 1-106 was expressed in 
E. coli and used as substrate in an in vitro kinase assays. CDK kinase complexes 
were immunoprecipitated with Cyclin E, Cyclin A and Cyclin B 1 antibodies and 
shown to phosphorylate CDC6 in the in vitro kinase assay (data not shown). Since 
all the tested kinases were able to phosphorylate hCDC6 in vitro a different approach 
was taken to understand if one or more of the Cyclin/CDK complexes regulate 
human CDC6.
4.3.1 CDC6 interacts with an active HI kinase in vitro and in vivo
To test if hCDC6 itself is associated with an active HI kinase, a GSThCDCô fusion 
protein, purified from E. coli, was incubated with cell extracts, and the associated 
complexes were analysed for H I kinase activity (Figure 4.5A). Indeed, the cell 
extract contained a kinase able to bind GSThCDCô and subsequently phosphorylate 
H I and GSThCDCô, while GST was not associated with HI kinase activity. To 
confirm this interaction in vivo, hCDCô was expressed in U 20S cells. Cell extracts 
prepared from cells transfected with an empty expression vector or an hCDCô 
expression vector were used for immunoprécipitations followed by in vitro kinase 
assays. As shown in Figure 4.5B, the hCDCô immunoprécipitation contains kinase 
activity capable of phosphorylating HI and hCDCô. These data show that hCDCô 
interacts in vitro and in vivo with a kinase that is able to phosphorylate HI and 
notably also hCDCô.
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Figure 4.5 CDC6 interacts with an HI kinase in vitro and in vivo.
(A) GST (2 |ig) or GSThCDCô (2 |ig) were incubated with 100 |ig of U20S cell extract. Associated 
complexes were collected with glutathione agarose beads and assayed for in vitro HI kinase 
activity. (B) U2GS cells were transfected with the pCMV empty vector (Mock) or the 
pCMVHAhCDCô expression plasmid. Cell extracts were immunoprecipitated with 12CA5, and 
processed for in vitro kinase assay. The bands corresponding to phosphorylated GSThCDCô, 
HAhCDCô and HI are indicated.
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4.3.2 Cyclin A/CDK2 interacts with CDC6 in vitro and in vivo
To reveal the identity of the interacting kinase, the possibility that CDC6 interacts 
directly with one or more of the cyclins was examined. To test this, bacterially 
produced GSThCDCô and in vitro translated Cyclin E, Cyclin A and Cyclin B were 
mixed in a GST-binding assay. Figure 4.6A shows that CDC6 preferentially binds 
Cyclin An in vitro, whereas weaker interactions with Cyclin E and Cyclin B 1 were 
observed. As positive control, a GSTp27 fusion protein was shown to bind all three 
cyclins, while the negative control (GST) did not show any interaction with the 
cyclins. The same pattern was observed using cell extracts as a cyclin source (Figure 
4.6B). So in conclusion, the in vitro binding experiments show, that CDC6 binds 
weakly to Cyclin E and Cyclin B and with high affinity to Cyclin A, in contrast to 
p i 07 that binds Cyclin E and Cyclin A, and p27 that binds all three cyclins tested.
Cyclin A has been shown to associate with both CDK2 (in S-phase) and CDC2 (in 
late S-G2)(Nasmyth, 1996). To test which catalytic subunit of the Cyclin A complex 
is associated with CDC6 , the membranes from the GST-binding assay described 
above were probed for CDK2 and CDC2 (Figure 4.6B). Only the fast migrating, 
active form of CDK2 interacts with CDC6 , whereas no association was found with 
CDC2 or the inactive form of CDK2 (data not shown). As positive controls, p i 07 
was shown to bind CDK2, while p27 was shown to bind both forms of CDK2 and 
CDC2. These data demonstrate that CDC6 associates specifically with the active 
Cyclin A/CDK2 complex in vitro.
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Figure 4.6 CDC6 binds Cyclin A/CDK2 in vitro .
(A) GSThCDCô binds in vitro translated Cyclin A. GSThCDCô, GSTp27 and GST were incubated 
with in vitro translated cyclins in a binding assay as described in “materials and methods”. The 
protein complexes were separated on a 10% acrylamide gel. 1 pi of the in vitro translation reactions 
are shown as controls (input). (B) GSThCDCô binds Cyclin A and CDK2 from U20S cell extract. 
GST, GSThCDCô, GSTplO? and GSTp27 were incubated with U20S cell extract, and associated 
complexes were precipitated with glutathione agarose beads. The presence of the different cyclins 
and CDKs were visualized by Western blotting. 10 pg of U20S cell extract were loaded as control 
(Cell extract).
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To investigate the identity of the in vivo associated kinase cell extracts prepared from 
U 20S  cells transfected with either empty vector (mock) or an hCDC6 expression 
vector were used to immunoprecipitate hCDC6 and associated proteins. The 
immunoprécipitations were analysed by Western blotting and Cyclin A and CDK2 
were shown to interact with hCDC6 in vivo (Figure 4.7A). These in vivo assays 
confirmed that hCDC6 preferentially binds Cyclin A and the active fast migrating 
form of CDK2. Furthermore, no specific interaction with Cyclin E or CDC2 was 
detected in these assays (Figure 4.7A), suggesting that CDC6 interacts preferentially 
with Cyclin A/CDK2 in vivo.
To confirm  that endogenous CDC6 and Cyclin A also interacts in vivo antibodies 
against CDC6 were obtained. Polyclonal rabbit antibodies were raised against 
GSThCDCô 1-106 (X27) and two synthetic peptides (one N-terminal (120 and L20), 
and one C-term (M20 and N20)). The antibodies were affinity purified and all 
recognized overexpressed CDC6 by Western blotting, but were unable to detect the 
endogenous CDC6 in the same assay (results not shown). In collaboration with the 
group of Jiri Bartek at the Danish Cancer Society mouse monoclonal antibodies were 
obtained against the full length GSThCDCô protein. Two clones (DCS 180 and DCS 
181) were characterized further. They recognize a 60-62 kDa protein in cell lysate 
and in immunoprécipitations (Figure 4.7B). Immunoprécipitations of cell extracts 
from C33A cells using the mouse monoclonal antibodies and the polyclonal rabbit 
antibodies show that X27, L20 and 120 (less efficiently) are able to 
immunoprecipitate the endogenous human CDC6 protein (figure 4.7C).
To investigate if CDC6 and Cyclin A are associated at physiological concentrations 
human CDC6 was immunoprecipitated from U 20S  cell lysates and tested for 
coimmunoprecipitation of Cyclin A. Cyclin A was present in CDC6 
immunoprécipitations but not in a control immunoprécipitation (figure 4.7D).
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Therefore, CDC6 and Cyclin A associate in vivo, also when the two proteins are 
present in physiological concentrations.
In summary the data show that a complex containing CDC6/Cyclin A/CDK2 most 
likely exists in vivo in exponentially growing cells, and that CDC6 interacts 
specifically with the active kinase complex.
4.3.3 A Cy-motif in hCDC6 mediates the interaction with cyclin A/CDK2
To map the region in hCDC6 implicated in Cyclin A/CDK2 binding, a series of 
deletion mutants were constructed removing sections of hCDC6 from the N- and the 
C-termini (see figure 4.4). The various hCDC6 mutants were expressed transiently in 
U 20S  cells and tested for their ability to interact with an H l/hC D C 6 kinase. As 
demonstrated in Figure 4.8, the first 1-290 amino acids of human CDC6 were 
sufficient for kinase binding, whereas deletion of amino acids 1-110 abolishes the 
interaction with the kinase. The lower panel shows that all CDC6 deletions were 
expressed (Figure 4.8A). These results suggest that a region between 1-110 is 
sufficient to bind the active Cyclin A/CDK2 complex, and in agreement with this, a 
GST fusion protein containing the first 106 amino acids of hCDC6 was shown to 
bind Cyclin A (Figure 4.8D).
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Figure 4.7 CDC6 interacts with the Cyclin A/CDK2 complex in vivo.
(A) Ectopically expressed HCDC6 interacts with Cyclin A/CDK2. U20S cells were transfected with 
the hCDC6 expression vector (pCMVHAhCDCô) or empty vector (Mock) and the cell extracts were 
used for immunoprécipitation (12CA5) and analysed by Western blotting. Cyclin A, CDK2, and 
hCDC6 bands are indicated with arrows. 10 pg of U20S cell extract was used as control. The 
expression of HAhCDCô is shown in the lower panel using 12CA5 to detect the expressed proteins. 
Asterisks indicate background bands due to cross reaction of 12CA5 with cellular polypeptides. (B 
and C) Identification of endogenous CDC6. Immunoprécipitations of CDC6 from C33A cell extract 
using the indicated antibodies were analysed by Western blotting using DCS 181. (D) Cyclin A 
associates with human CDC6. Human CDC6 was immunoprecipitated from U20S cell extracts 
using CDC6 antibodies. As control 12CA5 (C) and anti Cyclin A antibodies were used. The 
presence of Cyclin A in the immunoprecipitates was analysed by Western blotting using a 
polyclonal antibody to Cyclin A.
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Several cyclin binding proteins (e.g. substrates and inhibitors) have been shown to 
bind cyclins via a Cy-motif (Zhu et ah, 1995; Adams et al., 1996; Chen et al., 1996). 
Examination of the primary sequence of hCDC6 and the other mammalian CDC6 
molecules revealed a putative Cy-motif in the N-terminus of hCDC6 between amino 
acids 93-100. The motif is also conserved in mouse and Xenopus CDC6 . Additional 
deletions showed that the first 46 amino acids are not required for kinase binding, 
whereas deletion of amino acids 93-100 containing the putative Cy-motif almost 
abolishes the interaction between hCDC6 and the kinase (Figure 4.8B). In these 
assays, the precipitated hCDC6 proteins were always phosphorylated when 
associated with H I kinase activity. To demonstrate a correlation between associated 
H l/hC D C 6 kinase activity and the ability to bind Cyclin A/CDK2, U 20S and COS 
cells were transfected with plasmids encoding wild type or the dl 93-100 mutant of 
hCDC6 . Cyclin A and CDK2 were readily observed in the immunoprécipitations 
from wild type hCDC6 transfected cells, whereas no Cyclin A or CDK2 were 
detected in immunoprécipitations from hCDC6 dl 93-100 expressing cells (Figure 
4.8C). The data therefore strongly suggest that hCDC6 interacts with Cyclin 
A/CDK2 via a Cy-motif similar to those found in E2F-1, p21, CDC25A and p i 07. 
hCDC6 (and E2F-1) interacts specifically with Cyclin A, in contrast to p 2 1, 
CDC25A and p i07 that can bind both Cyclin A and Cyclin E. It is not know, if this 
specificity is due to the sequence of the Cy-motif, or whether sequences outside this 
region are important for the specificity.
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Figure 4.8 CDC6 binds Cyclin A/CDK2 via a N-terminal Cy-motif.
(A) Amino acids 1-110 of hCDC6 are required for kinase association. Extracts from U20S cells, 
transfected with expression vectors encoding the indicated hCDC6 deletion mutants, were analysed 
by immunoprécipitation followed by in vitro kinase assay. The phosphorylated hCDC6 molecules 
and HI are indicated. Western blot analysis with 12CA5 shows the expression of the deletion 
mutants (lower part of panel A). (B) The Cy-motif between amino acids 93-100 is required for 
kinase interaction. Kinase assays and Western blot analysis were performed as in A. (C) Deletion of 
the Cy-motif (amino acids 93-100) abolishes binding of hCDC6 to Cyclin A/CDK2 in U20S and 
COS cells. Expression plasmids encoding HAhCDCô and HAhCDCô dl 93-100 were transfected 
into U20S and COS cells and immunoprecipitated with 12CA5. The presence of interacting proteins 
was analysed by Western blotting. 10 pg of total cell extract was used as control (Cell extract). The 
expression of hCDCô and hCDCô dl 93-100 in total extracts is shown (lower panel). Asterisks 
indicate background bands due to cross reaction of 12CA5 with cellular polypeptides. (D) 
GSThCDCô 1-106 interacts with Cyclin A/CDK2. In vitro binding experiments using different 
GSThCDCô fusion proteins were performed as described in the legend to figure 4.6B.
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4.4 Phosphorylation of human CDC6 regulates (^localization
As described above, human CDC6 is phosphorylated by several Cyclin/CDK 
complexes in vitro, but the interaction with the Cyclin A/CDK 2 complex suggests 
that CDC6 is a specific substrate of this kinase. To investigate if CDC6 is 
phosphorylated in vivo, U 20S cells were transfected with hCDC6 expression 
vectors, and subsequently cultured for 3 hours in the presence of radioactive orto- 
phosphate. Immunoprécipitation of hCDC6 demonstrated that the protein is 
phosphorylated in vivo (Figure 4.9A).
4.4.1 CDC6 is phosphorylated on CDK phosphorylation sites in vivo
The primary sequence of human CDC6 contains three perfect CDK consensus 
phosphorylation sites (S/T-P-X-R/K) at aa 54, 74 and 106 and in addition three S/T- 
P sites without a perfect consensus. To establish a role of CDC6 phosphorylation and 
to map the phosphorylation sites in hCDC6 mutants with amino acid substitutions in 
the three consensus phosphorylation sites were created. The serine residues of the 
phosphorylation sites (S54, S74 and S106) were mutated, into alanine residues 
(hCDC6 AAA) blocking the phosphorylation, or into aspartic acid (hCDC6 DDD) to 
mimic constitutive phosphorylation. U 20S cells transfected with either control 
vector, hCDC6 , or the triple alanine mutant, were labeled in vivo with 32P. As 
demonstrated in Figure 4.9A, only the wild type protein was phosphorylated in vivo, 
whereas both the wild type and the triple A mutant were efficiently expressed and 
immunoprecipitated (Figure 4.9A, Western). These data show that hCDC6 is 
phosphorylated on CDK consensus phosphorylation sites in vivo, and that mutations 
of the three CDK consensus phosphorylation sites is sufficient to prevent 
phosphorylation of hCDC6 in vivo.
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Figures 4.9 CDC6 is phosphorylated in vivo on CDK phosphorylation sites.
(A) In vivo phosphorylation of hCDC6. U20S cells transfected with empty vector (Mock), 
pCMVHAhCDCô or pCMVHAhCDCô AAA, were labeled with (32P)-orto-phosphate for three 
hours. Cell extracts were immunoprecipitated with 12CA5. The precipitated proteins were separated 
on a 10 % acrylamide gel, transferred to a Nylon membrane and exposed to autoradiographic film 
(32P). The membrane was subsequently probed with 12CA5 to confirm the successful 
immunoprécipitation of both hCDCô wild type and hCDCô AAA (Western). Protein size markers 
(in kDa) are shown to the left. (B) hCDCô is exclusively phosphorylated on serine residues. 
Phosphoamino acid analysis of 32P-labeled wild type CDC6 was performed as described in materials 
and methods. (C) In vivo ^P-labeling of hCDCô, hCDCô AAS and hCDCô ASS (as in A). (D) 
Tryptic phosphopeptide maps of CDC6 mutants. The 32P labeled proteins were analysed by 
phosphopeptide mapping as described in materials and methods. Astéries show the dye position 
after running and x marks the sample loading point.
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Phosphoamino acid analysis of the 32P-labeled hCDC6 protein showed as expected 
that hCDC6 is only phosphorylated on serines in vivo (Figure 4.9B). Wild type 
CDC6 and two other CDC6 mutants with one or two phosphorylation sites mutated 
(SSA and SA A) were labeled with 32P in vivo (figure 4.9C) and the labeled proteins 
were analysed by phosphopeptide mapping. The wild type protein gave two strong 
signals after tryptic digestion. The SSA phosphorylation mutant gave a similar 
pattern whereas the phosphopeptide map of the SAA mutant showed only one of the 
spots. These results indicate that serine 54 and serine 74 are the mayor 
phosphorylation sites in hCDC6 (Figure 4.9D).
The Cy-motif of CDC6 is located between serine 74 and serine 106 suggesting that 
the two most N-terminal phosphorylation sites will be differently located in relation 
to the catalytic part of the kinase complex compared to serine 106. This gives some 
sterical differences that could explain why the two must N-terminal sites are the best 
kinase substrates. It was noted that the alignment of human, mouse and Xenopus 
CDC6 proteins shows a stronger conservation around the S54 and S74 
phosphorylation sites than in the vicinity of S106 (figure 4.3).
The introduction of point mutations in the phosphorylation sites, close to the Cy- 
motif, could in theory change the structure of the protein and interfere with the kinase 
interaction, and thereby indirectly affect the phosphorylation status of the proteins. To 
investigate if the mutations in hCDC6 influence the association with the kinase 
complex, the ability of the hCDC6 mutants to interact with Cyclin A and CDK2 was 
examined. Immunoprécipitation assays demonstrated that both Cyclin A and CDK2 
are associated with hCDC6 AAA and hCDC6 DDD, but not with the hCDC6 dl 93- 
100 mutant as previously shown (Figure 4.10A). The expression of all proteins was 
confirmed by Western blotting. Subsequently, the activity of the associated kinase 
complex was tested in an in vitro kinase assay (Figure 4.10B). As shown in Figure
4.1 OB, both the alanine (AAA) and the aspartic acid (DDD) mutants were able to
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interact with the active kinase complex. It was noticed that only the wild type protein 
was phosphorylated in these assays. These data exclude the formal possibility that the 
observed 32P signal could be due to binding of radioactive phosphate in the nucleotide 
binding site of CDC6 . These results demonstrate that mutations of the 
phosphorylation sites in hCDC6 does not affect the interaction with the Cyclin 
A/CDK2 complex
It further suggests, that the introduced amino acid substitutions in hCDC6 AAA and 
hCDC6 DDD have not changed the structure of the proteins dramatically. In 
conclusion, these data show that phosphorylation of CDC6 does not influence the 
stability of the tertiary complex containing CDC6/Cyclin AZCDK2.
4.4.2 Localization of mammalian CDC6 is cell cycle regulated
Protein phosphorylation regulates many cellular processes, including protein-protein 
interactions, protein stability, kinase activity, and protein localization. To 
investigate the functional consequence(s) of CDC6 phosphorylation by Cyclin 
A/CDK2 the subcellular localization of CDC6 was analysed. Using anti-CDCb 
antibodies, U 20S  cells transfected with a hCDC6 expression plasmid were subjected 
to immunofluorescence. As shown in Figure 4.11, hCDC6 is located both in the 
nucleus and in the cytoplasm. Some cells show only nuclear staining and some only 
cytoplasmic, and some show both nuclear and cytoplasmic staining. The staining 
pattern was identical in CV-1 and HeLa cells (data not shown). Different fixation 
protocols confirmed that the observed cytoplasmic localization was not due to 
diffusion of the protein during fixation (data not shown). Since the nuclear and 
cytoplasmic localization of CDC6 could be explained by cell cycle regulated 
localization of CDC6 , cells were co-stained for CDC6 , and PCNA and BrdU as 
markers of S-phase (Bravo and Macdonald-Bravo, 1987).
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Figure 4.10 CDC6 phosphorylation mutatants interact with Cyclin A/CDK2.
(A) U 20S cells were transfected with HCDC6 expression plasmids, and hCDC6 wild type and 
mutant proteins were immunoprecipitated. The association of Cyclin A and CDK2 with hCDC6 
proteins was assessed by Western blotting. As control, the expression of hCDC6 and hCDC6 
mutants was evaluated by Western blotting using 12CA5 (lower panel). Asterisks mark background 
bands due to cross reaction of 12CA5 with cellular polypeptides. (B) U20S cells were transfected 
with expression plasmids encoding hCDC6, hCDC6AAA and hCDC6 DDD proteins. hCDC6 
proteins were immunoprecipitated, and hCDC6 associated kinase activity was assayed in an in vitro 
kinase assay. Phosphorylated hCDC6 proteins and H I are indicated.
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Ectopically expressed CDC6 is exclusively cytoplasmic in cells positive for BrdU 
and in cells with strong nuclear staining of PCNA (Fig. 4.11 A), whereas nuclear 
staining was observed in cells negative for BrdU incorporation and low nuclear 
PCNA staining. These data suggest that CDC6 is relocalized to the cytoplasm during 
S-phase. To ascertain the phase of the cell cycle at which CDC6 is nuclear, CDC6 
and p i S ubexp ression  plasmids were cotransfected in U20S cells. Overexpression 
of the cyclin dependent kinase inhibitor p 16,NK4 causes a G1 arrest in pRB positive 
cell lines (Bartek et al., 1996). When coexpressed with p i 6 , hCDC6 was located 
dominantly in the nucleus (Figure 4.13B), indicating that hCDC6 is nuclear in G l. 
These results suggest that CDC6 is nuclear in early phases of the cell cycle and that 
CDC6 becomes cytoplasmic during S phase of the cell cycle.
To further investigate at which stage of the cell cycle CDC6 changes from being a 
predominantly nuclear protein to become cytoplasmic, transfected cells were 
synchronized and the localization of hCDC6 evaluated. Interestingly, hCDC6 is 
predominantly nuclear in cells synchronized by aphidicolin (a DNA polymerase 
inhibitor that blocks replication initiation), whereas a more pronounced cytoplasmic 
staining of CDC6 was seen in cells arrested by a double thymidine block (figure
4.1 IB). Similar to the thymidine treated cells, CDC6 is predominantly located in the 
cytoplasm when cells are treated with hydroxy-urea, which also blocks cells in the 
beginning of S-phase (data not shown). These results indicate that the change in 
CD C6 subcellular localization coincides with initiation of DNA replication and 
activation of Cyclin A/CDK2. Since chemically induced cell cycle synchrony may 
have hidden artifacts, the timing of the change in subcellular location of CDC6 was 
confirmed using a less invasive protocol. This was done in collaboration with Jiri 
Lukas at the Danish Cancer Society by microinjection of CDC6 expression plasmids 
in serum starved Rat 12 cells.
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Figure 4.11 The localization of CDC6 changes as cells enter S-phase.
(A) U20S cells were transfected with pCMVHAhCDC6. 36 hours after transfection, the cells were 
fixed and starned for hCDC6 using ant,-hCDC6 (red) polyclonal rabbit antiserum (L20) and 
costained with ant, PCNA (green) and anti-BrdU-HTC (green). Immunostainings were counter 
stained with DAPI to visual,ze the nucleus. Arrows mark the position of corresponding cells ,n 
different pictures. (B) Drug treatment defines different points during the G l-S  transition of hCDCf 
localization. U 20S cells transfected with hCDC6 were subjected to the indicated synchronization 
drugs and stained for localization of hCDC6 (red).
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After injection the cells were restimulated with serum and CDC6 localization and 
BrdU incorporation were measured by immunostaining at different time points. In 
agreement with the previous results, these experiments demonstrated a strong 
correlation between cytoplasmic localization of CDC6 and the initiation of DNA 
replication. Thus, during early and late G l phase, CDC6 was localized strictly within 
cell nuclei. None of the cells with nuclear CDC6 incorporated BrdU. Around 12 
hours after serum stimulation, cells with mixed nuclear and cytosolic or purely 
cytosolic CDC6 protein were detected. The appearance of cytosolic CDC6 closely 
correlated with S-phase entry since all such cells were also BrdU-positive, 
demonstrating that the localization of CDC6 changes as cells enter S-phase (Petersen 
et al., 1999). Similar data describing cell cycle regulated changes in localization of 
CDC6 was reported by others (Saha et al., 1998) confirming the result that CDC6 is 
nuclear in G l and relocates to the cytoplasm in S-phase.
To test if the subcellular localization of endogenous CDC6 is similarly regulated 
during the cell cycle, the various antibodies were tested for their ability to detect 
endogenous CDC6 by immunofluorescence. An affinity purified polyclonal 
antibody, raised against the N-terminal 106 amino acids of hCDC6 , was 
demonstrated to specifically stain endogenous CDC6 based on two criteria. First, 
when the affinity purified antibody was preincubated with the antigen, the specific 
staining was lost (data not shown). Second (and more important), there was a strict 
correlation between the observed staining of CDC6 and the increased amount of 
CDC6 present in cells after serum stimulation (figure 4.12A). The monkey cell line 
CV-1 was used for these experiments as CV- cells can be synchronized by serum 
starvation and express CDC6 detectable by Western blotting and 
immunofluorescence. In these cells CDC6 accumulates 9 hours after serum 
stimulation, whereas Cyclin A appears just before cells enter S phase around 15 
hours after serum stimulation (figure 4.12A). In parallel with the protein samples, 
cover slips were fixed and stained for the presence of CDC6 (Figure 4.12B). The
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immunofluorescence showed that CDC6 accumulated in the nucleus 9 hours after 
serum stimulation, and at 18 hours after serum stimulation, when approximately 60% 
of the total population of cells were in S-phase, CDC6 were both in the nucleus and 
in the cytoplasm (more disperse staining). 24 hours after serum stimulation, when 
almost all cells were in S-phase (most likely late S), the majority of CDC6 was 
localized in the cytoplasm. These data confirm that the subcellular localization of 
endogenous CDC6 is regulated during the cell cycle, and that CDC6 changes from 
being almost exclusively nuclear in G l to become predominantly cytoplasmic during 
S-phase. It is likely that the abrupt change in localization observed with ectopically 
expressed hCDC6 is due to increased amounts of "free" CDC6 , whereas the 
relocalization of endogenous mammalian CDC6 takes place throughout S-phase.
4.4.3 The localization of CDC6 is regulated by phosphorylation
Since the timing of relocalization of CDC6 from the nucleus to the cytoplasm 
correlates with entry into S phase and the appearance of Cyclin A/CDK2 kinase 
activity (Pines and Hunter, 1990; Pagano et al., 1992; Carbonaro-Hall et al., 1993) 
the subcellular localization of the CDC6 phosphorylation mutants were examined. 
Immunofluorescence demonstrated that the non-phosphorylatable CDC6 mutant 
(hCDC6 AAA) is dominantly nuclear (Figure 4.13A), and that the mutant with 
constitutive-mimicked phosphorylation (hCDC6 DDD) remains cytoplasmic. An 
additional mutant hCDC6 AAS was shown to be mainly nuclear (4.13C) in 
agreement with that serine 54 and serine 74 appear to be the main phosphorylation 
sites in vivo. To control that these alterations in subcellular localization were not due 
to changes in cell cycle profiles of the transfected cells, FACS analysis of the 
transfected cells was performed. This analysis showed that the expression of hCDC6 
and the hCDC6 mutants had a similar effect on the cell cycle profile of the 
transfected cells (see below). Taken together these data suggest that phosphorylation 
of CDC6 regulates the subcellular localization of the protein
106
Results
A
0 3 6 9 12 15 18 21 24 time (hours)
    — ' Cyclin A
Figure 4.12 Endogenous CDC6 relocalizes to the cytoplasm during S-phase.
(A) The expression of CDC6 is growth regulated. CV-1 cells were serum starved for 48 hours, and 
stimulated to reenter the cell cycle by addition of serum. Cell extracts were prepared at the indicated 
time points after serum addition, and analysed by Western blotting for CDC6 and Cyclin A 
expression using D C SlSland rabbit polyclonal anti Cyclin A antibody. (B) The subcellular 
localization of CDC6 changes during S-phase. In parallel to the time course described above, cover 
slips were fixed (at the indicated time points) and stained for CDC6 using an affinity purified 
polyclonal antibody raised against the N-terminal 106 amino acids of human CDC6 (X27).
107
Results
hCDC6 wt hCDC6 AAA hCDC6 DDD hCDC6 dl 93-100
a hCDC6
DAPI
B
a hCDC6
DAPI
hCDC6 wt
+ p16
hCDC6 AAA 
+ p16
hCDC6 DDD 
+ p16
hCDC6 dl 93-100 
+ p16
hCDC6 AAS DAPI
Figure 4.13 Localization of CDC6 is regulated by phosphorylation.
(A) hCDC6, HCDC6 AAA, HCDC6 DDD and hCDC6 dl 93-100 were expressed in U 20S cells by 
transient transfection of pCMV expression plasmids. Cover slips were stained for hCDC6 using a 
polyclonal rabbit anti-hCDC6 serum (X27). (B) p l6  only affects the localization of wild type 
hCDC6. The same hCDC6 mutants as in A were expressed together with p l6  and stained for 
hCDC6 localization. (C) Immunostaining of overexpressed hCDC6 AAS. DAPI stainings are shown 
below each picture.
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In addition phosphorylation of CDC6 have no influence on the CDC6/Cyclin 
A/CDK2 interaction since both hCDC6 AAA and hCDC6 DDD mutant proteins bind 
Cyclin A/CDK2 .In agreement with this notion, hCDC6 dl 93-100 localization is, 
similar to the non-phosphorylatable hCDC6 mutant, mainly nuclear (Figure 4.13A). 
Furthermore, the coexpression of p 16INK4 with the hCDC6 DDD mutant demonstrates 
that inhibition of CDK activity in the transfected cells was not sufficient to alter the 
subcellular localization of this mutant (Figure 4.13B). In conclusion, our data strongly 
suggest that the phosphorylation of CDC6 relocalizes the protein from the nucleus to 
the cytoplasm during S phase. In agreement with these results, Serine 54 and the 
following basic residues of the phosphorylation site were found to be critical for 
nuclear localization of human CDC6 by others (Takei et al., 1999).
Since our data suggest that the phosphorylation of CDC6 by Cyclin A/CDK2 is 
responsible for the relocalization of CDC6 during S-phase, one prediction would be 
that CDC6 becomes phosphorylated when cell enter S phase. To test this prediction, 
C V -1 cells were synchronized by serum starvation, and at different times after 
addition of serum the cells were labeled with radioactive phosphate (32P). 
Immunoprécipitations of CDC6 showed that endogenous CDC6 is increasingly 
phosphorylated when cells enter S-phase (Figure 4.14A). As a control for these 
experiments, W estern blotting showed that CDC6 was expressed in all the processed 
samples (Figure 4.14B), and FACS analysis confirmed that the cells were 
successfully synchronized.
In conclusion the expression of the mammalian CDC6 protein was shown to be growth 
regulated and the subcellular localization to be controlled by Cyclin A/CDK2 
phosphorylation. In early phases of the cell cycles, where CDC6 is not 
phosphorylated, CDC6 is localized in the nucleus, and as Cyclin A/CDK2 is activated 
and cells progress into S-phase CDC6 becomes predominantly cytoplasmic.
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Figure 4.14 Phosphorylation of CDC6 is cell cycle regulated.
(A) CV-1 cells were serum starved for 48 hours and subsequently restimulated with serum. The cells 
were labeled with (32p)-0rthophosphate for 3 hours before the indicated time points were the cells 
were harvested. CDC6 was immunoprecipitated with the monoclonal antibody DCS 181. 
Immunoprécipitations with DCS181 and 12CA5 (control) using cell extracts from asynchronous 
growing cells labeled for 3 hours with 32P were performed as controls. In vitro translated 35S-labeled 
HAHCDC6 protein was analysed on SDS-PAGE together with the immunoprécipitations. The 
asterisk indicates a background band due to cross reaction of DCS 181 with a cellular protein. 
Molecular weight markers are indicated to the left. (B) In parallel to the above time course, non­
labeled samples were prepared for Western blotting and FACS analysis.
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4.5 Effects of CDC6 and CDC6 mutants on cell cycle progression
Transcriptional activation of E2F target genes and the phosphorylation of CDK 
substrates govern progression through the mammalian cell cycle. The mammalian 
CDC6 gene is regulated by E2F (Hateboer et ah, 1998; Ohtani et ah, 1998; Yan et 
ah, 1998) , and CDC6 is, as described above, a substrate of the Cyclin A/CDK2 
complex. It was therefore interesting to test if the ability of E2F to stimulate S-phase 
entry could be reconstituted by CDC6 and other E2F targets and if phosphorylation 
of CD C6 has a role in regulating cell cycle progression. Both the Cyclin E and 
Cyclin A genes are transcriptionally regulated by E2F (DeGregori et ah, 1995;
Ohtani et al., 1995; Schulze et al., 1995). On the basis of several experiments, Cyclin 
E is now believed to be one of the, if not the, most important E2F regulated gene at 
the G 1/S transition (reviewed by Helin, 1998). As described above the Cyclin 
A/CDK2 complex binds and phosphorylates CDC6 . Therefore, the effect of hCDC6 , 
Cyclin E and Cyclin A overexpression on cell cycle progression was analysed. 
Cotransfections with CD20 were performed to enable selection of transfected cells 
for cell cycle profile analysis (van den Heuvel and Harlow, 1993). U 20S  cells were 
transfected with pCMVCD20, pCM VhCDCô or/and Cyclin E or Cyclin A 
expression vectors, and the cell cycle profiles of the CD20 positive cells were 
analysed. As shown in figure 4.15A overexpression of hCDC6 leads to a minor 
accumulation of cells in S-phase as does the expression of either Cyclin E or Cyclin 
A. Coexpression of human CDC6 with either Cyclin E or Cyclin A induced a 
substantial number of cells to enter S-phase. The experiment was repeated in other 
cell lines with the same result (data not shown).
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Figure 4.15 Effect of CDC6 overexpression on cell cycle progression.
(A) Human CDC6 induces S-phase when coexpressed with Cyclin E or Cyclin A. U20S were 
transfected with expression plasmids encoding the indicated proteins and the cell cycle profiles of 
the CD20 positive cells are shown. The data are representatives of several independent experiments.
(B) Mutation of the CDK phosphorylation sites in CDC6 does not abrogate cell cycle progression 
(as in A).
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Both the Cyclin E and the Cyclin A associated kinase activities are essential for S- 
phase entry. The phosphorylation of key substrates is believed to promote the 
initiation of DNA replication. Hence, if phosphorylation of human CDC6 by the 
Cyclin A/CDK2 complex is essential for entry into S-phase mutation of the 
phosphorylation sites should inhibit this process. The effect on cell cycle progression 
of overexpression of hCDC6 mutants was examined. U 20S  cells were transiently 
transfected with CD20 and different expression vectors. The cell cycle profiles of the 
CD20 positive cells demonstrate that overexpression of the hCDC6 phosphorylation 
mutants, like wild type hCDC6 , lead to a slight increase in the amounts of S-phase 
cells (figure 4.15B). These data suggest that phosphorylation of hCDC6 is not 
essential for initiation of DNA replication, although it can not be excluded that the 
endogenous hCDC6 protein is able to overcome the hCDC6 mutants or that the 
introduced mutations somehow abrogate the function of CDC6 . Therefore, the 
increase of S-phase cells observed when hCDC6 is coexpressed with a cyclin, is 
likely due to an additive effect and not a cooperative effect. In agreement with 
hCDC6 phosphorylation not being essential for DNA replication in mammalian 
cells, also CdclS phosphorylation were shown to be dispensable for initiation of 
DNA replication in S. pombe (Jallepalli et al., 1997; Lopez-Girona et al., 1998). The 
role of Cdc6p phosphorylation is not clear, but deletion of the first 46 N-terminal 
amino acids, containing several putative CDK phosphorylation sites, has no effect on 
cell proliferation (Drury et al., 1997). Together these data suggest that 
phosphorylation of CDC6 proteins is not directly linked with the initiation of DNA 
replication.
As mentioned before, one characteristic of E2F-1 is its ability to induce DNA 
replication when overexpressed in quiescent rat fibroblasts. So far, no E2F target has 
been able to do that, and it is likely that the effect is obtained by the coordinated 
activation of several genes. In collaboration with J. Lukas at the Danish Cancer 
Society, a human CDC6 expression vector alone or in combination with Cyclin E,
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were microinjected into in serum starved Rati cells to test if expression of hCDC6 
would induce DNA replication under these conditions. In these assays no induction 
of DNA replication was observed, but when the cells were by examined by 
immunofluorescence only overexpression of Cyclin E was confirmed. The inability 
to express human CDC6 in quiescent cells makes it impossible to evaluate if CDC6 
has any effect on S phase entry in this system. Next, to understand if CDC6 
phosphorylation is important for cells to enter S-phase from a quiescent state, the 
phosphorylation mutant hCDC6 AAA was injected into serum starved cells and the 
ability of the cells to enter S-phase upon serum stimulation was evaluated. Although 
the cells enter S-phase with a slight delay, no block of DNA-synthesis was observed, 
confirming the data from the tranfections experiments, demonstrating that 
phosphorylation of hCDC6 is not necessary for S-phase progression.
The inability to positively identify the ectopically expressed human CDC6 in starved 
cells, indicates that a cellular system down regulates the expression of the protein, 
even when expressed from a CMV promoter, that supports transcription and 
following expression of genes as Cyclin E and E2F-1 in the same experimental set 
up. An explanation could be that the human CDC6 protein is highly unstable under 
these conditions, preventing accumulation of the mammalian CDC6 protein in serum 
starved cells.
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4.6 Human CDC6 is degraded by the ubiquitin pathway
Ubiquitin mediated degradation is an important mechanism regulating cell cycle 
progression (see introduction). Cell cycle transitions are dependent on ubiquitination 
and degradation of specific proteins. The yeast proteins Cdc6p and CdclS have 
recently been found to be degraded by the ubiquitin pathway, and the instability of 
Cdc6p and C dclS  is dependent on SCF (Skp 1 -Cdc53/Cullin-F-box) complex 
members (Drury et al., 1997; Kominami and Toda, 1997; Jallepalli et al., 1998; 
Sanchez et al., 1999a).
4.6.1 Human CDC6 protein has a short half-life
To test if the human CDC6 , as the yeast homologues, is a short lived protein U 20S  
and MRC5 cells were treated with cyclohexamide (CHX) in a time course 
experiment. Protein samples were analysed by Western blotting to investigate if and 
how quickly human CDC6 would be degraded in the absence of protein synthesis.
As shown in figure 4.16 the human CDC6 protein has a short half life, and is 
degraded with kinetics similar to p53. The results show that the human CDC6 both 
in primary fibroblasts (MRC5) and in a transformed cell line (U 20S) is a short lived 
protein with an estimated T 1/2 of 60-90 minutes.
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Figure 4.16 Human CDC6 has a short half-life.
U 20S and MRC5 cells were treated with cyclohexamide as indicated. (A) Time in hours (B) Time 
in minutes. The expression of human CDC6, p53 and actin as loading control was analysed by 
Western blotting.
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4.6.2 Proteasome inhibitors stabilize human CDC6
In both S. cerevisiae and S. pombe the degradation of Cdc6p /C d c l8 is mediated by 
ubiquitination (Drury et ah, 1997; Kominami and Toda, 1997; Jallepalli et ah, 1998; 
Sanchez et ah, 1999a). Proteins degraded by the ubiquitin pathway accumulate in the 
presence of inhibitors of the proteasome. To test if the degradation of CDC6 in 
mammalian cells is due to proteasome mediated degradation, U 20S  and MRC5 cells 
were cultured in the presence of MG 132, LLM and Lactacystein. These drugs are 
potent inhibitors of the proteasome (MG 132 and lactacystein) and the calpain 
proteases (MG 132 and LLM) (Lee and Goldberg, 1998). The treatment with MG 132 
and lactacystein led to increased levels of CDC6 whereas the addition of DMSO and 
LLM  had no effect (figure 4.17A). These results demonstrate that the mammalian 
CD C 6 is a short lived protein which turn over is likely mediated by ubiquitination 
followed by degradation by the proteasome.
4.6.3 Human CDC6 is poly-ubiquitinated in vivo
To obtain further evidence for ubiquitin mediated degradation of human CDC6 , 
experiments were performed to test if human CDC6 is poly-ubiquitinated in vivo. 
HeLa cells were transfected with a hCDC6 expression vector, an HA-ubiquitin 
expression vector or with both together. The transfections were done in duplicates, 
one plate was treated with MG 132 and the other with DMSO as a control. The cells 
were lysed in RIPA buffer and the extracts used for immunoprécipitations of CDC6 . 
The immunoprécipitations were analysed by Western blotting and probed with an 
antibody to CDC6 (figure 4.17B lane 1-8). Endogenous CDC6 was found to be 
ubiquitinated in samples from cells treated with MG 132. Ectopic expression of 
hCDC6 further increased the amount of poly-ubiquitinated CDC6 observed. 
Ubiquitinated CDC6 was observed as a ladder of proteins with a higher molecular
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weight than CDC6 itself. The incorporation of HA-tagged ubiquitin was evaluated 
with 12CA5 (figure 4.17B lane 9-12). The 12CA5 antibody and the anti hCDC6 
antibody recognizes different epitopes of the poly-ubiquitinated hCDC6 probably 
explaining the difference between the observed signals, as was also noted by others 
in similar types of experiments (Marti et al., 1999).
The identification of poly-ubiquitinated CDC6 in vivo strongly suggests that the turn 
over of the mammalian CDC6 protein is controlled by ubiquitination, targeting the 
protein for degradation by the proteasome.
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Figure 4.17 Human CDC6 is degraded by the ubiquitin pathway.
(A) U20S and MRC5 cells were treated for 8 hours with the indicated drugs. DMSO was used as 
control.. The expression of CDC6, p53 and actin was evaluated by Western blotting. (B)
Identif ication of poly-ubiquitinated CDC6 in vivo. HeLa cells were transfected with the indicated 
expression vectors, and cell lysates prepared in RIPA buffer including 5 mM NEM. CDC6 was 
immunoprecipitated using polyclonal anti CDC6 antibody (X27) and analysed by Western blotting 
using DCS 181 (lane 1-8) and 12CA5 (lane 9-12). The presence of poly-ubiquitinated CDC6 is 
indicated.
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4.7 Cell cycle regulated expression of CDC6
The expression of yeast Cdc6p and CdclS is controlled by both transcriptional 
activation and protein degradation (see introduction). The degradation of yeast 
Cdc6p and CdclS takes place at the G l-S  transition and is dependent on the SCF 
complex. Degradation of C dclS prevents reinitiation of DNA replication (Jallepalli 
et al., 1997), whereas degradation of Cdc6p does not seem to be essential for 
viability of S. cerevisiae (Drury et al., 1997). The mammalian CDC6 gene is 
transeriptional^aetivated by E2F when quiescent cells are restimulated to enter the 
cell cycle (Hateboer et al., 1998; Ohtani et al., 1998; Yan et al., 1998) correlating 
with the accumulation of CDC6 protein. The protein level of mammalian CDC6 is 
not, as S. cerevisiae Cdc6p and S. pombe CdclS, downregulated as cells enter and 
progress through S-phase (figure 4.12A and 4.14B).
To clarify, if the protein level of the mammalian CDC6 protein is cell cycle 
regulated in cycling cells, the abundance of CDC6 was analysed in synchronized 
populations of proliferating cells. U 20S  cells were synchronized by centrifugal 
élutriation and the different fractions were analysed by flow cytometry to determine 
the cell cycle distribution of the samples. Protein extracts from fractions with 
different cell cycle profiles were analysed by Western blotting (figure 4 .ISA). The 
expression of CDC6 in the samples from the élutriation shows that very little CDC6 
is present in the sample containing mainly G l cells (F3), whereas all the other 
samples contain an almost equal amount of CDC6 . Expression of Cyclin B in the 
same samples was analysed to confirm that the synchronization had been successful. 
Cyclin B is, as CDC6 , absent in the G l sample. The cell cycle regulated expression 
of CDC6 was also observed in chemically synchronized cells. HeLa cells were 
synchronized with nocodazole. The cells were released, and samples for W estern 
blotting and FACS analysis were taken at different time points. As before, a dramatic
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down regulation of CDC6 was observed in G l samples, whereas high level of CDC6 
was, also here, observed in the S-phase and mitotic samples (figure 4.18B).
Using two different synchronization protocols, it was demonstrated that the protein 
level of CDC6 changes dramatically in every cell cycle, and not only when cells 
enter and exit the cell cycle. The timing of expression of CDC6 in mammalian cells 
is different from the published expression pattern of S. cerevisiae Cdc6p and S. 
pombe CdclS. Cdc6p and CdclS are expressed in late mitosis and G l and decrease 
rapidly as cell enter S-phase (Nishitani and Nurse, 1995; Piatti et al., 1995; Muzi- 
Falconi et al., 1996). The high level of CDC6 observed in metaphase arrested HeLa 
cells shows that the expression of human CDC6 is fundamentally different from the 
expression of the S. pombe CdclS protein, that was shown to be highly unstable at 
this point of the cell cycle (Baum et al., 1998).
4.8 CDC6 expression is, in part, regulated by proteolysis
The previous data demonstrate that CDC6 is highly unstable and it is likely that the 
instability of CDC6 contribute to the cell cycle regulated expression pattern of 
CD C6 in mammalian cells. To study the role of CDC6 degradation it is essential to 
know how CDC6 is targeted for degradation.
4.8.1 The instability of hCDC6 depends on N-terminal residues
To understand which region of CDC6 that mediates the degradation of CDC6 , 
different hCDC6 deletion mutants were expressed in HeLa cells. Samples were 
treated with cyclohexamide for 6 hours. After 6 hours in the absence of protein 
synthesis, the endogenous CDC6 is degraded.
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Figure 4.18 The level of human CDC6 fluctuates in proliferating cells.
(A) U 20S cells were elutriated and the expression of CDC6 and Cyclin B in different fractions was 
analysed. The percentages of cells in G l and S in the individual samples are indicated below the 
blots. (B) HeLa cells were synchronized in mitosis by a thymidine block followed by a nocodazole 
block. Samples were harvested at the indicated time points after release and analysed for the 
expression of CDC6 and Cyclin B. In parallel, samples for FACS analysis were prepared and the 
percentages of cells in Gl and S-phases is indicated below. In both experiments actin was used as a 
loading control.
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Figure 4.19A shows that the C-terminal deletion mutants are subjected to the same 
regulation as the endogenous CDC6 . Interestingly, deletion of the first 110 N- 
terminal amino acids residues abolished this regulation. This hCDC6 mutant is 
expressed at almost the same level in cells treated with cyclohexamide as in the 
untreated sample. As control for the treatment, the expression of the endogenous 
CD C6 is shown to be down- and upregulated. The mutant lacking the 185 N- 
terminal amino acids is likewise, also more stable than the endogenous CDC6 .
The N-terminal of human CDC6 contains, as described above, several CDK 
phosphorylation sites and the cyclin binding motif. Also the N-terminal regions of 
Cdc6p and Cdc 18 have been shown to regulate the stability of these molecules (Drury 
et al., 1997; Kominami and Toda, 1997). Phosphorylation of Cdc 18, and likely Cdc6p, 
by S and M-phase CDKs links the proteins to the SCF complex, leading to 
ubiquitination and degradation of Cdc 18 (Jallepalli et ah, 1997; Jallepalli et ah, 1998). 
It seems that this could be true also for the mammalian CDC6 protein. The 
phosphorylation mutants described previously were tested in the same assay as the 
deletion mutants. If, phosphorylation targets hCDC6 for degradation, the hCDC6 
AAA mutant should be stabilized, whereas the DDD mutant should be highly unstable. 
As seen in 4.19B the mutations in the phosphorylation sites have a minimal effect on 
the stability of the human CDC6 protein in proliferating HeLa cells. Both mutants are 
degraded in the presence of cyclohexamide and stabilized by inhibition of the 
proteasome. The conclusion drawn from these experiments, is that degradation of 
mammalian CDC6 appears to be independent on phosphorylation status. Therefore, 
other N-terminal sequence motifs most target the hCDC6 protein for degradation.
Several mechanisms have been implicated in regulating ubiquitination. Degradation of 
p53 is regulated by changes in subcellular localization (Freedman and Levine, 1998). 
Therefore, the subcellular localization of the hCDC6 deletion mutants was 
investigated.
123
Results
Mock 111-560 186-560 1-420 1-363
endogenouODC6
hCDC6 m utants
B
human CDC6 (56-64) r k r l g d d n l  
Cyclin B1 r t a l g d i g n
Psdlp (S. C.) RLPLAAKDN
Geminin r r t l k v i q p
HA-hCDC6 mutants
Figure 4.19 Degradation of human CDC6 depends on N-terminal residues.
(A) Different hCDC6 deletion mutants were expressed at low levels in HeLa cells, and treated with 
cyclohexamide (CHX) for 6 hours. One transfection mix were prepared per construct, and shared 
between three dishes to obtain equal transfection efficiency. The Western blots were probed with an 
anti CDC6 antibody (DCS 181) that recognizes a central part of human CDC6 present in all hCDC6 
mutants. (B) Alignment of hCDC6 aa 56-64 with destruction box sequences from Cyclin B l, Pdslp 
and Geminin. (C) The instability of hCDC6 is independent on the CDK phosphorylation sites. The 
stability of the phosphorylation mutants were assayed as in A. The hCDC6 mutants were identified 
with anti HA antibody to distinguish them from the endogenous CDC6 protein.
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As seen in figure 4.20A the stable hCDC6 111-560 and hCDC6 186-560 deletion 
mutants were shown to be mainly cytoplasmic. To investigate if the stabilization of 
these mutant could be due to the cytoplasm localization a NLShCDC6 111-560 
mutants was constructed. The fusion of an NLS sequence to hCDC6 111-560 did not 
confer instability to the protein (figure 4.19C and 4.20B). As the hCDC6 111-560 
and NLS-hCDC6 111-560 are both stable and the hCDC6 DDD and hCDC6 AAA 
mutants, that are differently located, are both unstable, it seems unlikely that the 
subcellular localization of human CDC6 regulates the stability of human CDC6 .
Data obtained on the localization and the stability of hCDC6 mutants are 
summarized in figure 4.20B. The half life of the N-terminal deletion mutants is 
estimated to be more than 3 hours.
4.8.2 Identification of a destruction box sequence in hCDC6
Two major ubiquitin ligases are involved in cell cycle regulation. The SCF ubiquitin 
ligase complex is active in S-phase and the anaphase promoting complex (ABC) is 
active in M and G1 and GO (see introduction). The SCF complex has been 
implicated in the degradation of the yeast Cdc6p /C dcl8 molecules (Drury et al., 
1997; Kominami and Toda, 1997; Jallepalli et ah, 1998; Sanchez et ah, 1999a), but 
the expression pattern and the data presented above suggest that human CDC6 is 
differently regulated. The expression of human CDC6 parallels Cyclin B in 
synchronized U 20S  and HeLa cells (figure 4.18), suggesting that human CDC6 as 
Cyclin B could be a target of the mammalian anaphase promoting complex. 
Ubiquitination and degradation of Cyclin B and other APC targets dependent on a 
destruction box sequence frequently found in the N-terminal part of the protein 
(Glotzer et ah, 1991; Hershko, 1997).
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Figure 4.20 Degradation of HCDC6 is not regulated by localization.
(A). The indicated hCDC6 deletion mutants were expressed in U20S cells and the subcellular 
localization was analysed using 12CA5. (B) The table summarizes the localization and 
stability/instability of hCDC6 mutants.
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A comparison of the primary sequence of hCDC6 with destruction box sequences in 
Cyclin B, Pdslp  and Geminin revealed a putative destruction box sequence at aa 56- 
64 (figure 4.3 and figure 4.21 A). The peptide is located C-terminal to serine 54 and 
is highly conserved in human, mouse and Xenopus CDC6 proteins (figure 4.3), 
whereas the yeast Cdc6p and CdclS proteins are not very homologous to the CDC6 
proteins from higher eukaryotes in this region. A deletion mutant removing 4 amino 
acid residues (aa 58-61) of the putative destruction box was constructed. The 
conserved arginine was not mutated as it is also a part of the consensus CDK 
phosphorylation site needed for correct localization of human CDC6 (this study and 
Takei et al., 1999). The stability of NLShCDC6 111-560 and the putative destruction 
box mutant (hCDC6 dl 58-61) was tested in an assay as described above. The 
N LShCDC6 111-560 was stable in this assay whereas the stability of hCDC6 58-61 
was only modestly stabilized (4.21 B). These assays were performed in 
exponentially growing cells and cell cycle specific regulated degradation may 
therefore be difficult to detect.
As previously described, it has not been possible to express wild type hCDC6 in 
serum starved cells. It is known that the APC complex is active in mitosis, G1 and in 
quiescent cells (se introduction). To test if the inability to express hCDC6 in 
quiescent cells is dependent on proteasome mediated degradation and the putative 
destruction box sequence in hCDC6 , expression vectors encoding wild type and 
mutant hCDC6 were microinjected in serum starved R ati cells. After 6 hours the 
expression was evaluated by immunofluorescence. The wild type hCDC6 protein 
was detected only in few injected cells, but if the cells were cultured in the presence 
of the proteasome inhibitor (MG 132) almost all injected cells expressed hCDC6 . 
This demonstrates that the inability to express human CDC6 in quiescent cells is due 
to proteasome mediated degradation. The stability of the different hCDC6 mutants 
was tested by microinjection of expression plasmids in quiescent cells.
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Figure 4.21 The N-terminal deletion stabilizes CDC6 in quiescent cells.
(A) Rati cells were synchronized by serum deprivation, and microinjected with different hCDC6 
expression plasmids together with an EGFP expression vector. The cover slips were fixed 6 hours 
after injection and stained with an anti CDC6 antibody (M20) and the positively injected cells were 
identified by the expression of the green fluorescence protein. Nuclei were stained with Dapi. (B) 
Quantification of hCDC6 positive cells compared to the number of EGFP positive cells. The result 
of three independent microinjection experiments is shown.
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Expression of hCDC6 111-560 and the destruction box mutant (hCDC6 dl 58-61) 
was observed in many injected cells in the absence of proteasome inhibitor (figure 
4.22 A and B).
These data demonstrate that the expression level of human CDC6 , as the yeast 
homologues, is highly regulated and controlled by both transcriptional activation and 
regulated proteolysis. The results show that the degradation of hCDC6 in quiescent 
cells is, mediated by the N-terminal of hCDC6 , and in part, by a peptide with 
homology to destruction box sequences. The role of the destruction box m otif 
predicts that human CDC6 is ubiquitinated by APC. Furthermore, the periodic 
protein expression of human CDC6 strengthens the hypothesis that the mammalian 
CDC6 protein is an APC substrate and that ubiquitination of CDC6 by the APC 
controls the protein level of human CDC6 during cell cycle progression.
4.8.3 Deregulated expression of hCDC6 leads to loss of cell viability
The level of mammalian CDC6 is lowest just after mitosis. The metaphase to 
anaphase transition is in S. cerevisiae dependent on the degradation of P dslp  
(Cohen-Fix et al., 1996; Yamamoto et al., 1996). Whereas the degradation of the 
mitotic cyclins is needed for exit of mitosis but not for initiation of mitosis in either 
S. cerevisiae (Surana et al., 1993) or higher eukaryotes (Holloway et ah, 1993). In 
addition the APC has been implicated in the degradation of Geminin, an inhibitor of 
DNA replication (McGarry and Kirschner, 1998). The role of substrate degradation 
has been addressed by expression of mutants with disrupted d-box sequences. The 
identification of hCDC6 as a putative APC substrate, and the stabilization of the d- 
box mutant enables the elucidation of a putative role of hCDC6 destruction in cell 
cycle regulation. If mammalian CDC6 must be degraded for cells to go through 
mitosis, expression of the d-box mutant should result in accumulation of cells in
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mitosis. Another possibility is that the high level of hCDC6 in early G1 will lead to 
stimulation of S-phase entry compared to the wild type hCDC6 protein. As 
previously, hCDC6 and hCDC6 mutants were expressed together with CD20 in 
transient transfection experiment, and the cell cycle distribution analysed. The 
expression of hCDC6 dl 58-61 did not have any dramatic effect on the cell cycle 
(data not shown). So far, it has been impossible to establish cell lines with high 
levels of hCDC6 overexpression indicating that deregulated expression is toxic for 
mammalian cells. In the plates with cells transfected with hCDC6 and hCDC6 
mutants dying cells was regularly observed and the amount of dead cells was 
increased by transfection with NLShCDC6 111-560 and hCDC6 58-61. FACS 
samples were prepared at different time points after transfection with different
w
hCDC6 constructs and analysed for the presence of cells with a DNA content lo /e r  
than 2N (sub G l)  as an indicator for cell death. As shown in figure 4.22 A and B, the 
expression of NLShCDC6 111-560 and hCDC6 dl 58-61 led to an increase of the 
sub G l population, indicating that the expression of these hCDC6 mutants was 
highly toxic. Immunostainings of cells cultured on cover slips showed that many 
cells expressing high levels of hCDC6 and hCDC6 mutants were dying with an 
apoptotic like phenotype. The data suggests that deregulation of hCDC6 has 
dramatic consequences for the cell and furthermore it suggests that regulation of 
both the localization and degradation of hCDC6 are important regulatory 
mechanisms.
4.8.4 Future directions
In the previously described experiments in which the stability of the hCDC6 mutants 
was tested it was observed that the d-box mutant is not as stabile as the hCDC6 111- 
560 mutant in proliferating cells. This could indicate that the deletion of the four 
amino acids in the putative destruction box does not completely prevent the
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Figure 4.22 Induction of cell death in cells expressing CDC6 mutants.
(A) Quantification of the sub G l populations in HeLa cells at different timepoints after transfection. 
HeLa cells were transfected with expression plasmids encoding the indicated hCDC6 proteins and 
analysed by FACS at 24, 34 and 48 hours after removal of the precipitate. (B) The FACS diagrams 
of the samples harvested after 34 hours. (C) Immunostaining of cells expressing hCDC6 and 
hCDC6 mutants at 34 hours after transfection. The cells were stained using M20 and the nuclei 
counterstained with Dapi.
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interaction with the APC, or that other N-terminal sequences are involved in 
controlling the degradation of mammalian CDC6.
It is essential to understand if the degradation of mammalian CDC6 is cell cycle 
regulated. The above data could be explained by a double mechanism regulating the 
degradation of hCDC6. If the identified d-box sequence is important for degradation 
of hCDC6 in GO, G l and part of mitosis other sequences could target the protein for 
degradation in S and G2. From the above described data it can not be excluded that 
phosphorylation could specifically regulate degradation of hCDC6 at a specific point 
in S-phase which is not detected in exponentially growing cells. The main S-phase 
E3 ligase is the SCF complex. It is not yet clear which signal targets proteins for 
degradation by SCF in mammals. In yeast, CDK phosphorylation of the substrates 
triggers ubiquitination and thereby degradation. In mammalian cells some substrates 
might by marked for degradation by phosphorylation but resent data demonstrate 
that E2F-1 degradation by the mammalian SCF complex does not depend on 
phosphorylation, but on the N-terminal region, that mediates the interaction with the 
SCF complex (Marti et ah, 1999). Therefore, other sequences than the 
phosphorylation sites, could mediate interaction of human CDC6 with the SCF, and 
thereby target hCDC6 for degradation in S-phase.
A correlation between degradation and ubiquitination is expected, but is should be 
tested if the different hCDC6 mutants are ubiquitinated in vivo or alternatively in 
vitro. An in vitro ubiquitination assay for hCDC6 could be usefull to test the 
different mutants and if possible to test if the ubiquitination of hCDC6 is APC and/or 
SCF dependent. Finally, it is also possible that mammalian CDC6 degradation is 
initiated by ubiquitination of CDC6 by a E3 ligase that is distinct from the SCF and 
APC complexes. Alternatively, if cell extracts could support ubiquitination of 
hCDC6 in vitro, extracts from synchronized cells could be used to test the stability of 
the different mutants. In this way it could be tested which domains of hCDC6 that
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regulate the degradation of hCDC6 at different point of the cell cycle. If other 
destabilizing elements can be identified in hCDC6 mutants of these would be useful 
to establish the role of hCDC6 degradation in cell cycle regulation.
It is possible that the degradation of mammalian CDC6 is necessary in mitosis in
mammalian cells to allow the new replication complexes to form correctly. It is not
clear why high levels of hCDC6 expression is toxic. It would be interesting to test if 
v
c o n tin u ^  expression of hCDC6 interferes with the association of other replication 
proteins with DNA or otherwise disturbs the structure of chromatin in a way that 
prohibits DNA replication or chromosome separation.
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5. Discussion
Cell cycle progression in eukaryotes is regulated by cyclic changes in protein 
activities obtained by coordinated transcriptional activation of specific genes, timed 
activation of the cyclin dependent kinases and regulated protein degradation. The 
identification of mammalian homologues to yeast proteins involved in cell cycle 
regulation and the control of DNA replication suggests that the mechanisms 
regulating these processes are conserved in all eukaryotes. In this work, the cell 
cycle regulated expression of the mammalian CDC6 protein, its regulation by the 
cyclin dependent kinases and the ubiquitination system has been described.
The human CDC6 gene was identified by homology to the CdclS protein from S. 
pombe. The central region of the CDC6 proteins is highly conserved in all species.
An alignment, of the human CDC6 protein with yeast and other mammalian CDC6 
proteins, shows that all the proteins contain CDK phosphorylation sites, although the 
position and surroundings are more homologous between the human, mouse and 
Xenopus CDC6 than between human CDC6 and yeast Cdc6p/Cdcl8. Similarly, the 
cyclin binding domain and the putative destruction box sequence are found only in 
CDC6 molecules from multicellular organisms. It is therefore likely, that the 
function of CDC6 is conserved within different species, but that the activity of the 
protein is controlled by different mechanisms.
The data presented here suggest that the protein level of CDC6 in mammalian cells 
is controlled by E2F dependent transcriptional regulation and by ubiquitin mediated 
degradation. Furthermore the subcellular localization of mammalian CDC6 is 
regulated by Cyclin A/CDK2 phosphorylation. All together the ability of mammalian 
CDC6 to stimulate DNA replication is restricted to a period in late G l and S-phase.
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5.1 Cyclin A/CDK2 phosphorylation of mammalian CDC6
The regulation of cell cycle progression in eukaryotes is governed by CDKs. At least 
nine different CDKs have been described so far, which can associate with a similar 
number of cyclins (Morgan, 1997). Cyclins/CDKs are widely believed to 
phosphorylate proteins, whose activities are essential for traversing cell cycle 
boundaries. Thus, to understand the molecular mechanisms that regulate cell 
proliferation, it is fundamental to identify the substrates, whose activities are 
regulated by the CDKs.
The results presented in this thesis demonstrate that mammalian CDC6, a protein 
essential for the initiation of DNA replication, is phosphorylated by Cyclin A in 
association with CDK2, and that this phosphorylation regulates the function of 
hCDC6 by altering its subcellular localization. The data show that human CDC6 
binds to Cyclin A/CDK2 in vitro and in vivo, and that this binding is dependent on a 
Cy-motif, also present in other proteins known to interact with Cyclin A and/or 
Cyclin E dependent kinases. Moreover, it has been demonstrated that m am malian 
CDC6 is both a nuclear and a cytoplasmic protein in exponentially growing cells, 
and that the subcellular localization of CDC6 changes during S-phase. The 
subcellular localization of human CDC6 appears to be regulated by CDK 
phosphorylation, since a non-phosphorylatable mutant of hCDC6, in which the 
phospho acceptor sites were substituted with alanines, was predominantly nuclear. 
Similarly, deletion of the Cy-motif, abolishing the interaction with Cyclin A/CDK2, 
results in constant nuclear localization of hCDC6. In addition, a hCDC6 mutant, in 
which the serines in the CDK sites were substituted by aspartic acid residues to 
mimic constitutive hCDCb phosphorylation, was always detected in the cytosol. 
Finally, phosphorylation of mammalian CDC6 is cell cycle regulated, and the 
phosphorylation correlates with the relocalization of CDC6 to the cytoplasm.
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Several lines of evidence suggest that mammalian CDC6 is a specific substrate for 
Cyclin A/CDK2 in vivo. First, Cyclin A, but not Cyclin E or Cyclin B 1, binds to 
hCDC6 with high affinity in vitro. Second, Cyclin A, but not Cyclin E, associates with 
hCDC6 in vivo. Third, CDK2, and not CDC2, is found associated with hCDC6 in vivo. 
Fourth, the change in subcellular localization of hCDC6 occurs in S phase coinciding 
with the appearance of Cyclin A/CDK2 kinase activity, but several hours later than the 
initial appearance of Cyclin D and Cyclin E kinase activities (Dulic et al., 1992; 
Pagano et al., 1992; Matsushime et al., 1994; Meyerson and Harlow, 1994). The 
combined set of data strongly suggest that mammalian CDC6 is a specific substrate for 
Cyclin A/CDK2 in vivo. Hence, mammalian CDC6 is the first identified substrate for 
Cyclin A/CDK2 with a putative role in regulating the initiation of DNA replication.
In yeast, expression of CDC6 and cdcl8+ is tightly, and both Cdc6p and CdclS are 
unstable proteins whose de novo protein synthesis is required for initiation of DNA 
replication (Kelly et al., 1993; Nishitani and Nurse, 1995; Piatti et al., 1995; Muzi- 
Falconi et al., 1996). The phosphorylation of CdclS by CDKs has recently been shown 
to target CdclS for degradation, and a non-phosphorylatable mutant of CdclS, induces 
rereplication more efficiently than wild type CdclS (Jallepalli et al., 1997). The role of 
Cdc6p phosphorylation in S. cerevisiae has not been reported. It is known that the Clb- 
dependent kinases (both the S-phase promoting Clb5 and Clb6, and the M-phase 
promoting Clbl-4) prevent rereplication by blocking the formation of the 
preReplication Complex (Piatti et al., 1996) and that Cdc6p interacts with the 
Cdc28/Cyclin B kinase (Elsasser et al., 1996). Overexpression of Cdc6p allows Cdc6p 
to associate with chromatin in G2 and M, but does not recruit MCM proteins, 
suggesting that S- and M-phase kinases inhibits the association of the MCMs, but not 
Cdc6p, with origins of replication (Tanaka et al., 1997).
Previously, it has been demonstrated that CDC6 transcription is activated in mid-to- 
late Gl when cells enter the cell cycle from a quiescent state, whereas the mRNA
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level is only modestly altered during the cell division cycle in proliferating cells 
(Williams et al., 1997; Hateboer et al., 1998; Leone et al., 1998). In contrast to the 
yeast homologues, the level of mammalian CDC6 is not downregulated in S-phase 
suggesting that the activity of the protein is restricted by another mechanism. The 
presented data suggests that the activity of mammalian CDC6 is regulated by 
phosphorylation, and that the phosphorylation targets mammalian CDC6 to the 
cytoplasm during S-phase. It is still unclear if the observed change in subcellular 
localization is due to active nuclear export or if the cytoplasmic accumulation of 
mammalian CDC6 is achieved by inhibition of nuclear transport in combination with 
nuclear degradation of the mammalian CDC6 protein after initiation of DNA 
replication. In this connection, it is noteworthy that hCDC6 does not contain a 
consensus nuclear localization signal (NLS) or a nuclear exclusion signal (NES).
Both, Xenopus CDG6 (Coleman et al., 1996) and the S. cerevisiae Cdc6p proteins 
(Jong et al., 1996), contain putative NLS sequences that are not conserved in the 
human and mouse CDC6 molecules. Therefore, the subcellular localization of 
mammalian CDC6 may be mediated by protein-protein interactions. In agreement 
with the data presented here, serine 54 and the basic residues of the phosphorylation 
site were shown to be important for nuclear localization of hCDC6 (Takei et al.,
1999). Therefore, the phosphorylation site including the basic amino acids maybe part 
of a NLS that is masked by phosphorylation. In agreement with this, deletion of the 
N-terminal of hCDC6 resulted in cytoplasmic localization of the mutant hCDC6 
protein, favoring the model that the non-phosphorylated N-terminal of CDC6 contains 
a NLS needed for nuclear localization of hCDC6. It will require further studies to 
understand if phosphorylation of mammalian CDC6 stimulates active transport of the 
protein from the nucleus to the cytoplasm during S-phase. Recent reports, 
demonstrate that nuclear export of Cdc25C in various species is mediated by a 
phosphorylation specific interaction between Cdc25C and 14-3-3 proteins (Lopez- 
Girona et al., 1998; Dalai et al., 1999; Kumagai and Dunphy, 1999). The cytoplasmic
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localization of phosphorylated mammalian CDC6 could theoretically be regulated by 
a similar mechanism.
As described in the introduction, CDK activity is both required for entry into S-phase 
of the cell cycle and for restricting replication to “once and only once” per cell cycle 
in yeast. Cyclin A/CDK2 kinase activity is required for entry into S-phase (Girard et 
al., 1991; Pagano et al., 1992) and the demonstration that mammalian CDC6 is 
phosphorylated by Cyclin A/CDK2 makes it is conceivable that mammalian CDC6 is 
an essential substrate for Cyclin A/CDK2, and that the phosphorylation of mammalian 
CDC6 is required for cells to initiate DNA synthesis. If tins was true, a non- 
phosphorylatable mutant of hCDC6 that retained all biochemical activities of hCDC6 
should work as dominant negative and prevent progression into S-phase of the cell 
cycle. In the assays described in this thesis it does not appear to be the case. The non- 
phosphorylatable mutant of hCDC6 (hCDC6 AAA) does not prevent DNA replication 
in transfected or micro injected cells, suggesting that phosphorylation of hCDC6 is 
not required for cells to enter S-phase. Consistent with the notion that phosphorylation 
of the mammalian CDC6 protein is not essential for S phase entry, it was recently 
shown that phosphorylation of CdclS in S. pombe is not required for cells to enter S 
phase (Jallepalli et al., 1997). In a recent report, others have shown that the expression 
of a similar hCDC6 mutant (GFPhCDC6 AAA) prolongs Gl in infected HSF8 cells 
(Jiang et al., 1999), indicating that inability to phosphorylate hCDC6 may delay the 
onset of DNA replication.
The results strongly suggest that phosphorylation of mammalian CDC6 by Cyclin 
A/CDK2 abolishes the ability of mammalian CDC6 to stimulate the formation of the 
preReplication Complex, which in higher eukaryotes is yet to be defined. An 
interesting question is if phosphorylation of CDC6 molecules is a mechanism by 
which higher eukaryotes prevent rerephcation of origins during S-G2-M. In contrast 
to the ability of CdclS and the non-phosphorylatable mutant of CdclS to induce
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rereplication when overexpressed, it has not been possible to prove that 
overexpression of hCDC6 or the non-phosphorylatable mutants of hCDC6 are 
sufficient by themselves to induce rereplication in mammalian cells.
The inability to establish cell lines with overexpression of hCDC6 has limited the 
experimental approaches to transient transfections of the different hCDC6 mutants. 
The short experimental period in this type of assay may not be an adequate 
experimental set up to look for endoreplication in mammalian cells. The 
establishment of cell lines with conditional expression of hCDC6 and hCDC6 mutants 
could be a way to overcome this problem. The ability to control the expression of 
hCDC6 and hCDC6 mutants would allow us to test if the non-phosphorylatable 
hCDC6 mutants stimulate rerephcation under various conditions.
A second question that remains to be answered is the functionality of the ectopically 
expressed hCDC6 and h CDC6 mutants. The lack of a mammalian in vitro DNA 
replication assay has made it difficult to address this point. A cell free replication 
system based on HeLa and NIK , V 3T3 cell nuclei has been described (Krude et al., 
1997; Stoeber et al., 1998), and Xenopus CDC6 was here shown to stimulate DNA 
replication (Stoeber et al., 1998). Such a system could be very useful, to test if the 
hCDC6 mutants retain the ability to stimulate DNA replication. This could clarify if 
phosphorylation of hCDC6 is involved in regulation of DNA replication, furthermore 
it would be possible to test which domains of hCDC6 are needed for stimulation of 
DNA synthesis. Alternatively, as the S cerevisiae CDC6 gene was shown to function 
in S. pombe cdclS defective strains (Sânchez et al., 1999b), it could be tested if the 
human CDC6 gene could complement similar mutants, although previous data 
demonstrated that hCDCÔ does not complement 5. cerevisiae cdc6 mutant strains 
(Piatti, unpubl.). The possibility that phosphorylation of mammalian CDC6 restricts 
DNA replication to once and only once per cell cycle in mammalian cells, has not 
been experimentally exhausted. It would be interesting to see if expression of hCDC6
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and hCDC6 mutants in nocodazole arrested cells would enhance the rereplication 
phenotype of cells lacking functionally p53.
Overexpression of Cdc6p is not sufficient to induce rereplication in S. cerevisiae 
(Piatti et al., 1995; Piatti et al., 1996), but surprisingly Cdc6p induces rerephcation 
when overexpressed in S. pombe (Sânchez et al., 1999b). A dominant mutant of 
CDC6, cdc6-3, with point mutations within the conserved leucine zipper and a non­
conserved region, was shown to induce rerephcation when overexpressed (Liang and 
Stillman, 1997). Leucine zippers are known to mediate protein-protein interactions, 
and the destruction of the leucine zipper in cdc6-3 may suggest that this “gain-of- 
function” mutant cannot be inactivated due to the loss of specific protein-protein 
interactions. Unfortunately, the phosphorylation status of this mutant was not 
analysed, but high CDK levels did not block reinitiation of DNA rephcation (Liang 
and Stillman, 1997). This suggests that CDK inhibition of rephcation is mediated via 
Cdc6p through the leucine zipper. Further studies are required to test if the leucine 
zipper is imphcated in regulation of mammalian CDC6 function, and if the 
phosphorylation of mammalian CDC6 is a mechanism by which rerephcation is 
prevented. Endorephcation in mammalian cells has been observed in many situations 
where the activity of the cyclin dependent kinases is deregulated. In theory this could 
allow mammahan CDC6 to reenter the nucleus and to stimulate the formation of the 
preRephcation Complexes licensing the chromosomes for a new round of DNA 
rephcation in the absence of intervening mitosis. Similarly, it could be speculated that 
the cytoplasmic mammahan CDC6 could be recruited to the nucleus in response to 
DNA damage to allow DNA rephcation to proceed afterwards. It would therefore be 
interesting to examine the localization of mammahan CDC6 in response to DNA 
damage and in cells that undergo endorephcation. However, it is likely that there are 
other CDK targets than mammahan CDC6 imphcated in preventing rerephcation, 
explaining the inabihty to detect an accumulation of cells with rerephcated DNA upon 
overexpression of hCDC6.
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5.2 Ubiquitin mediated degradation of mammalian CDC6
Ubiquitin mediated degradation of specific proteins is essential for cell cycle 
progression. In all eukaryotes two multisubunit complexes have evolved as 
specialized ubiquitin ligases (E3) targeting proteins for degradation by the 26S 
proteasome in a cell cycle regulated fashion (reviewed by Peters, 1998). The Skpl- 
Cdc53/Cullin-F-box (SCF) ligase is activated in late Gl and remains active until 
mid-mitosis and is involved in degradation of the G1 cyclins and CDK inhibitors 
(SicIp, Ruml, Farl and p27). The anaphase promoting complex (APC) is essential 
for progression though mitosis and is needed for the turnover of Pdsl p/Cut 2 and the 
mitotic cyclins.
The mammalian CDC6 protein is regulated by several post-transcriptional^ 
mechanisms. Data presented here demonstrate that mammalian CDC6 is an unstable 
protein and that the turnover of human CDC6 is regulated by ubiquitin mediated 
degradation. The degradation of human CDC6 likely contributes to the cell cycle 
regulated expression of the human CDC6 protein. The mammalian CDC6 protein is 
not present in quiescent cells, and it is induced as cells enter Gl and S-phase. In 
proliferating cells human CDC6 disappears as cells progress though mitosis and 
reaccumulates during the next Gl. The expression profile is reminiscent of Cyclin B 
and other proteins which expression is controlled, in part, by the anaphase promoting 
complex. Ubiquitination of proteins by APC is dependent on destruction box motifs 
present in the substrates. An N-terminal destruction box sequence was identified in 
hCDC6. Mutation of this sequence stabilized hCDC6 in quiescent cells.
The human CDC6 protein was shown to have a short half life, of around one hour, 
similar to that of p53 which is known to be a highly unstable protein and to be 
regulated by ubiquitin mediated degradation. The instability of human CDC6 was 
shown to be dependent on the 26S proteasome, as the degradation of the protein was
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prevented in the presence of proteasome inhibitors. Furthermore, poly-ubiquitinated 
human CDC6 was identified in vivo, when the proteasome was inhibited. Also the 
yeast CDC6 proteins, Cdc6p and CdclS have recently been shown to be degraded by 
the proteasome suggesting that the turnover of CDC6 molecules in different species 
is similarly regulated (Drury et al., 1997; Jallepalli et al., 1998; Sânchez et al., 
1999a).
In mammalian cells transcriptional regulation of the CDC6 gene is dependent on the 
E2F transcription factors and transcription is activated as cells progress from 
quiescence into S-phase (Hateboer el al., 1998; Ohtani et al., 1998; Yan et al., 1998). 
It is less clear if CDC6 is transcriptionally activated by E2F in cycling celt although 
some changes in the CDC6 mRNA level were observed in cells released from a 
double thymidine block (Leone et al., 1998). A careful examination of mRNA and 
protein levels of mammalian CDC6 in proliferating cells will be required to 
understand the contribution of transcriptional and post-transcriptional regulatory 
mechanisms in regulation of the expression of the mammalian CDC6 protein. The 
yeast CDC6 and Cdcl8+ genes are transcriptionally activated in mitosis and until 
late Gl. The Cdc6p and CdclS proteins are unstable from initiation of S-phase until 
exit of mitosis. This give a peak of protein expression in Gl of both Cdc6p and 
CdclS (Drury et al., 1997; Baum et al., 1998). The results presented here 
demonstrate that mammalian CDC6 is differently regulated. The mammalian CDC6 
protein accumulates in Gl but the level remains constant throughout S-phase and 
until exit of mitosis, where the CDC6 protein abruptly disappears. The cell cycle 
regulated expression of human CDC6 was demonstrated by chemically 
synchronization of cells in mitosis and by centrifugal élutriation. The expression 
pattern of CDC6 in mammalian cells suggests that the DNA replication stimulating 
function of mammalian CDC6 occurs in late Gl and S-phase. It still remains to be 
demonstrated if CDC6 also in mammalian cells is responsible for recruitment of
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proteins to origins of replication. If so, it is likely to take place later in the 
mammalian cell cycle than it does in yeast.
The molecular mechanisms involved in ubiquitination of Cdc6p, CdclS and CDC6 
in mammalian cells seem to be similar though different. Examination of several 
hCDC6 deletion mutants revealed that the 110 N-terminal amino acids residues of 
hCDC6 contain a destabilizing element. In S. cerevisiae and S. pombe similar N- 
terminal deletion mutants have been shown to stabilize Cdc6p and CdclS (Drury et 
al., 1997; Kominami and Toda, 1997). The periodic instability of Cdc6p and CdclS 
follows the activity of the SCF complex, and several components of the SCF have 
been shown to be involved in the degradation of Cdc6p and CdclS (Drury et al., 
1997; Kominami and Toda, 1997; Jallepalli et al., 1998; Sânchez et al., 1999a; Wolf 
et al., 1999). More specifically, the CdclS protein is targeted for degradation by 
CDK phosphorylation (Jallepalli et al., 1997; Jallepalli et al., 1998). As described in 
this thesis CDK phosphorylation of human CDC6 results in relocalization of 
mammalian CDC6 from the nucleus to the cytoplasm. Reexamination of the hCDC6 
phosphorylation mutants in a degradation assay demonstrated that the N-terminal 
hCDC6 phosphorylation sites are not part of a major destabilizing element in 
mammalian CDC6. Furthermore, the decrease in CDC6 protein level takes place 
when CDK activity is low and coincides with the degradation of Cyclin B, a well 
characterized substrate of the anaphase promoting complex (APC).
It was impossible to detect overexpression of hCDC6 in quiescent fibroblasts unless 
the cells were treated with a proteasome inhibitor, demonstrating that a proteolytic 
activity against mammalian CDC6 exist in quiescent cells. The anaphase promoting 
complex is active in mitosis, Gl and GO (Brandeis and Hunt, 1996). A destruction 
box sequence was identified in human CDC6 in a region highly conserved in 
m am m alian CDC6 proteins. Deletion of the N-terminal of hCDC6 or mutation of the 
destruction box sequence allowed expression of CDC6 in quiescent cells. This
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demonstrates that the N-terminal of hCDC6 and more specifically the destruction 
box sequence is at least partly, responsible for mediating the degradation of hCDC6 
in quiescent cells. The involvement of a destruction box sequence in regulation the 
expression of hCDC6 indicates that mammalian CDC6 may be marked for 
degradation by APC in GO and possibly Gl.
The degradation of several APC and SCF substrates is essential for cell cycle 
transitions. If degradation of mammalian CDC6 is needed for cell cycle progression, 
expression of a stable mutant that retains all other functions of human CDC6 would 
be expected to block cell cycle progression. Overexpression of stabilized hCDC6 
mutants (NLShCDC6 111-560 and hCDC6 dl 5.8-61) did not block cell cycle 
progression in proliferating cells but the deregulated expression of these mutants led 
to loss of cell viability to a higher extent than overexpression of wild type hCDC6. 
This may give an explanation to the inability to obtain cell lines with high level of 
hCDC6 overexpression. Cells tolerate low levels of ectopically expressed hCDC6 
protein, probably since they are able to regulate is it as the endogenous protein. From 
the performed experiments it is unclear what triggers the induction of cell death. The 
mutants with the strongest phenotype are likely able to retain expression of hCDC6 
in M-Gl where the endogenous protein is absent, and the role of the nuclear 
localization suggests that both degradation and localization of hCDC6 are important 
regulatory features.
In yeast, cdc6 and cdclS null strains undergo a reductional anaphase suggesting that 
Cdc6p and CdclS repress mitosis (Kelly et al., 1993; Piatti et al., 1995). As 
described previously mammalian and yeast CDC6 are differently regulated and their 
role in mitosis appears to be very different. Cdc6p and CdclS are needed for 
delaying mitosis in response to DNA damage, and this is dependent on the ATPase 
domain, and thereby on the ability of Cdc6p/Cdcl8 to stimulate DNA replication, 
and the generation of a signal for ongoing DNA synthesis. In S. pombe this function
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appears to be part of a cell cycle checkpoint since it is dependent on rad and hus 
genes (Greenwood et al., 1998). It will be interesting to understand if mammalian 
CDC6 has a direct role in regulation of mitosis or if the downregulation of 
mammalian CDC6 in mitosis is necessary for resetting of replication origins.
The finding that CDÇ6 degradation in mammalian cells in GO is dependent on a d- 
box sequence adds a novel protein to the list of putative APC substrates. Previous 
studies have demonstrated that the anaphase promoting complex is essential for both 
the metaphase-anaphase transition and the exit of mitosis. The expression of human 
CDC6 follows Cyclin B suggesting that human CDC6 as Cyclin B is ubiquitinated 
by the APC complex in the end of mitosis. It has been know for some time, that the 
APC remains active in Gl and quiescent cells presumably to guarantee that no S- 
phase and M-phase cyclins accumulate (Brandeis and Hunt, 1996). The data 
described here suggests that the APC also prevents accumulation of the mammalian 
CDC6 protein.
As described in section 4.7.5 it is important to establish if the degradation of hCDC6 
is cell cycle regulated and to understand which domains contribute to the instability 
of CDC6. It is clear from the data presented here that other N-terminal motifs than 
the d-box are involved in regulating the turnover of hCDC6. As for the 
phosphorylation mutants, it would be of great interest to establish cell lines with 
regulatable expression of different mutants. It would also be interesting to 
investigate the regulation of mammalian CDC6 expression in primary cell lines as 
the level of human CDC6 is increased in transformed cell lines. This could simply be 
due to the increased proliferation rate of transformed cells compared to primary 
cells, but it could also indicate that expression of the mammalian CDC6 protein is 
deregulated in transformed cells, which could be caused by both transcriptional 
activation of the hCDC6 gene and/or deregulation of the degradation pathway(s).
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5.3 Complete cell cycle regulation of mammalian CDC6
From the above data it appears that expression of the mammalian CDC6 proteins is 
fully controlled by E2F dependent transcriptional regulation, Cyclin A/CDK2 
phosphorylation and ubiquitin mediated degradation. In summary, the mammalian 
CDC6 protein accumulates in the nucleus in Gl until the activation of Cyclin 
A/CDK leads to redistribution of the mammalian CDC6 protein to the cytoplasm. As 
the cells progress through mitosis human CDC6 is degraded and de novo protein 
synthesis of human CDC6 is needed for the cells to enter S-phase again. As in yeast 
S-phase CDK inhibits the ability of mammalian CDC6 to stimulate DNA replication, 
by inducing relocation of the protein to the cytoplasm and not by targeting the 
protein for degradation. The mammalian CDC6 protein is degraded as cells progress 
through mitosis and the instability is likely mediated by a destruction box sequence 
in the N-terminal of hCDC6. Intriguingly, the regulation of DNA replication and 
mitosis is thereby coupled via the regulation of the mammalian CDC6 protein.
5.4 DNA replication, E2F and pocket proteins
The transcriptional regulation of key cell cycle regulators by E2F complexes is 
widely believed to be one of the most important features of cell cycle regulation. 
ORC1 (Ohtani et al., 1996; Asano and Wharton, 1999), MCM genes (Ohtani et al., 
1999) and CDC6 itself (Hateboer et al., 1998; Ohtani et al., 1998; Yan et al., 1998) 
are regulated by E2F. In yeast, the Origin Recognition Complex binds DNA 
throughout the cell cycle, and the activity and the abundance of the ORCs do not 
seem to be cell cycle regulated (Muzi-Falconi and Kelly, 1995; Grallert and Nurse, 
1996). In Drosophila ORC1 expression is cell cycle regulated in some cell types and 
overexpression can induces DNA replication in some tissues (Asano and Wharton, 
1999). This demonstrates that cell type specific regulatory mechanisms of regulating
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DNA replication exist in Drosophila and probably also in other organisms and that 
members of the ORC can be limiting for DNA replication.
Interestingly, it has been suggested that E2F, in addition to regulate gene 
transcription of cell cycle regulators, also plays a more direct role in the regulation of 
DNA replication in Drosophila. It was observed that during chorion gene 
amplification in Drosophila, regulated localization of dORC2 is dependent on wild 
type dE2F (Royzman et al., 1999). It has also been observed that pRB, pl07 and 
p i30 proteins colocalize with MCM proteins and sites of DNA replication in a cell 
cycle regulated fashion. This specific regulation was observed in primary fibroblasts 
and not in transformed cell lines (E. Harlow, personal communication). Furthermore 
the retinoblastoma protein has been shown to interact with MCM7 (Sterner et al., 
1998). The DNA replication initiation start site in the Chinese hamster dehydrofolate 
reductase (DHFR) origin locus is specified at a distinct point during Gl (Wu and 
Gilbert, 1996), which is lost upon transformation with simian virus 40 (Wu et al., 
1998). These observations suggest that the E2F - pocketprotein complexes and their 
regulation might be directly involved in formation of replication complexes in 
mammalian cells, and that the formation of replication complexes is deregulated in 
transformed cells.
Several mammalian origins of replication are located within genes knovato be
t
regulated by E2F including the DHFR origin locus and the c-myc gene (Huberman, 
1995; Helin, 1998), thereby the binding of E2F and pocket proteins could be 
involved in origin selection in mammalian cells.
The identification and characterization of origins of replication in mammalians is 
essential for the ability to understand the complex regulation of initiation of DNA 
replication in mammalian cells. It is still not clear if the mammalian homologues of 
the yeast replication proteins function similarly in mammalian cells. Experiments in 
Xenopus egg extracts show that the chromatin association of Xenopus ORCs changes
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^ough the cell cycle (Rowles et al., 1996; Rowels et al., 1999) supporting the 
evidence from Drosophila, that the origin recognition complex in higher eukaryotes 
is a regulatable complex. It also remains to be clarified if MCM proteins associate 
with the origin recognition complex on DNA in mammalian cells. Previous studies 
have not been able to demonstrate this, rather oppositely, human ORC and MCM 
proteins were shown to bind different DNA fragments (Ritzi et al., 1998). This study 
was performed in HeLa cells and the formation of replication complexes may, as 
mentioned, be deregulated in transformed cells. Further studies will be required to 
understand the molecular mechanisms regulating DNA replication in mammals. The 
identification of molecules involved DNA replication over the last years and the 
development and improvement of eukaryote in vitro replication assays have been 
enormous. The research in this field will probably also in the coming years obtain 
further insight into the regulatory mechanisms of eukaryote chromosome duplication 
as new molecules are being identified and characterized.
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